

# CITATION REPORT

List of articles citing

New response evaluation criteria in solid tumours:  
revised RECIST guideline (version 1.1)

DOI: 10.1016/j.ejca.2008.10.026

European Journal of Cancer, 2009, 45, 228-47.

**Source:** <https://exaly.com/paper-pdf/46668322/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2251	Optimizing Sedative Dose in Preterm Infants. 277-292		
2250	Systemic Therapy in Gynaecological Cancers. 52-61		
2249	.		
2248	.		
2247	Interpretation of PET/CT findings in patients with advanced lung cancer who have undergone pleurodesis. <b>2014</b> , 8, 452		1
2246	Preoperative serum tumor marker levels in gastric cancer. <b>2014</b> , 30, 145-9		12
2245	A Low Noise CMOS Integrated Signal Processor for Multi-Element Particle Detectors. <b>1988</b> ,		3
2244	Diffusion Weighted Imaging in Cancer. <b>1996</b> ,		
2243	Role of everolimus in the treatment of renal cell carcinoma. <b>2009</b> , 5, 699-706		6
2242	Nodal staging. <b>2009</b> , 9, 104-11		60
2241	[PET/CT in breast cancer: an update]. <b>2009</b> , 96, 1053-70		5
2240	Targeted molecular therapies in thyroid carcinoma. <b>2009</b> , 53, 1061-73		8
2239	Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. <b>2009</b> , 19, 1393-400		60
2238	Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. <b>2009</b> , 104, 1852-4		23
2237	New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma. <b>2009</b> , 9, 1159-67		14
2236	Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. <b>2009</b> , 15, 7412-20		2380
2235	Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. <b>2009</b> , 14, 816-27		41

2234	Distinguishing between anti-neutrophil cytoplasmic antibody patterns in inflammatory bowel disease: is the "atypical pattern" adding more information?. <b>2009</b> , 104, 1854-5	8
2233	Standards for PET image acquisition and quantitative data analysis. <b>2009</b> , 50 Suppl 1, 11S-20S	592
2232	Improving cancer outcomes through international collaboration in academic cancer treatment trials. <b>2009</b> , 27, 5109-14	42
2231	Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. <b>2009</b> , 106, 16375-80	150
2230	Novel designs and end points for phase II clinical trials. <b>2009</b> , 15, 1866-72	58
2229	Measuring response with FDG-PET: methodological aspects. <b>2009</b> , 14, 369-77	57
2228	Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. <b>2009</b> , 193, W301-7	87
2227	Innovative zielgerichtete Therapie des fortgeschrittenen Nierenzellkarzinoms. <b>2009</b> , 41, 152-157	
2226	Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?. <b>2009</b> , 5, 871-88	3
2225	Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. <b>2009</b> , 50, 1760-9	59
2224	Commentary: troublesome words, linguistic precision, and medical oncology. <b>2009</b> , 14, 445-7	3
2223	Has quantitative multimodal imaging of treatment response arrived?. <b>2009</b> , 15, 6473-5	2
2222	Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. <b>2009</b> , 14 Suppl 2, 30-40	46
2221	Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. <b>2009</b> , 27, 5650-9	103
2220	Frontiers of Biomedical Imaging Science 2009: workshop report and research opportunities. <b>2009</b> , 69, 7902-4	2
2219	Alternate endpoints for screening phase II studies. <b>2009</b> , 15, 1873-82	68
2218	Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. <b>2009</b> , 106, 19801-6	263
2217	Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. <b>2009</b> , 94, 1493-9	85

2216	Incidental PET/CT findings in the cancer patient: how should they be managed?. <b>2009</b> , 146, 274-81	65
2215	Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. <b>2009</b> , 9, 208	61
2214	Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. <b>2009</b> , 36, 302-11	34
2213	Molecular imaging of breast cancer. <b>2009</b> , 18 Suppl 3, S66-73	73
2212	Therapiemonitoring mittels CT und MRT: methodische Grundlagen. <b>2009</b> , 15, 457-464	1
2211	Aktuelle Entwicklungen in der Bildgebung beim nichtkleinzelligen Bronchialkarzinom. <b>2009</b> , 15, 496-501	
2210	Predictive value of the clinically and scintigraphically important bone lesions in hormone-refractory prostate cancer (HRPC). <b>2009</b> , 11, 773-4	
2209	Evolving end points for clinical trials in advanced colorectal cancer. <b>2009</b> , 5, 135-139	1
2208	Targeted therapies in thyroid cancer. <b>2009</b> , 4, 275-85	2
2207	Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. <b>2009</b> , 185, 775-81	37
2206	Monitoring cancer therapy with PET: probably effective, but more research is needed. <b>2009</b> , 36, 1520-5	6
2205	A statistical model for the dependence between progression-free survival and overall survival. <b>2009</b> , 28, 2669-86	43
2204	Imaging metastatic bone disease from carcinoma of the prostate. <b>2009</b> , 101, 1225-32	90
2203	Role of Imaging in Prostate Cancer: A Review. <b>2009</b> , 13, 68-87	1
2202	Imaging response to systemic therapy for bone metastases. <b>2009</b> , 19, 2495-507	61
2201	Assessing tumor response to therapy. <b>2009</b> , 50 Suppl 1, 1S-10S	193
2200	Cancer clinical trial outcomes: any progress in tumour-size assessment?. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 225-7	7.5 30
2199	Individual patient data analysis to assess modifications to the RECIST criteria. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 248-60	7.5 144

2198	Evaluation of lymph nodes with RECIST 1.1. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 261-7	7.5	184
2197	Validation of novel imaging methodologies for use as cancer clinical trial end-points. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 290-9	7.5	94
2196	A simulation study to evaluate the impact of the number of lesions measured on response assessment. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 300-10	7.5	46
2195	Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 2249-52	7.5	33
2194	Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 2930-4	7.5	94
2193	Recommendations for the assessment of progression in randomised cancer treatment trials. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 281-9	7.5	93
2192	Biomarkers in oncology drug development. <b>2009</b> , 3, 24-32		23
2191	From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. <b>2009</b> , 50 Suppl 1, 122S-50S		2458
2190	Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sources. <b>2009</b> , 2, 198-210		44
2189	Computed tomography in metastatic renal cell carcinoma. <b>2009</b> , 30, 359-66		8
2188	Radiology reporting templates in oncology: a time for change. <b>2009</b> , 53, 511-3		12
2187	Standardised tumour, node and metastasis reporting of oncology CT scans. <b>2009</b> , 53, 345-52		3
2186	Appréciation de la réponse : évolution des concepts. <b>2009</b> , 65, S84-S87		
2185	Neoadyuvancia en cáncer de mama. <b>2009</b> , 13, 157-174		1
2184	Évaluation en oncologie : comment je fais en imagerie ?. <b>2009</b> , 49, 392-406		
2183	Current readings in nuclear medicine. <b>2009</b> , 34, 264-8		
2182	Stable disease is a valid end point in clinical trials. <b>2009</b> , 15, 374-8		13
2181	Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. <b>2009</b> , 15, 401-5		59

2180	Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies. <b>2009</b> , 15, 426-30	9
2179	Other paradigms: randomized discontinuation trial design. <b>2009</b> , 15, 431-4	7
2178	Response rates: a valuable signal of promising activity?. <b>2009</b> , 15, 361-5	5
2177	Successful treatment of lung cancer with gefitinib and EGFR mutation status determination using EBUS-TBNA samples in an extremely old patient. <b>2009</b> , 48, 1905-7	7
2176	Évaluation par imagerie en cancérologie : de la définition des standards internationaux à l'exercice pratique. <b>2009</b> , 4, 1-12	
2175	Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?. <b>2009</b> , 15, 354-60	13
2174	Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. <b>2009</b> , 15, 421-5	28
2173	Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. <b>2010</b> , 16, 3215-25	45
2172	Prediction of lymph node manifestations in malignant lymphoma: significant role of volumetric compared with established metric lymph node analysis in multislice computed tomography. <b>2010</b> , 34, 564-9	19
2171	Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients. <b>2010</b> , 5, 376-9	16
2170	Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. <b>2010</b> , 5, 1551-8	105
2169	Prediction and Monitoring of Therapeutic Response by Molecular Imaging. <b>2010</b> , 6, 29-32	
2168	Tomodensitométrie abdominale : principes et applications. <b>2010</b> , 5, 1-11	
2167	Thymoma and thymic carcinoma: molecular pathology and targeted therapy. <b>2010</b> , 5, S286-90	64
2166	Tumor response evaluation in oncology: current update. <b>2010</b> , 34, 479-84	38
2165	Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. <b>2010</b> , 33, 557-69	30
2164	Surgical and radiologic staging of cervical cancer. <b>2010</b> , 22, 15-20	13
2163	Intra- and interobserver variability of linear and volumetric measurements of brain metastases using contrast-enhanced magnetic resonance imaging. <b>2010</b> , 45, 49-56	40

2162	Dose reduction for semi-automated volumetry of hepatic metastasis in MDCT studies. <b>2010</b> , 45, 77-81	8
2161	Angiogenesis in non-small cell lung cancer: imaging with perfusion computed tomography. <b>2010</b> , 25, 142-50	19
2160	Current world literature. <b>2010</b> , 22, 87-93	
2159	Semiautomatic lymph node segmentation in multislice computed tomography: impact of slice thickness on segmentation quality, measurement precision, and interobserver variability. <b>2010</b> , 45, 82-8	13
2158	Targeting the type I insulin-like growth factor system for breast cancer therapy. <b>2010</b> , 11, 1121-32	18
2157	Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution. <b>2010</b> , 21, 553-8	14
2156	[Phases 0, 1 and 2 oncology clinical trials: current questions]. <b>2010</b> , 97, 55-63	1
2155	QA procedures for multimodality preclinical tumor drug response testing. <b>2010</b> , 37, 4806-16	1
2154	Validation of an algorithm for the nonrigid registration of longitudinal breast MR images using realistic phantoms. <b>2010</b> , 37, 2541-52	17
2153	Preliminary trial of adjuvant surgery for advanced gastric cancer. <b>2010</b> , 1, 743-747	28
2152	Standard outcome measures for thymic malignancies. <b>2010</b> , 5, 2017-23	109
2151	Restaging by endobronchial ultrasound-guided transbronchial needle aspiration in patients with inoperable advanced lung cancer. <b>2010</b> , 49, 787-90	10
2150	Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. <b>2010</b> , 72, 1165-72	29
2149	Evaluating the extent of cell death in 3D high frequency ultrasound by registration with whole-mount tumor histopathology. <b>2010</b> , 37, 4288-97	9
2148	When and how often should PET scans be performed in the management of cervical cancer?. <b>2010</b> , 10, 983-6	2
2147	Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival. <b>2010</b> , 5, 491-6	35
2146	Volume assessment accuracy in computed tomography: a phantom study. <b>2010</b> , 11, 3037	38
2145	[Not Available]. <b>2010</b> , 65, 367-72	1

2144	Assessing cancer drugs for reimbursement: methodology, relationship between effect size and medical need. <b>2010</b> , 65, 373-7, 367-72	2
2143	FDA phantom CT database: a resource for the assessment of lung nodule size estimation methodologies and software development. <b>2010</b> ,	2
2142	COMBINED EFFECTS OF SELECTIVE PHOTOTHERMAL THERAPY AND IMMUNOADJUVANT AGAINST STAGE IV BREAST CANCER. <b>2010</b> , 03, 279-284	3
2141	Ovarian cancer: the role of functional imaging as an end point in clinical trials. <b>2010</b> , 20, 971-8	4
2140	Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer. <b>2010</b> , 20, 979-84	30
2139	Imaging ovarian cancer and peritoneal metastases--current and emerging techniques. <b>2010</b> , 7, 381-93	87
2138	RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. <b>2010</b> , 20, 1456-67	124
2137	Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?. <b>2010</b> , 20, 2890-8	80
2136	ESUR guidelines: ovarian cancer staging and follow-up. <b>2010</b> , 20, 2773-80	117
2135	Is conflict of interest in our best interest?. <b>2010</b> , 37, 1063-8	4
2134	Tumor shrinkage assessed by volumetric MRI in the long-term follow-up after stereotactic radiotherapy of meningiomas. <b>2010</b> , 186, 423-9	32
2133	[Systemic therapy of renal cell carcinoma]. <b>2010</b> , 49, 1543-50; quiz 1551	1
2132	Registration and functional analysis of CT dynamic image sequences for the follow-up of patients with hepatic tumors undergoing antiangiogenic therapy. <b>2010</b> , 31, 263-270	5
2131	Head and neck sarcoma: report of a case treated by intensity-modulated radiation therapy. <b>2010</b> , 15, 305-9	1
2130	Nouveaux développements en IRM en oncologie. <b>2010</b> , 12, 187-196	3
2129	Biomarqueurs en imagerie pour l'évaluation des nouvelles thérapies anticancéreuses. <b>2010</b> , 12, 178-186	
2128	PART 1 p53 adapted preoperative radiotherapy for T2 and T3 rectal cancer. A study of the p53 research group. <b>2010</b> , 42, 18-23	1
2127	Response, disease-free survival, and overall survival: What matters for whom?. <b>2010</b> , 42, 5-7	1

2126	[Implications of modern anticancer therapies for palliative care concepts]. <b>2010</b> , 24, 633-41	2
2125	Qualitative and quantitative assessment of endpoints in clinical trials. <b>2010</b> , 3, 33-36	0
2124	Castration-refractory prostate cancer: New drugs in the pipeline. <b>2010</b> , 27, 285-96	17
2123	White paper on imaging biomarkers. <b>2010</b> , 1, 42-45	48
2122	Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. <b>2010</b> , 31, 351-7	41
2121	Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. <b>2010</b> , 5, 39-52	88
2120	Targeted therapies in renal cell cancer: recent developments in imaging. <b>2010</b> , 5, 95-112	43
2119	Multi-modality morphological correlation of axillary lymph nodes. <b>2010</b> , 5, 343-50	3
2118	Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature. <b>2010</b> , 37, 6-10	8
2117	The role of magnetic resonance imaging in oncology. <b>2010</b> , 12, 606-13	18
2116	Response assessment challenges in clinical trials of gliomas. <b>2010</b> , 12, 68-75	34
2115	Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis. <b>2010</b> , 27, 217-31	11
2114	[CT-PET and evaluation of therapy response. is the size really important?]. <b>2010</b> , 29, 184-8	3
2113	[Functional imaging of tumors. Part 2]. <b>2010</b> , 52, 208-20	3
2112	Improving CT prediction of treatment response in patients with metastatic colorectal carcinoma using statistical learning theory. <b>2010</b> , 11 Suppl 3, S15	3
2111	Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer. <b>2010</b> , 10, 483-8	17
2110	Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. <b>2010</b> , 10, 368	120
2109	Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. <b>2010</b> , 10, 480	22

2108	Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. <b>2010</b> , 58, 906-11	48
2107	Quantitative methodology using CT for predicting survival in patients with metastatic colorectal carcinoma: a pilot study. <b>2010</b> , 34, 196-202	1
2106	Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. <b>2010</b> , 15, 102-14	41
2105	Targeted therapy of thyroid cancer. <b>2010</b> , 80, 592-601	64
2104	"Clinical benefit rate" in phase 2 gynecologic cancer trials: implying more than the data support?. <b>2010</b> , 117, 348-9	
2103	Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. <b>2010</b> , 117, 467-72	14
2102	Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. <b>2010</b> , 116, 2332-42	46
2101	Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. <b>2010</b> , 52, 1741-9	305
2100	Gastrointestinal stromal tumors: current management. <b>2010</b> , 102, 530-8	37
2099	Optimizing resection for "responding" hepatic metastases after neoadjuvant chemotherapy. <b>2010</b> , 102, 1002-8	5
2098	Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. <b>2010</b> , 16, 767-72	45
2097	Molecular targeted therapies for patients with refractory thyroid cancer. <b>2010</b> , 22, 448-55	19
2096	Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. <b>2010</b> , 22, 818-27	44
2095	Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives. <b>2010</b> , 73, 202-12	54
2094	Gamma knife radiosurgery as a therapeutic strategy for intracranial sarcomatous metastases. <b>2010</b> , 76, 513-9	50
2093	Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. <b>2010</b> , 78, 696-702	34
2092	Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. <b>2010</b> , 54, 1035-7	19
2091	Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). <b>2010</b> , 55, 369-73	52

2090	Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document. <b>2010</b> , 8, 28-37	178
2089	PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives. <b>2010</b> , 8, 163-87	25
2088	Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. <b>2010</b> , 12, 418-26	20
2087	Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. <b>2010</b> , 101, 882-8	20
2086	Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. <b>2010</b> , 103, 196-200	77
2085	Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. <b>2010</b> , 103, 597-606	21
2084	Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate. <b>2010</b> , 103, 1400-6	109
2083	Translating cancer research into targeted therapeutics. <b>2010</b> , 467, 543-9	269
2082	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. <b>2010</b> , 10, 760-74	802
2081	Perfusion CT and US of colorectal cancer liver metastases: a correlative study of two dynamic imaging modalities. <b>2010</b> , 36, 1626-36	16
2080	Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. <b>2010</b> , 23, 641-5	29
2079	Positron emission tomography: current status and future challenges. <b>2010</b> , 40, 19-29	17
2078	Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture. <b>2010</b> , 16, 5766-72	12
2077	Response Evaluation Criteria in Cancer of the Liver (RECICL). <b>2010</b> , 51, 261-266	17
2076	Pedagogical immigration to 3D virtual worlds: A critical review of underlying themes and their concepts. <b>2010</b> ,	4
2075	Perfusion magnetic resonance imaging of the liver. <b>2010</b> , 16, 1598-609	92
2074	Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis. <b>2010</b> , 8, 2647-58	10
2073	Antivascular therapy for epithelial ovarian cancer. <b>2010</b> , 2010, 372547	7

2072	Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. <b>2010</b> , 2010, 412985	46
2071	Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy. <b>2010</b> , 2010,	27
2070	Imaging in clinical trials. <b>2010</b> , 10 Spec no A, S74-82	23
2069	Tumour response evaluation with fluorodeoxyglucose positron emission tomography: research technique or clinical tool?. <b>2010</b> , 10 Spec no A, S68-72	8
2068	Paclitaxel as neoadjuvant therapy for high grade angiosarcoma of the spleen: a brief report and literature review. <b>2010</b> , 4, 107-10	16
2067	Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. <b>2010</b> , 5, e12965	34
2066	Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies. <b>2010</b> , 21, 3-11	21
2065	Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine. <b>2010</b> , 2, 111-24	2
2064	Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria. <b>2010</b> , 11, 618-26	19
2063	Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how?. <b>2010</b> , 10 Spec no A, S179-88	54
2062	Volumes to learn: advancing therapeutics with innovative computed tomography image data analysis. <b>2010</b> , 16, 4493-5	9
2061	Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. <b>2010</b> , 9, 2243-54	38
2060	Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab. <b>2010</b> , 16, 4236-45	43
2059	Clinical trials data collection: when less is more. <b>2010</b> , 28, 5019-21	8
2058	Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. <b>2010</b> , 28, 3994-4005	306
2057	Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. <b>2010</b> , 21, 936-41	75
2056	Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy. <b>2010</b> , 21, 2195-2200	4
2055	Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?. <b>2010</b> , 16, 5956-62	32

2054 Principles of Cancer Treatment. **2010**, 1-9

2053 Finding the right dose for cancer therapeutics--can we do better?. **2010**, 16, 1085-7

3

2052 Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. **2010**, 28, 1322-8

37

2051 Multiparametric imaging of tumor response to therapy. **2010**, 256, 348-64

178

2050 <sup>111</sup>In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. **2010**, 51, 1707-15

38

2049 Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging. **2010**, 9, 673-81

24

2048 Detection of tumor response to a vascular disrupting agent by hyperpolarized <sup>13</sup>C magnetic resonance spectroscopy. **2010**, 9, 3278-88

61

2047 Metastatic disease response to treatment: how many lesions to measure?. **2010**, 28, e81; author reply 82

2

2046 Bar the windows but open the door to randomization. **2010**, 28, 3104-6

16

2045 Progress in cancer chemotherapy with special stress on molecular-targeted therapy. **2010**, 40, 855-62

15

2044 Living with imperfection. **2010**, 28, 191-2

30

2043 Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring. **2010**, 6, 21-32

22

2042 Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. **2010**, 303, 1062-9

145

2041 A phantom study of nodule size evaluation with chest tomosynthesis and computed tomography. **2010**, 139, 140-3

14

2040 Assessing oncologic benefit in clinical trials of immunotherapy agents. **2010**, 21, 1944-1951

45

2039 Optimal lesion number for evaluation of tumor response in response evaluation criteria in solid tumors. **2010**, 28, e159-60; author reply e161

7

2038 The integration of quantitative multi-modality imaging data into mathematical models of tumors. **2010**, 55, 2429-49

34

2037 A novel approach to the assessment of response to chemotherapy in sarcoma imaged with PET-FDG. **2010**,

1

2036	Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. <b>2010</b> , 18, 651-9	43
2035	Phase II proof-of-concept study of pazopanib monotherapy in treatment-naïve patients with stage I/II resectable non-small-cell lung cancer. <b>2010</b> , 28, 3131-7	120
2034	[18F]FDG PET/CT imaging of colorectal cancer: a pictorial review. <b>2010</b> , 86, 174-82	27
2033	Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. <b>2010</b> , 21, 2324-2332	89
2032	Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. <b>2010</b> , 15, 969-75	116
2031	Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). <b>2010</b> , 21, 195-198	28
2030	Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. <b>2010</b> , 51, 1870-7	88
2029	Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. <b>2010</b> , 21, 19-26	31
2028	Imaging in drug development: will it deliver on the promise of personalised medicine?. <b>2010</b> , 83, 453-5	1
2027	Functional imaging of renal cell carcinoma. <b>2010</b> , 7, 258-66	32
2026	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2010</b> , 21 Suppl 5, v15-9	92
2025	Use of modified RECIST criteria to improve response assessment in targeted therapies: challenges and opportunities. <b>2010</b> , 9, 20-2	17
2024	Partial volume correction for volume estimation of liver metastases and lymph nodes in CT scans using spatial subdivision. <b>2010</b> ,	1
2023	Targeted radionuclide therapy for neuroendocrine tumours: principles and application. <b>2010</b> , 91, 1-15	19
2022	18-Fluorodeoxyglucose positron emission tomography as a tool for response prediction in solid tumours. <b>2010</b> , 65, 291-9	10
2021	Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. <b>2010</b> , 195, 281-9	251
2020	Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. <b>2010</b> , 256, 511-8	114
2019	Modeling opportunities in comparative oncology for drug development. <b>2010</b> , 51, 214-20	33

2018	Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. <b>2010</b> , 30, 52-60	2453
2017	Measurement accuracy and reproducibility of semiautomated metric and volumetric lymph node analysis in MDCT. <b>2010</b> , 195, 979-85	19
2016	Radioembolization for colorectal liver metastases. <b>2010</b> , 7,	1
2015	Does primary tumour volumetry performed early in the course of definitive concomitant chemoradiotherapy for head and neck squamous cell carcinoma improve prediction of primary site outcome?. <b>2010</b> , 83, 964-70	15
2014	Quantitative imaging in oncology patients: Part 1, radiology practice patterns at major U.S. cancer centers. <b>2010</b> , 195, 101-6	37
2013	High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. <b>2010</b> , 95, E54-7	59
2012	Quantitative imaging in oncology patients: Part 2, oncologists' opinions and expectations at major U.S. cancer centers. <b>2010</b> , 195, W19-30	25
2011	New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. <b>2010</b> , 195, W221-8	153
2010	Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. <b>2010</b> , 18, 1874-84	180
2009	Suitability of semi-automated tumor response assessment of liver metastases using a dedicated software package. <b>2010</b> , 182, 581-8	13
2008	Semiautomated segmentation for volumetric analysis of intratumoral ethiodol uptake and subsequent tumor necrosis after chemoembolization. <b>2010</b> , 195, 1220-30	45
2007	Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET?. <b>2010</b> , 255, 164-72	30
2006	nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. <b>2010</b> , 9, 515-23	13
2005	Dendritic cell vaccines for brain tumors. <b>2010</b> , 21, 139-57	40
2004	[MRI evaluation of residual breast carcinoma after neoadjuvant chemotherapy]. <b>2010</b> , 91, 693-9	4
2003	Hepatic perfusion imaging: concepts and application. <b>2010</b> , 18, 465-75, x	13
2002	Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat. <b>2010</b> , 12, 697-707	19
2001	Multiparametric magnetic resonance imaging, spectroscopy and multinuclear ( $^{23}\text{Na}$ ) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. <b>2010</b> , 17, 1477-85	42

2000	Assessment of Response to Therapy for Bone Metastases: Is it Still a Challenge in Oncology?. <b>2010</b> , 5, 311-26	2
1999	Imaging of Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias. <b>2010</b> , 15-62	2
1998	Imaging tumour cell metabolism using hyperpolarized <sup>13</sup> C magnetic resonance spectroscopy. <b>2010</b> , 38, 1220-4	35
1997	Imaging renal cell carcinoma with ultrasonography, CT and MRI. <b>2010</b> , 7, 311-25	34
1996	Imaging the life and death of tumors in living subjects: Preclinical PET imaging of proliferation and apoptosis. <b>2010</b> , 2, 483-95	18
1995	Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. <b>2010</b> , 69, 105-9	20
1994	Methodological aspects of lung cancer clinical trials in the era of targeted agents. <b>2010</b> , 67, 127-35	26
1993	Involved field radiotherapy for locally advanced non-small cell lung cancer: isolated mediastinal nodal relapse. <b>2010</b> , 70, 218-20	2
1992	TGFBI expression is associated with a better response to chemotherapy in NSCLC. <b>2010</b> , 9, 130	53
1991	Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case. <b>2010</b> , 8, 109	8
1990	Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis. <b>2010</b> , 8, 40	16
1989	DNA polymerase $\beta$ protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. <b>2010</b> , 8, 126	43
1988	First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3lg) enhances immune responses and antitumor activity. <b>2010</b> , 8, 71	164
1987	Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. <b>2010</b> , 11, 396-404	49
1986	Functional imaging of tumors. Part 2. <b>2010</b> , 52, 208-220	3
1985	Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. <b>2010</b> , 21, 1751-1755	68
1984	Myeloma Bone Disease. <b>2010</b> ,	2
1983	Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. <b>2010</b> , 21, 2278-2283	45

1982	Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations. <b>2010</b> , 257, 523-31		114
1981	RECIST versus volume measurement in medical CT using ellipsoids of known size. <b>2010</b> , 18, 8151-9		17
1980	A resource for the assessment of lung nodule size estimation methods: database of thoracic CT scans of an anthropomorphic phantom. <b>2010</b> , 18, 15244-55		44
1979	An open-source toolkit for the volumetric measurement of CT lung lesions. <b>2010</b> , 18, 15256-66		19
1978	Data sets for the qualification of volumetric CT as a quantitative imaging biomarker in lung cancer. <b>2010</b> , 18, 15267-82		12
1977	Apport de la TEP/TDM au 18FDG dans la stadification initiale et l'évaluation précoce de la réponse thérapeutique des rhabdomyosarcomes pédiatriques. <b>2010</b> , 34, 655-663		2
1976	FDG PET/CT in oncology: "raising the bar". <b>2010</b> , 65, 522-35		31
1975	Imaging in gastrointestinal stromal tumours: current status and future directions. <b>2010</b> , 65, 584-92		19
1974	An introduction to functional and molecular imaging with MRI. <b>2010</b> , 65, 557-66		40
1973	Molecular biology of breast cancer stem cells: potential clinical applications. <b>2010</b> , 36, 485-91		50
1972	Multikinase inhibitors in thyroid cancer. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 1012-8	7.5	13
1971	Two decades at the cross-roads of biology, physics and epidemiology: lessons learned in [18F]-FDG positron emission tomography in oncology. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 2150-8	7.5	1
1970	Motion in Games. <b>2010</b> ,		1
1969	Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma. <b>2010</b> , 40, 1195-203		17
1968	[Assessment and importance of clinical trial endpoints in various areas of medicine]. <b>2010</b> , 104, 250-7; discussion 258		1
1967	Positron emission tomography-computed tomography reporting in radiation therapy planning and response assessment. <b>2010</b> , 31, 516-29		7
1966	Patient and image data management in positron emission tomography-computed tomography for radiation therapy and therapy response assessment. <b>2010</b> , 31, 480-9		3
1965	Therapy response evaluation with positron emission tomography-computed tomography. <b>2010</b> , 31, 490-5		3

1964	Targeting breast cancer stem cells. <b>2010</b> , 4, 404-19	155
1963	Potential pitfalls in the design and reporting of clinical trials. <b>2010</b> , 11, 694-700	2
1962	Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. <b>2010</b> , 11, 992-1000	88
1961	The use of volumetric CT as an imaging biomarker in lung cancer. <b>2010</b> , 17, 100-6	37
1960	Randomized phase II trials: inevitable or inadvisable?. <b>2010</b> , 28, 2641-7	61
1959	Origin of Cancers. <b>2010</b> ,	1
1958	Diffusion-Weighted MR Imaging. <b>2010</b> ,	10
1957	Imaging Tumors of the Lung and Pleura. <b>2010</b> , 1-40	2
1956	Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. <b>2010</b> , 17, 1175-85	5
1955	Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. <b>2010</b> , 29, 70	70
1954	Longitudinal assessment of cyst-like lesions of the knee and their relation to radiographic osteoarthritis and MRI-detected effusion and synovitis in patients with knee pain. <b>2010</b> , 12, R172	29
1953	Improved endpoints for cancer immunotherapy trials. <b>2010</b> , 102, 1388-97	439
1952	A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer. <b>2010</b> , 28, 865-71	5
1951	Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. <b>2010</b> , 49, 509-14	71
1950	Modeling tumor growth and treatment response based on quantitative imaging data. <b>2010</b> , 2, 338-45	9
1949	Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. <b>2010</b> , 28, 1963-72	2543
1948	Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. <b>2010</b> , 10, 119-28	67
1947	Targeted treatments in colorectal cancer: state of the art and future perspectives. <b>2010</b> , 59, 838-58	38

1946	Potential of imaging biomarkers for characterization of renal masses. <b>2010</b> , 10, 781-6	3
1945	Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. <b>2010</b> , 10, 825-35	13
1944	Melanoma vaccines: developments over the past 10 years. <b>2011</b> , 10, 853-73	26
1943	Treating rheumatic patients with a malignancy. <b>2011</b> , 13, 223	23
1942	Radiation treatment outcomes for unresectable hepatocellular carcinoma. <b>2011</b> , 50, 1191-8	15
1941	Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent. <b>2011</b> , 175, 10-20	14
1940	Advanced aggressive fibromatosis: Effective palliation with chemotherapy. <b>2011</b> , 50, 455-61	46
1939	Treatment of Borrmann type IV gastric cancer with a neoadjuvant chemotherapy combination of docetaxel, cisplatin and 5-fluorouracil/leucovorin. <b>2011</b> , 39, 2096-102	12
1938	Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. <b>2011</b> , 114, 769-79	127
1937	Multiplexed PET probes for imaging breast cancer early response to VEGF $\beta$ Gel treatment. <b>2011</b> , 8, 621-8	20
1936	Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. <b>2011</b> , 29, 3114-9	110
1935	Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. <b>2011</b> , 1, 241-253	3
1934	[Management of brain metastases from non-small cell lung carcinoma]. <b>2011</b> , 167, 579-91	6
1933	Research reporting standards for radioembolization of hepatic malignancies. <b>2011</b> , 22, 265-78	163
1932	Other PET Tracers and Prospects for the Future. <b>2011</b> , 6, 91-7	
1931	3D Assessment of Lymph Nodes vs. RECIST 1.1. <b>2011</b> , 18, 391-4	10
1930	The role of functional MRI and PET/CT in evaluation of patients with primary and recurrent ovarian cancer. <b>2011</b> , 3, 333-343	2
1929	The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. <b>2011</b> , 185, 54-9	58

1928	[Imaging features and evaluation of liver lesions after non-surgical therapy]. <b>2011</b> , 92, 632-58	4
1927	Invited commentary. <b>2011</b> , 22, 1362-3	1
1926	Consolidation of hepatic arterial inflow by embolization of variant hepatic arteries in preparation for yttrium-90 radioembolization. <b>2011</b> , 22, 1364-1371.e1	29
1925	Perfusión aislada de extremidades. Experiencia inicial del Instituto Nacional de Cancerología, 2007-2008. <b>2011</b> , 15, 67-74	1
1924	Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan. <b>2011</b> , 4, 328-35	19
1923	A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment. <b>2011</b> , 6, 299-311	3
1922	Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. <b>2011</b> , 22, 1545-52	156
1921	[Management of refractory thyroid cancers]. <b>2011</b> , 72, 149-57	5
1920	Diffusion MR imaging for monitoring of treatment response. <b>2011</b> , 19, 181-209	105
1919	[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]. <b>2011</b> , 28, 51-7	6
1918	Comparison of semiautomated and manual measurements for simulated hypo- and hyper-attenuating hepatic tumors on MDCT: effect of slice thickness and reconstruction increment on their accuracy. <b>2011</b> , 18, 626-33	1
1917	New Imaging Techniques for 90Y Microsphere Radioembolization. <b>2011</b> , 01,	5
1916	Imaging in renal cell carcinoma. <b>2011</b> , 25, 687-715	21
1915	Recent advances in immunotherapy for the treatment of prostate cancer. <b>2011</b> , 11, 997-1009	15
1914	Methodological and practical challenges for personalized cancer therapies. <b>2011</b> , 8, 135-41	138
1913	Opportunities and pitfalls of cancer imaging in clinical trials. <b>2011</b> , 8, 517-27	28
1912	Imaging of renal cell carcinoma: state of the art and recent advances. <b>2011</b> , 86, 125-39	26
1911	New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. <b>2011</b> , 73, 63-9	43

1910	The role of positron emission tomography in management of small cell lung cancer. <b>2011</b> , 73, 121-6	30
1909	Management strategies for recurrent platinum-resistant ovarian cancer. <b>2011</b> , 71, 1397-412	114
1908	Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. <b>2011</b> , 18, 192-8	154
1907	Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. <b>2011</b> , 18, 3657-65	130
1906	Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. <b>2011</b> , 30, 30	63
1905	Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. <b>2011</b> , 18, 89-96	22
1904	Efficacy of dosimetric versus empiric prescribed activity of <sup>131</sup> I for therapy of differentiated thyroid cancer. <b>2011</b> , 96, 3217-25	72
1903	Principles of Anticancer Drug Development. <b>2011</b> ,	
1902	Radiotherapy for Hodgkin Lymphoma. <b>2011</b> ,	2
1901	Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: good clinical response. <b>2011</b> , 86, 256-60	8
1900	Cancer Systems Biology, Bioinformatics and Medicine. <b>2011</b> ,	3
1899	Neuroendocrine Tumors. <b>2011</b> ,	7
1898	Colorectal cancer vaccines in clinical trials. <b>2011</b> , 10, 899-921	23
1897	Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. <b>2011</b> , 66, 224-36	43
1896	A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. <b>2011</b> , 37, 373-84	43
1895	Parental consanguineous marriages and clinical response to chemotherapy in locally advanced breast cancer patients. <b>2011</b> , 302, 109-12	3
1894	Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma. <b>2011</b> , 15, 54-63	28
1893	Translational imaging endpoints to predict treatment response to novel targeted anticancer agents. <b>2011</b> , 14, 224-35	10

1892	Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 983-9	7.5	18
1891	Recommendations for capture, validation and summarisation of data from studies using RECIST. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 697-701	7.5	4
1890	Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 1763-71	7.5	36
1889	Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 1955-61	7.5	91
1888	Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 1759-62	7.5	8
1887	Tumour growth rates and RECIST criteria in early drug development. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 2512-6	7.5	55
1886	Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 2603-6	7.5	86
1885	Semi-automated volumetric analysis of artificial lymph nodes in a phantom study. <b>2011</b> , 80, e451-7		9
1884	Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma. <b>2011</b> , 37, 245-51		16
1883	A phase I/II study of neoadjuvant chemotherapy with Pemetrexed (Alimta) in rectal cancer. <b>2011</b> , 37, 583-8		7
1882	Novel oncologic drugs: what they do and how they affect images. <b>2011</b> , 31, 2059-91		62
1881	[Refractory thyroid cancers]. <b>2011</b> , 40, 1189-98		6
1880	Radioembolisation des tumeurs hépatiques par microsphères marquées à l'yttrium-90. <b>2011</b> , 35, 224-231		17
1879	Évaluation de la réponse thérapeutique par tomographie par émission de positons (TEP) au 18fluoro-désoxyglucose (FDG) en oncologie-hématologie. <b>2011</b> , 35, 600-607		5
1878	Carboplatin and gemcitabine in patients with advanced and/or metastatic urothelial cancers: A phase II study. <b>2011</b> , 2, 31-35		2
1877	Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. <b>2011</b> , 54, 695-704		129
1876	EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. <b>2011</b> , 55, 1309-16		253
1875	Cancer immunotherapy--revisited. <b>2011</b> , 10, 591-600		282

1874	Molecular imaging of the small renal mass. <b>2011</b> , 29, 589-92	4
1873	Imaging of lung cancer in the era of molecular medicine. <b>2011</b> , 18, 424-36	33
1872	End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. <b>2011</b> , 29, 3695-704	164
1871	GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. <b>2011</b> , 12, 1061-73	23
1870	Imaging characteristics following 90yttrium microsphere treatment for unresectable liver cancer. <b>2011</b> , 55, 111-8	32
1869	Embolization of parasitized extrahepatic arteries to reestablish intrahepatic arterial supply to tumors before yttrium-90 radioembolization. <b>2011</b> , 22, 1355-62	29
1868	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <b>2011</b> , 13, R67	161
1867	Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. <b>2011</b> , 72, 333-9	37
1866	Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. <b>2011</b> , 101, 250-4	99
1865	BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. <b>2011</b> , 10, 2000-7	77
1864	Intra-arterial brachytherapy of hepatic malignancies: watch the flow. <b>2011</b> , 8, 115-20	19
1863	Targeted systemic radiotherapy of pheochromocytoma and medullary thyroid cancer. <b>2011</b> , 41, 369-73	10
1862	Radiographic and metabolic response rates following image-guided stereotactic radiotherapy for lung tumors. <b>2011</b> , 99, 18-22	29
1861	Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. <b>2011</b> , 99, 166-71	56
1860	Diagnostic and staging impact of radiotherapy planning FDG-PET-CT in non-small-cell lung cancer. <b>2011</b> , 101, 284-90	27
1859	Change in the growth rate of localized pancreatic adenocarcinoma in response to gemcitabine, bevacizumab, and radiation therapy on MDCT. <b>2011</b> , 81, 452-9	8
1858	Retrospective study of palliative radiotherapy in newly diagnosed head and neck carcinoma. <b>2011</b> , 81, 958-63	35
1857	Low-dose radiotherapy in indolent lymphoma. <b>2011</b> , 81, e1-6	19

1856	Liver metastases on quantitative color mapping of the arterial enhancement fraction from multiphasic CT scans: evaluation of the hemodynamic features and correlation with the chemotherapy response. <b>2011</b> , 80, e278-83	12
1855	Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. <b>2011</b> , 377, 1846-54	317
1854	Practical management of imatinib in gastrointestinal stromal tumors. <b>2011</b> , 15, 533-45	4
1853	Is neoadjuvant chemotherapy necessary for patients with initially resectable colorectal liver metastases in the era of effective chemotherapy?. <b>2011</b> , 15, 206-17	2
1852	Pilot study of a pediatric metronomic 4-drug regimen. <b>2011</b> , 2, 960-5	55
1851	Trans-arterial 90yttrium radioembolization for patients with unresectable tumors originating from the biliary tree. <b>2011</b> , 10, 349-354	8
1850	From Clinical Trials to Clinical Practice: Predictors of Response to Erlotinib in Advanced Non-Small Cell Lung Cancer Patients Pretreated with Chemotherapy. <b>2011</b> , 97, 160-165	9
1849	BIOMARKERS AND PUBLIC-PRIVATE PARTNERSHIPS. 193-194	
1848	Discovery and Development of Drugs Targeting Tumor Invasion and Metastasis. 600-611	2
1847	New antiangiogenics in non-small cell lung cancer treatment: Vargatef (BIBF 1120) and beyond. <b>2011</b> , 7, 429-40	9
1846	Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer. <b>2011</b> , 71, 15	4
1845	Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. <b>2011</b> , 18,	
1844	Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. <b>2012</b> , 11, 259-65	33
1843	Imaging follow-up of RF ablation of lung tumours. <b>2011</b> , 11 Spec No A, S123-8	11
1842	Contrast-enhanced ultrasound in oncology. <b>2011</b> , 11 Spec No A, S167-73	17
1841	Can CD44+/CD24- Tumor Cells Be Used to Determine the Extent of Breast Cancer Invasion Following Neoadjuvant Chemotherapy?. <b>2011</b> , 14, 175-80	2
1840	[Not Available]. <b>2011</b> , 153, 27-31	
1839	[Brain metastasis of breast cancer; imaging evaluation]. <b>2011</b> , 98, 399-407	1

1838 IMAGING BIOMARKERS IN DRUG DEVELOPMENT: CASE STUDIES. 222-264

1837 Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. **2011**, 2011, 231789 40

1836 Grand challenges for cancer imaging and diagnosis. **2011**, 1, 15 1

1835 Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?. **2011**, 22, 183-7 10

1834 GAVeCeLT\* consensus statement on the correct use of totally implantable venous access devices for diagnostic radiology procedures. **2011**, 12, 292-305 15

1833 Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. **2011**, 26, 94-101 30

1832 Computer-aided evaluation of breast MRI for the residual tumor extent and response monitoring in breast cancer patients receiving neoadjuvant chemotherapy. **2011**, 12, 34-43 15

1831 FDG PET/CT in cancer therapy monitoring: computer-assisted analysis of baseline together with up to two follow-ups. **2011**, 50, 83-92 2

1830 A novel method for volumetric MRI response assessment of enhancing brain tumors. **2011**, 6, e16031 36

1829 Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. **2011**, 6, e23303 38

1828 The Effect of Neoadjuvant Chemotherapy on Hormone Receptor Status, HER2/neu and Prolactin in Breast Cancer. **2011**, 97, 704-710 5

1827 Role of immunotherapy for renal cell cancer in 2011. **2011**, 9, 1011-8 21

1826 PET/CT with 3'-deoxy-3'-[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy. **2011**, 32, 348-55 14

1825 Contemporary management of metastatic castration-resistant prostate cancer. **2011**, 21, 241-7 7

1824 The usefulness of Tc-99m-tetrofosmin SPECT/CT in the detection of residual tumors and axillary lymph node metastases in breast cancer patients following neoadjuvant therapy. **2011**, 36, 997-1002 6

1823 Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway. **2011**, 22, 463-7 22

1822 Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro. **2011**, 34, 45-57 32

1821 The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature. **2011**, 11, 746-52 2

1820	The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. <b>2011</b> , 32, 106-12	47
1819	Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging. <b>2011</b> ,	3
1818	CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. <b>2011</b> , 197, W1060-6	29
1817	Recurrent thyroid cancer: a molecular-based therapeutic breakthrough. <b>2011</b> , 23, 235-40	7
1816	Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging. <b>2011</b> , 35, 690-6	45
1815	PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study. <b>2011</b> , 36, 526-32	27
1814	Current and future trends in imaging informatics for oncology. <b>2011</b> , 17, 203-10	11
1813	Metabolic response of rectal cancer assessed by 18-FDG PET following chemoradiotherapy is prognostic for patient outcome. <b>2011</b> , 54, 518-25	23
1812	Dual energy CT for monitoring targeted therapies in patients with advanced gastrointestinal stromal tumor: initial results. <b>2011</b> , 12, 547-57	18
1811	Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. <b>2011</b> , CD004787	146
1810	Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy. <b>2011</b> , 35, 167-73	19
1809	Laser immunotherapy for the treatment of human breast cancer: one-year follow up results. <b>2011</b> ,	
1808	Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis. <b>2011</b> , 45, 285-91	13
1807	Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial. <b>2011</b> , 6, 1915-22	8
1806	Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. <b>2011</b> , 2011, 190-191	
1805	Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer. <b>2011</b> , 21, 1573-8	22
1804	Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. <b>2011</b> , 140, 1319-1324	106
1803	Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. <b>2011</b> , 6, 1267-73	13

1802	Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress. <b>2011</b> , 1, 33-44	2
1801	Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma. <b>2011</b> , 25, 1047-52	15
1800	Cisplatin versus carboplatin in association with third-generation drugs for advanced non-small cell lung cancer. <b>2011</b> ,	2
1799	Design and endpoints of clinical and translational trials in advanced colorectal cancer. a proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD). <b>2011</b> , 6, 158-70	2
1798	Transesophageal ultrasound-guided fine-needle aspiration for the mediastinal restaging of non-small cell lung cancer. <b>2011</b> , 6, 1510-5	32
1797	Cisplatin and TRAIL enhance breast cancer stem cell death. <b>2011</b> , 39, 891-8	25
1796	Standard outcome measures for thymic malignancies. <b>2011</b> , 6, S1691-7	70
1795	FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. <b>2011</b> , 39, 91-100	3
1794	Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer. <b>2011</b> , 2, 1177-1181	16
1793	A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. <b>2011</b> , 6, 598-601	32
1792	Tumor volume measurement errors of RECIST studied with ellipsoids. <b>2011</b> , 38, 2552-7	8
1791	Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. <b>2011</b> , 6, 1930-7	66
1790	Automated 3-dimensional segmentation of pelvic lymph nodes in magnetic resonance images. <b>2011</b> , 38, 6178-87	13
1789	Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis. <b>2011</b> , 25, E541-51	17
1788	Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. <b>2011</b> , 13, e388-95	43
1787	Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. <b>2011</b> , 26, 1201-6	12
1786	Clinical features and natural history of hepatocellular adenomas: the impact of obesity. <b>2011</b> , 34, 664-74	78
1785	Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. <b>2011</b> , 34, 1193-201	86

1784	Tumour heterogeneity of mucosal melanomas during treatment with imatinib. <b>2011</b> , 165, 419-24	6
1783	New therapeutic options for metastatic malignant insulinomas. <b>2011</b> , 75, 277-84	42
1782	Diffusion-weighted imaging in evaluating the response to neoadjuvant breast cancer treatment. <b>2011</b> , 17, 610-9	50
1781	An audit strategy for progression-free survival. <b>2011</b> , 67, 1092-9	22
1780	Therapeutic cancer vaccines: are we there yet?. <b>2011</b> , 239, 27-44	218
1779	Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. <b>2011</b> , 11, 817-25	37
1778	Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration. <b>2011</b> , 154, 20-6	27
1777	A complex adaptive system using statistical learning theory as an inline preprocess for clinical survival analysis. <b>2011</b> , 6, 279-284	3
1776	The role of magnetic resonance imaging biomarkers in clinical trials of treatment response in cancer. <b>2011</b> , 38, 16-25	31
1775	Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma. <b>2011</b> , 122, 107-10	22
1774	Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. <b>2011</b> , 123, 553-6	55
1773	miRNA signature associated with outcome of gastric cancer patients following chemotherapy. <b>2011</b> , 4, 79	109
1772	Clinical trials in the era of personalized oncology. <b>2011</b> , 61, 365-81	43
1771	Hepatic arterial infusion of doxorubicin-loaded microsphere for treatment of hepatocellular cancer: a multi-institutional registry. <b>2011</b> , 213, 493-500	15
1770	Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion. <b>2011</b> , 12, 307-12	18
1769	Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. <b>2011</b> , 80, 40-53	55
1768	Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. <b>2011</b> , 59, 10-5	83
1767	Is tumor response important for renal carcinoma?. <b>2011</b> , 59, 16-7	4

1766	Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. <b>2011</b> , 20, 34-8	7
1765	Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. <b>2011</b> , 20, 319-23	36
1764	Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. <b>2011</b> , 138, 23-32	17
1763	Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. <b>2011</b> , 45, 1399-405	40
1762	Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine. <b>2011</b> , 5, 323-32	14
1761	Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer. <b>2011</b> , 8, 235-241	
1760	The diffusion-weighted imaging perfusion fraction $f$ is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. <b>2011</b> , 21, 281-90	109
1759	Semi-automated volumetric analysis of lymph node metastases during follow-up—initial results. <b>2011</b> , 21, 683-92	15
1758	Comparison of semi-automated and manual methods to measure the volume of liver tumours on MDCT images. <b>2011</b> , 21, 996-1003	7
1757	Neoadjuvant chemotherapy in breast cancer—response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. <b>2011</b> , 21, 1188-99	115
1756	Assessing response in bone metastases in prostate cancer with diffusion weighted MRI. <b>2011</b> , 21, 2169-77	77
1755	Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. <b>2011</b> , 18, 431-8	34
1754	Disease-related mortality within the first year after subtotal esophagectomy for cancer. <b>2011</b> , 18, 1139-44	3
1753	Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. <b>2011</b> , 18, 932-8	32
1752	Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. <b>2011</b> , 18, 1081-7	166
1751	Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. <b>2011</b> , 18, 2192-9	64
1750	Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0. <b>2011</b> , 31, 2093-105	61
1749	Monitoring of neoadjuvant chemotherapy using multiparametric, $^{23}\text{Na}$ sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. <b>2011</b> , 128, 119-26	56

1748	Linear accelerator-based stereotactic radiosurgery for brainstem metastases: the Dana-Farber/Brigham and Women's Cancer Center experience. <b>2011</b> , 104, 553-7	36
1747	Sequential FDG-PET/CT after neoadjuvant chemotherapy is a predictor of histopathologic response in patients with head and neck squamous cell carcinoma. <b>2011</b> , 13, 368-77	28
1746	Adjuvant surgical therapy for patients with initially-unresectable pancreatic cancer with long-term favorable responses to chemotherapy. <b>2011</b> , 18, 712-6	30
1745	The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression. <b>2011</b> , 459, 21-9	28
1744	Observed magnetic resonance imaging changes in pediatric patients treated with stereotactic radiosurgery for intracranial tumors. <b>2011</b> , 27, 399-406	6
1743	Japanese classification of gastric carcinoma: 3rd English edition. <b>2011</b> , 14, 101-12	2479
1742	Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study. <b>2011</b> , 16, 613-6	6
1741	Konventionelle bildgebende thorakale Diagnostik. <b>2011</b> , 8, 217-224	
1740	Tubulocystic renal carcinoma: a clinical perspective. <b>2011</b> , 29, 349-54	23
1739	Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients. <b>2011</b> , 29, 355-60	9
1738	[Lung cancer staging]. <b>2011</b> , 51, 135-44	0
1737	Molecular imaging in cancer treatment. <b>2011</b> , 38, 358-77	64
1736	Phase II study of radiopeptide <sup>177</sup> Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. <b>2011</b> , 38, 302-11	146
1735	<sup>18</sup> F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study. <b>2011</b> , 38, 1059-63	13
1734	FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. <b>2011</b> , 38, 1029-36	45
1733	<sup>18</sup> F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with <sup>90</sup> Y microspheres. <b>2011</b> , 38, 1037-45	73
1732	Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). <b>2011</b> , 38, 1669-74	74
1731	Total <sup>18</sup> F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. <b>2011</b> , 38, 1854-61	35

1730	Assessment of the treatment response of HCC. <b>2011</b> , 36, 300-14	44
1729	Current concepts in transarterial chemoembolization of hepatocellular carcinoma. <b>2011</b> , 36, 677-83	18
1728	Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. <b>2011</b> , 60, 1097-107	43
1727	Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy. <b>2011</b> , 34, 306-18	27
1726	Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. <b>2011</b> , 67, 847-53	22
1725	PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. <b>2011</b> , 68, 539-45	26
1724	Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. <b>2011</b> , 68, 1081-7	6
1723	Contrast-enhanced sonography in pediatrics. <b>2011</b> , 41 Suppl 1, S238-42	29
1722	Pediatric oncology and the future of oncological imaging. <b>2011</b> , 41 Suppl 1, S172-85	9
1721	Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. <b>2011</b> , 40, 181-6	12
1720	Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients. <b>2011</b> , 28 Suppl 1, S115-20	6
1719	Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy. <b>2011</b> , 13, 18-24	20
1718	A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study. <b>2011</b> , 13, 686-91	3
1717	FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. <b>2011</b> , 2, 354-62	35
1716	Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). <b>2011</b> , 2, 621-630	34
1715	Increase of angiogenic growth factors after hepatic artery embolization in patients with neuroendocrine tumours. <b>2011</b> , 32, 647-52	11
1714	BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells. <b>2011</b> , 32, 985-95	19
1713	Liver tumors segmentation from CTA images using voxels classification and affinity constraint propagation. <b>2011</b> , 6, 247-55	30

1712	Response assessment in neuro-oncology. <b>2011</b> , 13, 50-6	88
1711	Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials. <b>2011</b> , 11, 164	1
1710	Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. <b>2011</b> , 11, 295	46
1709	A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. <b>2011</b> , 11, 510	11
1708	Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. <b>2011</b> , 11, 67	29
1707	Evaluation of early imaging response criteria in glioblastoma multiforme. <b>2011</b> , 6, 121	15
1706	Preclinical multimodality phantom design for quality assurance of tumor size measurement. <b>2011</b> , 11, 1	14
1705	Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study group. <b>2011</b> , 56, 733-7	93
1704	Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. <b>2011</b> , 71, 1264-75	14
1703	Time-to-event analysis with treatment arm selection at interim. <b>2011</b> , 30, 3067-81	18
1702	How is retrospective independent review influenced by investigator-introduced informative censoring: a quantitative approach. <b>2011</b> , 30, 3373-86	5
1701	An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. <b>2011</b> , 10, 347-56	125
1700	Prognostic significance of expression of VEGF and Cox-2 in nasopharyngeal carcinoma and its association with expression of C-erbB2 and EGFR. <b>2011</b> , 103, 46-52	22
1699	The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. <b>2011</b> , 104, 661-6	12
1698	Monitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T?. <b>2011</b> , 34, 547-56	15
1697	Tumor imaging using hyperpolarized <sup>13</sup> C magnetic resonance spectroscopy. <b>2011</b> , 66, 505-19	208
1696	The role of <sup>18</sup> F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. <b>2011</b> , 86, 567-72	29
1695	Therapeutic response in musculoskeletal soft tissue sarcomas: evaluation by MRI. <b>2011</b> , 24, 750-63	22

1694	Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. <b>2011</b> , 54, 2238-44	84
1693	Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. <b>2011</b> , 117, 1262-71	83
1692	Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. <b>2011</b> , 117, 1377-85	39
1691	Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. <b>2011</b> , 117, 2637-42	64
1690	The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. <b>2011</b> , 117, 3963-71	30
1689	Response assessment in gastrointestinal stromal tumor. <b>2011</b> , 128, 1251-8	12
1688	Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. <b>2011</b> , 129, 2533-42	47
1687	Cohort study of patients with adrenal lesions discovered incidentally. <b>2011</b> , 98, 1383-91	39
1686	Positron emission tomography and colorectal cancer. <b>2011</b> , 77, 30-47	16
1685	Repeatedly identified differentially expressed proteins (RIDEPS) from antibody microarray proteomic analysis. <b>2011</b> , 74, 698-703	11
1684	Poly(ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges. <b>2011</b> , 1, 1545-1554	3
1683	Quantitative effects of using compressed sensing in dynamic contrast enhanced MRI. <b>2011</b> , 56, 4933-46	36
1682	MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. <b>2011</b> , 17, 5812-21	130
1681	<sup>177</sup> Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. <b>2011</b> , 52, 1041-7	114
1680	Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. <b>2011</b> , 197, W992-W1000	188
1679	The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example. <b>2011</b> , 45, 263-75	
1678	Response to treatment series: part 2, tumor response assessment--using new and conventional criteria. <b>2011</b> , 197, 18-27	56
1677	A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. <b>2011</b> , 17, 6840-6	42

1676	Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials. <b>2011</b> , 11, 549-59	35
1675	Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. <b>2011</b> , 197, W241-6	49
1674	Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. <b>2011</b> , 259, 574-82	71
1673	Oncologic imaging: a guiding hand of personalized cancer care. <b>2011</b> , 259, 633-40	42
1672	Targeted therapies for thyroid tumors. <b>2011</b> , 24 Suppl 2, S44-52	60
1671	Renal cell carcinoma: what the surgeon and treating physician need to know. <b>2011</b> , 196, 1255-62	11
1670	Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed. <b>2011</b> , 12, 865-71	37
1669	Liver lesion segmentation in MSCT: effect of slice thickness on segmentation quality, measurement precision and interobserver variability. <b>2011</b> , 183, 372-80	7
1668	Lung cancer in never smokers. <b>2011</b> , 32, 10-21	26
1667	PET zur Responsebeurteilung nach Strahlentherapie: Stand der Dinge. <b>2011</b> , 34, 120-124	
1666	Tumor markers in fine-needle aspiration washout for cervical lymphadenopathy in patients with known malignancy: preliminary study. <b>2011</b> , 197, W730-6	6
1665	Arterially directed therapies for hepatocellular carcinoma. <b>2011</b> , 197, W590-602	16
1664	MR evaluation of retroperitoneal fibrosis. <b>2011</b> , 183, 721-6	16
1663	[Radiological evaluation of tumor response in oncological studies (tumor response evaluation)]. <b>2011</b> , 183, 695-703	7
1662	[Computer assistance to improve therapy planning for head neck oncology]. <b>2011</b> , 90, 732-8	3
1661	Investigation on the use of deformable registrations in lymph node tracking over time. <b>2011</b> , 2011, 8037-40	
1660	Toward quantitative X-ray CT phantoms of metastatic tumors using rapid prototyping technology. <b>2011</b> ,	9
1659	Random walk-based automated segmentation for the prognosis of malignant pleural mesothelioma. <b>2011</b> ,	6

1658	Analysis of variability in manual liver tumor delineation in CT scans. <b>2011</b> ,	4
1657	Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer. <b>2011</b> , 196, W66-72	27
1656	Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study. <b>2011</b> , 29, 4199-204	45
1655	A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. <b>2011</b> , 17, 6313-21	49
1654	Enhancement characteristics of lymphomatous lymph nodes of the mediastinum. <b>2011</b> , 52, 1113-8	1
1653	Volume-of-interest assessment of oncologic response using 18F-FDG PET/CT: a phantom study. <b>2011</b> , 39, 14-8	2
1652	[18F]-3'-Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. <b>2011</b> , 17, 7664-72	72
1651	Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. <b>2011</b> , 17, 4504-12	77
1650	Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. <b>2011</b> , 80, 307-13	80
1649	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2011</b> , 22 Suppl 6, vi25-30	75
1648	Nanotechnology development and utilization: a primer for diagnostic and interventional radiologists. <b>2011</b> , 31, 1449-62	10
1647	Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. <b>2011</b> , 22, 288-94	112
1646	Different gene expression profiles in metastasizing midgut carcinoid tumors. <b>2011</b> , 18, 479-89	23
1645	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. <b>2011</b> , 13, 1364-9	268
1644	Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy. <b>2011</b> , 41, 1214-20	17
1643	Liver Metastasis: Biology and Clinical Management. <b>2011</b> ,	3
1642	The CT flare response of metastatic bone disease in prostate cancer. <b>2011</b> , 52, 557-61	41
1641	EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology. <b>2011</b> , 17, 7796-807	32

1640	Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography. <b>2011</b> , 17, 4814-24	18
1639	Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. <b>2011</b> , 16, 783-7	54
1638	Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. <b>2011</b> , 29, 2416-23	481
1637	<sup>18</sup> F-fluoromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. <b>2011</b> , 52, 437-44	29
1636	Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. <b>2011</b> , 16, 859-67	13
1635	Developing imaging strategies for castration resistant prostate cancer. <b>2011</b> , 50 Suppl 1, 39-48	44
1634	Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer. <b>2011</b> , 57, 147-55	12
1633	Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer. <b>2011</b> , 28, 252-7	65
1632	Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy: correlation of apparent diffusion coefficients with epithelial and stromal densities on histology. <b>2010</b> , 7, 201-10	12
1631	Hyponatremia of non-small cell lung cancer: Indian experience. <b>2011</b> , 32, 139-42	7
1630	Treatment of Advanced Hepatocellular Carcinoma: Sorafenib and Beyond. <b>2011</b> , 3, 39-47	
1629	Complete radiological response of colorectal liver metastases after chemotherapy: what can we expect?. <b>2011</b> , 28, 114-20	43
1628	Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. <b>2011</b> , 22, 145-148	44
1627	Optimal assessment of response in ovarian cancer. <b>2011</b> , 22 Suppl 8, viii49-viii51	15
1626	Randomized phase II trials: a long-term investment with promising returns. <b>2011</b> , 103, 1093-100	63
1625	A time to keep and a time to cast away categories of tumor response. <b>2011</b> , 29, 3109-11	13
1624	Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer. <b>2011</b> , 16, 1458-68	29
1623	Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study. <b>2011</b> , 41, 134-8	1

1622	Liver metastases from melanoma: hepatic intra-arterial chemotherapy. A retrospective study. <b>2011</b> , 23, 300-5	13
1621	Conventional MRI evaluation of gliomas. <b>2011</b> , 84 Spec No 2, S107-11	132
1620	Follow-up of known carcinoid liver metastases: is respiratory-gated t(2) fast spin-echo enough?. <b>2011</b> , 93, 241-8	7
1619	Des- $\gamma$ -carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. <b>2011</b> , 29, 321-5	44
1618	Early decrease in $\beta$ -fetoprotein, but not des- $\gamma$ -carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. <b>2011</b> , 81, 251-8	72
1617	Liver volume variations as a parameter to assess therapy response in advanced metastatic liver disease. <b>2011</b> , 34, 30-4	5
1616	Targeted-therapy and imaging response: a new paradigm for clinical evaluation?. <b>2011</b> , 6, 259-65	18
1615	Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIg). <b>2011</b> , 21, 419-23	400
1614	Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. <b>2011</b> , 261, 165-71	285
1613	Response to treatment series: part 1 and introduction, measuring tumor response--challenges in the era of molecular medicine. <b>2011</b> , 197, 15-7	25
1612	Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. <b>2011</b> , 6, 1895-901	96
1611	Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging--value of histogram analysis of apparent diffusion coefficients. <b>2011</b> , 261, 182-92	193
1610	Clinical end points and response criteria in mycosis fungoides and S $\acute{z}$ ary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <b>2011</b> , 29, 2598-607	407
1609	Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. <b>2011</b> , 64, 947-52	57
1608	Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. <b>2011</b> , 52, 1727-32	42
1607	Beyond chemotherapy: new agents for targeted treatment of lymphoma. <b>2011</b> , 8, 85-96	70
1606	Response rate to neoadjuvant chemotherapy measured on imaging predicts early recurrence and death in breast cancer patients with lymph node involvements. <b>2011</b> , 52, 241-6	3
1605	Recommended guidelines for the conduct and evaluation of prognostic studies in veterinary oncology. <b>2011</b> , 48, 7-18	61

1604	Imaging assessment of tumor response: past, present and future. <b>2011</b> , 7, 669-77	14
1603	Automated temporal tracking and segmentation of lymphoma on serial CT examinations. <b>2011</b> , 38, 5879-86	12
1602	Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). <b>2011</b> , 22, 2466-2470	147
1601	PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. <b>2011</b> , 105, 1850-5	54
1600	Objective assessment of tumour response to therapy based on tumour growth kinetics. <b>2011</b> , 105, 682-6	19
1599	EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. <b>2011</b> , 105, 255-62	39
1598	The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients. <b>2011</b> , 20, 305-7	5
1597	Computational approaches to assist in the evaluation of cancer treatment response. <b>2011</b> , 3, 233-246	3
1596	Do we need novel radiologic response criteria for brain tumor immunotherapy?. <b>2011</b> , 11, 619-22	22
1595	X-ray computed tomography: semiautomated volumetric analysis of late-stage lung tumors as a basis for response assessments. <b>2011</b> , 2011, 361589	13
1594	Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?. <b>2011</b> , 40, e29-33	29
1593	The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: a phase II study. <b>2011</b> , 27, 27-32	22
1592	Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. <b>2011</b> , 22, 1346-1352	140
1591	FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. <b>2011</b> , 16, 1111-9	58
1590	Quantifying sclerotic bone metastases with 2D ultra short TE MRI: a feasibility study. <b>2010</b> , 7, 211-8	6
1589	Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. <b>2011</b> , 260, 752-61	92
1588	A novel chemo-radiotherapy with low-dose daily cisplatin, 5-fluorouracil and doxorubicin for anaplastic thyroid carcinoma: a preliminary report. <b>2011</b> , 41, 1074-8	10
1587	Usefulness of semi-automatic volumetry compared to established linear measurements in predicting lymph node metastases in MSCT. <b>2011</b> , 52, 540-6	6

1586	It is time to include patients with brain tumors in phase I trials in oncology. <b>2011</b> , 29, 3211-3	20
1585	Clinical trial end points for high-grade glioma: the evolving landscape. <b>2011</b> , 13, 353-61	90
1584	New agents and new end points for recurrent gliomas. <b>2011</b> , 29, e245-6; author reply e247	5
1583	Minimizing the maximum expected sample size in two-stage Phase II clinical trials with continuous outcomes. <b>2012</b> , 22, 836-52	20
1582	Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies. <b>2012</b> , 53, 704-9	3
1581	Observer variability in a phase II trial - assessing consistency in RECIST application. <b>2012</b> , 51, 774-80	13
1580	Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model. <b>2012</b> , 18, 1073-81	24
1579	Reproducibility and clinical correlations of post-treatment changes on CT of prostate cancer bone metastases treated with chemotherapy. <b>2012</b> , 85, 1243-9	5
1578	Targeted Therapy and Molecular Genetics. <b>2012</b> , 539-560.e6	1
1577	Reduction in growth threshold for pulmonary metastases: an opportunity for volumetry and its impact on treatment decisions. <b>2012</b> , 85, 959-64	4
1576	Watching tumours gasp and die with MRI: the promise of hyperpolarised <sup>13</sup> C MR spectroscopic imaging. <b>2012</b> , 85, 697-708	27
1575	The ARCAD advanced colorectal cancer database--open for business. <b>2012</b> , 23, 281-282	11
1574	Adrenal lesions in patients with extra-adrenal malignancy - benign or malignant?. <b>2012</b> , 51, 215-21	10
1573	Predictive factors for radiation pneumonitis in oesophageal cancer patients treated with chemoradiotherapy without prophylactic nodal irradiation. <b>2012</b> , 85, 813-8	22
1572	Stereotactic Reirradiation of Recurrent Nasopharyngeal Carcinoma Using CyberKnife System: Preliminary Results. <b>2012</b> , 22, 23-30	
1571	Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management. <b>2012</b> , 2, 167	12
1570	Topotecan and cyclophosphamide in adults with relapsed sarcoma. <b>2012</b> , 2012, 749067	4
1569	Long-term disease control of a non-operable neuroendocrine tumor of the lung with lanreotide: a case study. <b>2012</b> , 5, 657-66	1

1568	The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution. <b>2012</b> , 5, 349-55	10
1567	Clinical safety and efficacy of Kanglaite® (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. <b>2012</b> , 13, 5319-21	61
1566	Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literature. <b>2012</b> , 2012, 907179	54
1565	Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions. <b>2012</b> , 53, 1359-66	18
1564	Can response to induction chemotherapy be a predictive marker for ultimate outcome in hypopharyngeal cancer?. <b>2012</b> , 146, 74-80	4
1563	Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). <b>2012</b> , 17, 260-6	153
1562	Sorafenib in metastatic thyroid cancer. <b>2012</b> , 19, 209-16	86
1561	[131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. <b>2012</b> , 97, 914-22	56
1560	The impact of acquisition time on image quality in whole-body 18F-FDG PET/CT for cancer staging. <b>2012</b> , 40, 255-8	11
1559	Radioembolization for the treatment of liver tumors general principles. <b>2012</b> , 35, 91-9	95
1558	Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. <b>2012</b> , 30, 2731-8	67
1557	Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trial. <b>2012</b> , 35, 105-9	7
1556	Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. <b>2012</b> , 18, 160-75	135
1555	Molecular imaging of prostate cancer. <b>2012</b> , 22, 320-7	48
1554	Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors. <b>2012</b> , 35, 537-42	30
1553	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2012</b> , 23 Suppl 7, vii56-64	342
1552	Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma. <b>2012</b> , 53, 281-6	10
1551	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2012</b> , 23 Suppl 7, vii11-9	356

1550	Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria. <b>2012</b> , 199, 809-15	60
1549	A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. <b>2012</b> , 104, 670-81	124
1548	Assessing response of myeloma bone disease with diffusion-weighted MRI. <b>2012</b> , 85, e1198-203	107
1547	Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: a prospective study. <b>2012</b> , 53, 191-8	12
1546	Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. <b>2012</b> , 11, 2526-34	165
1545	A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. <b>2012</b> , 82, 333-40	28
1544	Resampling phase III data to assess phase II trial designs and endpoints. <b>2012</b> , 18, 2309-15	23
1543	Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. <b>2012</b> , 18, 1386-94	494
1542	18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. <b>2012</b> , 53, 371-7	90
1541	Imaging of tumor viability in lung cancer: initial results using <sup>23</sup> Na-MRI. <b>2012</b> , 184, 340-4	15
1540	Genitourinary imaging: part 2, role of imaging in medical management of advanced renal cell carcinoma. <b>2012</b> , 199, W554-64	10
1539	Treatment of metastatic breast cancer in women aged 65 years and older. <b>2012</b> , 8, 455-69; quiz 470-1	19
1538	Radiologische Evaluation des Tumoransprechens in onkologischen Therapiestudien (Tumor Response Evaluation). <b>2012</b> , 33, 103-111	
1537	An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. <b>2012</b> , 33, 344-51	220
1536	External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with <sup>131</sup> I-MIBG. <b>2012</b> , 44, 405-10	45
1535	MSCT follow-up in malignant lymphoma: comparison of manual linear measurements with semi-automated lymph node analysis for therapy response classification. <b>2012</b> , 184, 795-804	6
1534	Lung, liver and lymph node metastases in follow-up MSCT: comprehensive volumetric assessment of lesion size changes. <b>2012</b> , 184, 820-8	12
1533	The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications. <b>2012</b> , 33, 33-59	745

1532	Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel. <b>2012</b> , 13, 156-63	12
1531	Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. <b>2012</b> , 262, 708-18	208
1530	Multikinase inhibitors in thyroid cancer. <b>2012</b> , 23 Suppl 10, x328-33	1
1529	A spotlight from prostate cancer. <b>2012</b> , 2, 301-3	
1528	US FDA draft Guidance Standard for Clinical Trial Imaging Endpoints: more than just imaging?. <b>2012</b> , 6, 839-47	5
1527	Early evaluation of targeted drugs using dynamic contrast-enhanced ultrasonography for personalized medicine. <b>2012</b> , 8, 1215-8	11
1526	Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study. <b>2012</b> , 8, 1605-12	7
1525	Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response. <b>2012</b> , 198, 1093-9	15
1524	Hepatic tumors: region-of-interest versus volumetric analysis for quantification of attenuation at CT. <b>2012</b> , 262, 853-61	28
1523	Peptide receptor radionuclide therapy (PRRT) with <sup>177</sup> Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). <b>2012</b> , 44, 411-4	60
1522	Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management. <b>2012</b> , 50, 1018-27	10
1521	EFSUMB guidelines 2011: comment on emergent indications and visions. <b>2012</b> , 33 Suppl 1, S39-47	17
1520	Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. <b>2012</b> , 97, 4040-50	136
1519	Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. <b>2012</b> , 20, 221-9	29
1518	Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas. <b>2012</b> , 12, 1217-28	11
1517	Reporting of preclinical tumor-graft cancer therapeutic studies. <b>2012</b> , 13, 1262-8	12
1516	Plasmid IL-12 electroporation in melanoma. <b>2012</b> , 8, 1734-8	29
1515	Pulmonary nodule size evaluation with chest tomosynthesis. <b>2012</b> , 265, 273-82	28

1514	Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. <b>2012</b> , 265, 939-48	89
1513	A cross-platform and distributive database system for cumulative tumor measurement. <b>2012</b> , 2012, 1266-9	2
1512	Informatics in radiology: improving clinical work flow through an AIM database: a sample web-based lesion tracking application. <b>2012</b> , 32, 1543-52	17
1511	Implementation of a controlled injection system for dynamic contrast-enhanced ultrasonography. <b>2012</b> ,	1
1510	CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. <b>2012</b> , 106, 633-7	26
1509	Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. <b>2012</b> , 18, 6373-83	391
1508	Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. <b>2012</b> , 11, 2704-8	68
1507	Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma. <b>2012</b> , 106, 1274-9	22
1506	Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization. <b>2012</b> , 264, 97-109	35
1505	Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents. <b>2012</b> , 106, 854-7	26
1504	Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. <b>2012</b> , 106, 1926-33	91
1503	A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. <b>2012</b> , 107, 604-11	15
1502	Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?. <b>2012</b> , 26, 1148-9	9
1501	Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. <b>2012</b> , 17, 1508-14	70
1500	Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. <b>2012</b> , 263, 53-63	97
1499	The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. <b>2012</b> , 23, 948-54	78
1498	Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. <b>2012</b> , 14, 667-73	79
1497	Assessment of Response to Therapy. <b>2012</b> , 279-322	2

1496	Surgical treatment of early stage small cell lung cancer. <b>2012</b> , 20, 694-8	8
1495	Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. <b>2012</b> , 30, 2684-90	71
1494	Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. <b>2012</b> , 18, 1120-8	42
1493	Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. <b>2012</b> , 58, 468-74	30
1492	2012 European thyroid association guidelines for metastatic medullary thyroid cancer. <b>2012</b> , 1, 5-14	102
1491	Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. <b>2012</b> , 39, 9-28	25
1490	Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. <b>2012</b> , 18, 6356-63	20
1489	Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. <b>2012</b> , 14, 491-5	57
1488	Cardiac tumors in a tertiary care cancer hospital: clinical features, echocardiographic findings, treatment and outcomes. <b>2012</b> , 7, e4	52
1487	(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. <b>2012</b> , 11, 65-9	7
1486	Three-dimensional segmented volumetric analysis of sporadic vestibular schwannomas: comparison of segmented and linear measurements. <b>2012</b> , 147, 737-43	36
1485	Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. <b>2012</b> , 19, L1-4	45
1484	Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy. <b>2012</b> , 2012, 139-154	18
1483	Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. <b>2012</b> , 6, 395-407	10
1482	PET/CT in renal and bladder cancers. <b>2012</b> , 20, 97-102	
1481	Peptide receptor radionuclide therapy of neuroendocrine tumors: Case series. <b>2012</b> , 20, 143-148	
1480	Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. <b>2012</b> , 53, 701-8	125
1479	New insight into the treatment of advanced differentiated thyroid cancer. <b>2012</b> , 2012, 437569	8

1478	BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. <b>2012</b> , 2, 791-7	160
1477	Hepatocellular carcinoma: natural history, current management, and emerging tools. <b>2012</b> , 6, 207-19	45
1476	Overcoming platinum resistance through the use of a copper-lowering agent. <b>2012</b> , 11, 1221-5	56
1475	Progression-free survival: meaningful or simply measurable?. <b>2012</b> , 30, 1030-3	223
1474	Tissue platinum concentration and tumor response in non-small-cell lung cancer. <b>2012</b> , 30, 3345-52	69
1473	Persistent neck disease after chemoradiation for head and neck squamous cell carcinoma. <b>2012</b> , 126, 1121-6	2
1472	A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. <b>2012</b> , 23, 860-6	33
1471	Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. <b>2012</b> , 23, 1687-93	61
1470	PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. <b>2012</b> , 53, 182-90	105
1469	Early FDG/PET scanning as a pharmacodynamic marker of anti-EGFR antibody activity in colorectal cancer. <b>2012</b> , 11, 1385-8	14
1468	[ <sup>18</sup> F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case. <b>2012</b> , 30, e246-9	5
1467	Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. <b>2012</b> , 25, 1118-23	35
1466	Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. <b>2012</b> , 22, 979-86	63
1465	Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma. <b>2012</b> , 35, 249-52	13
1464	Evaluation of the mRECIST and $\alpha$ -fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. <b>2012</b> , 83, 192-200	59
1463	Surgical results after downstaging of initially marginal or non-resectable liver metastases. <b>2012</b> , 30 Suppl 2, 143-9	4
1462	Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead. <b>2012</b> , 96, 261-71	46
1461	Chemotherapy Combined with Radionuclide Therapy. <b>2012</b> , 901-908	

1460	Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. <b>2012</b> , 263, 149-59	77
1459	Independent radiologic review in metastatic colorectal cancer: systematic review and meta-analysis. <b>2012</b> , 263, 86-95	4
1458	Bexarotene via CBP/p300 induces suppression of NF- $\kappa$ B-dependent cell growth and invasion in thyroid cancer. <b>2012</b> , 18, 442-53	25
1457	MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer. <b>2012</b> , 85, e995-1103	4
1456	The ARCAD clinical trials program: an update and invitation. <b>2012</b> , 17, 188-91	4
1455	Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. <b>2012</b> , 198, 737-45	138
1454	Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. <b>2012</b> , 23, 996-1001	33
1453	Second-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancer. <b>2012</b> ,	
1452	Primary Liver Cancer. <b>2012</b> , 163-182	1
1451	Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab. <b>2012</b> , 4, 151-157	26
1450	Systemic therapy for metastatic melanoma in 2012: dawn of a new era. <b>2012</b> , 10, 403-12	22
1449	Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1. <b>2012</b> , 46, 8-18	31
1448	Apoptosis imaging to monitor cancer therapy: the road to fast treatment evaluation?. <b>2012</b> , 13, 571-83	15
1447	Optimisation of reconstruction for the registration of CT liver perfusion sequences. <b>2012</b> ,	1
1446	Diagnostic Ability of Fluid-Attenuated Inversion Recovery MR Imaging to Detect Remnant or Recurrent Meningiomas after Resection. <b>2012</b> , 25, 163-71	3
1445	Diffusion-Weighted Imaging in Abdominal Oncology. <b>2012</b> , 8, 82-91	0
1444	Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. <b>2012</b> , 35, 66-72	99
1443	[18F]choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: influence of antiandrogen therapy - a preliminary study. <b>2012</b> , 33, 889-94	21

1442 Wie viel Progress steckt im progressionsfreien Überleben?. **2012**, 15, 12-13

1441 Monitoring molecular, functional and morphologic aspects of bone metastases using non-invasive imaging. **2012**, 13, 584-94

7

1440 Tumoren richtig ins Bild setzen. **2012**, 15, 51-57

1439 Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination. **2012**, 3, 662-666

6

1438 Electrochemotherapy for the Treatment of Recurrent Head and Neck Cancers: Preliminary Results. **2012**, 98, 308-313

36

1437 Interpretation of PET scans: do not take SUVs at face value. **2012**, 7, 1744-1746

8

1436 Approaches Used in Immunotherapy for Prostate Cancer. **2012**, 8, 238-244

1435 Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). **2012**, 47, 11-7

128

1434 PNET spine: morbid and mortal, but ignored till late. **2012**, 34, e164-9

4

1433 The role of positron emission tomography following radiosurgical treatment of malignant lung lesions. **2012**, 33, 607-12

3

1432 Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma. **2012**, 23, 1107-11

9

1431 Clinical trials in drug development: a minimalistic approach. **2012**, 24, 332-7

2

1430 Uterine sarcoma and aromatase inhibitors: Tom Baker Cancer Centre experience and review of the literature. **2012**, 22, 1006-12

33

1429 Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer. **2012**, 22, 865-8

24

1428 Preoperative chemotherapy with doxorubicin in Wilms tumor. **2012**, 34, e106-9

4

1427 Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. **2012**, 70, 234-43; discussion 243-4

159

1426 Improving T-cell immunotherapy for melanoma through a mathematically motivated strategy: efficacy in numbers?. **2012**, 35, 116-24

18

1425 Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas. **2012**, 47, 49-57

34

1424	Models for disease progression: new approaches and uses. <b>2012</b> , 92, 125-31	39
1423	Targeting cancer stem cells with natural products. <b>2012</b> , 13, 1054-64	24
1422	Impact of third-line treatment with irinotecan plus cetuximab on non-tumor standardized uptake values in patients with metastatic colorectal cancer. <b>2012</b> , 4, 131-134	1
1421	BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis. <b>2012</b> , 4, 141-145	3
1420	Tumors of the Vulva and Vagina. <b>2012</b> , 587-599	0
1419	Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC. <b>2012</b> , 3, 1064-1068	4
1418	Computer-aided lymph node segmentation in volumetric CT data. <b>2012</b> , 39, 5419-28	9
1417	Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. <b>2012</b> , 41, 1593-600	34
1416	Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. <b>2012</b> , 4, 1010-1016	11
1415	Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study. <b>2012</b> , 3, 761-766	4
1414	Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study. <b>2012</b> , 34, 664-72	11
1413	Prognostic impact of circulating tumor cells in patients with small cell lung cancer. <b>2012</b> , 7, 512-9	135
1412	References. <b>2012</b> , 223-241	
1411	Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective. <b>2012</b> , 3, 898-902	8
1410	Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. <b>2012</b> , 7, 993-1000	25
1409	Ultrashort TE in Cancer Imaging. <b>2012</b> ,	
1408	Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view. <b>2012</b> , 7, 1331-6	19
1407	EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. <b>2012</b> , 7, 98-104	76

1406	Outcome in disappearing colorectal cancer liver metastases during oxaliplatin-based chemotherapy. <b>2012</b> , 4, 905-909	12
1405	Structural and Molecular Imaging in Cancer Therapy Clinical Trials. <b>2012</b> , 387-412	
1404	[The role of FDG-PET-CT in the evaluation of primary systemic therapy in breast cancer: links between metabolic and pathological remission]. <b>2012</b> , 153, 1958-64	2
1403	Clinical trial of weekly paclitaxel chemotherapy for papillary thyroid carcinoma with squamous cell carcinoma component. <b>2012</b> , 59, 839-44	9
1402	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. <b>2012</b> , 379, 1893-901	744
1401	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <b>2012</b> , 380, 358-65	2233
1400	TFAP2E-DKK4 and chemoresistance in colorectal cancer. <b>2012</b> , 366, 44-53	133
1399	Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. <b>2012</b> , 23, 2937-2942	167
1398	Increased survival with enzalutamide in prostate cancer after chemotherapy. <b>2012</b> , 367, 1187-97	3075
1397	Identification of docetaxel resistance genes in castration-resistant prostate cancer. <b>2012</b> , 11, 329-39	74
1396	EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. <b>2012</b> , 33, 2061-8	24
1395	Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. <b>2012</b> , 77, 64-9	73
1394	Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer. <b>2012</b> , 84, 1071-7	53
1393	Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. <b>2012</b> , 18, 5796-805	68
1392	Imaging in oncology--over a century of advances. <b>2012</b> , 9, 728-37	18
1391	Mechanistic understanding in clinical practice: complementing evidence-based medicine with personalized medicine. <b>2012</b> , 18, 1000-5	5
1390	Different approaches to volume assessment of lymph nodes in computer tomography scans of head and neck squamous cell carcinoma in comparison with a real gold standard. <b>2012</b> , 82, 737-41	3
1389	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <b>2012</b> , 110, E661-6	47

1388	The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. <b>2012</b> , 17, 1225-39	352
1387	Clinical trial design in the age of molecular profiling. <b>2012</b> , 823, 19-34	2
1386	A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. <b>2012</b> , 18, 3440-51	41
1385	Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. <b>2012</b> , 7, 253-65	44
1384	Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. <b>2012</b> , 366, 707-14	1697
1383	Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. <b>2012</b> , 82, 3-10	87
1382	Imaging in Drug Development. <b>2012</b> , 327-341	
1381	Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. <b>2012</b> , 26, 135-41	36
1380	Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. <b>2012</b> , 30, 2377-83	89
1379	The developing cancer stem-cell model: clinical challenges and opportunities. <b>2012</b> , 13, e83-9	284
1378	Métastases hépatiques colorectales La réponse tumorale: pourquoi et comment l'évaluer ?. <b>2012</b> , 149, S6-S15	
1377	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. <b>2012</b> , 27, 1850-7	35
1376	Advances in molecular imaging for breast cancer detection and characterization. <b>2012</b> , 14, 206	26
1375	The stoichiometric production of IL-2 and IFN- $\gamma$ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. <b>2012</b> , 4, 149a120	47
1374	Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy. <b>2012</b> , 22, 2533-9	45
1373	Workflow-centred evaluation of an automatic lesion tracking software for chemotherapy monitoring by CT. <b>2012</b> , 22, 2759-67	10
1372	Intelligent image retrieval based on radiology reports. <b>2012</b> , 22, 2750-8	20
1371	Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer. <b>2012</b> , 269, 2391-9	3

1370	Intracranial meningeal hemangiopericytoma: 10 years experience of a tertiary care Institute. <b>2012</b> , 154, 1647-51	30
1369	Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC?. <b>2012</b> , 17, 610-5	20
1368	A case of intimal sarcoma of the pulmonary artery successfully treated with chemotherapy. <b>2012</b> , 17, 522-7	16
1367	Weekly low-dose Semustine in a patient with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) coupled with subcutaneous involvement and positive O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation. <b>2012</b> , 11, 544-547	
1366	Observe the efficacy of the air wave pressure therapeutic equipment in treatment of oxaliplatin nerve toxicity. <b>2012</b> , 11, 602-604	1
1365	Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer. <b>2012</b> , 136, 789-94	44
1364	Epigenetics as a therapeutic target in breast cancer. <b>2012</b> , 17, 191-204	91
1363	New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions. <b>2012</b> , 14, 653-66	33
1362	[Tumor necrosis factor $\beta$ and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas]. <b>2012</b> , 90, 114-20	6
1361	Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. <b>2012</b> , 40, 882-891.e1	36
1360	A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. <b>2012</b> , 82, 435-41.e1	79
1359	Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. <b>2012</b> , 82, 889-97	191
1358	Tumor shrinkage assessed by volumetric MRI in long-term follow-up after fractionated stereotactic radiotherapy of nonfunctioning pituitary adenoma. <b>2012</b> , 82, 1262-7	18
1357	Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer. <b>2012</b> , 82, e193-9	48
1356	Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer. <b>2012</b> , 83, 749-55	34
1355	Evaluation of an automatic registration-based algorithm for direct measurement of volume change in tumors. <b>2012</b> , 83, 1038-46	9
1354	Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. <b>2012</b> , 83, e377-83	25
1353	Residual $^{18}$ F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control. <b>2012</b> , 83, e551-5	63

1352	Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. <b>2012</b> , 188, 103-9	40
1351	Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. <b>2012</b> , 102, 45-50	30
1350	Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans. <b>2012</b> , 102, 377-82	18
1349	Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. <b>2012</b> , 102, 335-42	154
1348	The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker. <b>2012</b> , 31, 257-60	6
1347	Diagnostic yield of baseline and follow-up PET/CT studies in ablative therapy for non-small cell lung cancer. <b>2012</b> , 31, 301-7	1
1346	Potential application value of contrast-enhanced ultrasound in neoadjuvant chemotherapy of breast cancer. <b>2012</b> , 38, 2065-71	35
1345	Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. <b>2012</b> , 30, 695-703	19
1344	Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer. <b>2012</b> , 127, 217-22	10
1343	Human epididymis protein 4 (HE4) and ovarian cancer prognosis. <b>2012</b> , 127, 511-5	40
1342	Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. <b>2012</b> , 127, 451-5	34
1341	Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer. <b>2012</b> , 33, 1151-8	15
1340	Exacerbation of diabetic nephropathy mimicking thrombotic microangiopathy during sunitinib treatment for metastatic renal cell carcinoma. <b>2012</b> , 1, 183-189	0
1339	[Postmarketing surveillance study on the use of topotecan in small-cell lung cancer. Use of topotecan in a pneumology university department]. <b>2012</b> , 29, 680-7	
1338	Temporary balloon occlusion of the common hepatic artery for administration of yttrium-90 resin microspheres in a patient with patent hepatoenteric collaterals. <b>2012</b> , 23, 277-80	23
1337	Clinical utility of des- $\alpha$ -carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <b>2012</b> , 23, 927-36	16
1336	Explorative Study on the Predictive and Prognostic Value of Early Complete Metabolic Response By FDG-PET/CT During Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer. <b>2012</b> , 5, 2-9	2
1335	Anti-ovarian antibodies in sera of patients with ovarian tumors. <b>2012</b> , 148, 133-7	4

1334	Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. <b>2012</b> , 11, 297-303	6
1333	MDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: comparison of two-dimensional and volumetric techniques. <b>2012</b> , 19, 48-54	25
1332	Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study. <b>2012</b> , 105, 41-8	16
1331	Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice. <b>2012</b> , 14, 451-62	23
1330	Diagnostic yield of baseline and follow-up PET/CT studies in ablative therapy for non-small cell lung cancer. <b>2012</b> , 31, 301-307	
1329	Research imaging in an academic medical center. <b>2012</b> , 19, 762-71	6
1328	The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: A comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker. <b>2012</b> , 31, 257-260	
1327	Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. <b>2012</b> , 5, 19-25	77
1326	Using the Semantic Web and Web Apps to Connect Radiologists and Oncologists. <b>2012</b> ,	1
1325	Phase I-II study of radiopeptide <sup>177</sup> Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. <b>2012</b> , 27, 561-9	112
1324	High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. <b>2012</b> , 23, 618-624	213
1323	Multiple inguinal and pelvic lymph node metastases of malignant melanoma of the heel identified by common iliac lymphadenopathy. <b>2012</b> , 10, 118-21	1
1322	Neoadjuvant chemotherapy followed by radiotherapy and concurrent hyperthermia in patients with advanced-stage cervical cancer: a retrospective study. <b>2012</b> , 28, 554-61	6
1321	Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports. <b>2012</b> , 30, 712-20	9
1320	On the comparability of medical image measurements in cancer clinical trials. <b>2012</b> ,	
1319	Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. <b>2012</b> , 7, 541-554	33
1318	Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. <b>2012</b> , 28, 597-604	35
1317	Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice. <b>2012</b> , 8, 1193-7	4

1316	A software prototype for the assessment of tumor treatment response using diffusion and perfusion MR imaging. <b>2012</b> , 2012, 388-91	0
1315	Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy. <b>2012</b> , 12 Suppl 1, S217-24	15
1314	Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment. <b>2012</b> , 31 Suppl 1, S3-9	5
1313	Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). <b>2012</b> , 23, 182-186	104
1312	Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. <b>2012</b> , 19, 3002-11	41
1311	Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. <b>2012</b> , 30, 2401-7	192
1310	Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. <b>2012</b> , 51, 575-83	85
1309	Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. <b>2012</b> , 53, 872-80	77
1308	Approach to the patient with advanced differentiated thyroid cancer. <b>2012</b> , 166, 5-11	90
1307	Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. <b>2012</b> , 18, 6758-70	291
1306	Prognostic utility of tumor thickness at the tumor-normal interface in chemotherapy-treated hepatic colorectal metastasis. <b>2012</b> , 208, 235-9	8
1305	Cancer biomarkers: selecting the right drug for the right patient. <b>2012</b> , 11, 201-14	202
1304	Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma. <b>2012</b> , 97, 3046-50	13
1303	Safety evaluation of combination toceranib phosphate (Palladia <sup>®</sup> ) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study. <b>2012</b> , 10, 184-93	29
1302	Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. <b>2012</b> , 14, 162-70	10
1301	Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. <b>2012</b> , 14, 260-8	17
1300	Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy. <b>2012</b> , 14, 298-309	27
1299	Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study. <b>2012</b> , 14, 341-50	21

1298	Outcomes in patients with indeterminate pulmonary nodules undergoing resection for colorectal liver metastases. <b>2012</b> , 14, 448-54		12
1297	The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. <b>2012</b> , 32, 1165-71		13
1296	Why RECIST works and why it should stay--counterpoint. <b>2012</b> , 72, 5151-7; discussion 5158		20
1295	RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point. <b>2012</b> , 72, 5145-9; discussion 5150		61
1294	When progressive disease does not mean treatment failure: reconsidering the criteria for progression. <b>2012</b> , 104, 1534-41		96
1293	Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. <b>2012</b> , 56, 406-11		33
1292	A novel biliary stent loaded with (125)I seeds in patients with malignant biliary obstruction: preliminary results versus a conventional biliary stent. <b>2012</b> , 56, 1104-1111		65
1291	Role of the routine use of chest computed tomography and bone scan in staging workup of hepatocellular carcinoma. <b>2012</b> , 56, 1324-9		12
1290	Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. <b>2012</b> , 56, 1336-42		127
1289	Stereotactic body radiation therapy for nonresectable tumors of the pancreas. <b>2012</b> , 174, 319-25		83
1288	Intérêt de la TEP dans le bilan d'extension et l'évaluation de la maladie résiduelle des tumeurs testiculaires : étude rétrospective. <b>2012</b> , 36, 268-277		
1287	Clinical response to chemotherapy in locally advanced breast cancer was not associated with several polymorphisms in detoxification enzymes and DNA repair genes. <b>2012</b> , 419, 117-9		5
1286	Digital tomosynthesis of the chest: utility for detection of lung metastasis in patients with colorectal cancer. <b>2012</b> , 67, 232-8		36
1285	MRI features of the complete histopathological response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy. <b>2012</b> , 67, 546-52		21
1284	Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. <b>2012</b> , 38, 63-7		22
1283	The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 202-8	7.5	148
1282	Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 1495-502	7.5	15
1281	[(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 416-24	7.5	72

1280	Radiomics: extracting more information from medical images using advanced feature analysis. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 441-6	7.5	2278
1279	Qualification of imaging biomarkers for oncology drug development. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 409-15	7.5	61
1278	Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 1332-40	7.5	17
1277	Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 1512-8	7.5	30
1276	Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 1031-7	7.5	43
1275	Circulating tumour cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 3019-26	7.5	77
1274	Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 3027-35	7.5	94
1273	Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 2293-9	7.5	21
1272	Perfusion Computed Tomography (PCT) adopting different perfusion metrics: recurrence of brain metastasis or radiation necrosis?. <b>2012</b> , 81, 1246-52		10
1271	Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. <b>2012</b> , 81, 1173-8		70
1270	Assessment of colorectal hepatic metastases by quantitative T2 relaxation time. <b>2012</b> , 81, e536-40		5
1269	The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. <b>2012</b> , 38, 64-71		53
1268	The current status of S-100B as a biomarker in melanoma. <b>2012</b> , 38, 281-5		38
1267	Application of a stochastic model to response assessments in a study of squamous cell carcinoma of the head and neck. <b>2012</b> , 11, 462-7		
1266	Estimation of secondary endpoints in two-stage phase II oncology trials. <b>2012</b> , 31, 4352-68		2
1265	Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. <b>2012</b> , 12, 127		9
1264	A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. <b>2012</b> , 12, 108		5
1263	A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). <b>2012</b> , 12, 307		12

1262	Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. <b>2012</b> , 12, 356	19
1261	Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. <b>2012</b> , 12, 361	29
1260	Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). <b>2012</b> , 12, 483	9
1259	Fractionated radiosurgery for painful spinal metastases: DOSIS - a phase II trial. <b>2012</b> , 12, 530	15
1258	Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis. <b>2012</b> , 12, 609	11
1257	Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study. <b>2012</b> , 10, 41	29
1256	The immuno-oncology framework: Enabling a new era of cancer therapy. <b>2012</b> , 1, 334-339	32
1255	Nanoprobes for hybrid SPECT/MR molecular imaging. <b>2012</b> , 7, 719-33	20
1254	Neuroblastoma: the impact of biology and cooperation leading to personalized treatments. <b>2012</b> , 49, 85-115	32
1253	Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy. <b>2012</b> , 82, 298-304	20
1252	Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer. <b>2012</b> , 3, 363-368	4
1251	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <b>2012</b> , 23, 1207-1213	36
1250	PET for Measuring Therapy Response After Radionuclide Therapy. <b>2012</b> , 917-929	
1249	Hepatic manifestations of tuberous sclerosis complex: a genotypic and phenotypic analysis. <b>2012</b> , 82, 552-7	21
1248	Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib. <b>2012</b> , 16, 2010-6	26
1247	A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer. <b>2012</b> , 16, 2342-9	21
1246	Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: A retrospective clinical study. <b>2012</b> , 3, 341-347	20
1245	Crizotinib: in locally advanced or metastatic non-small cell lung cancer. <b>2012</b> , 72, 99-107	32

1244	Pharmacotherapy options for advanced thyroid cancer: a systematic review. <b>2012</b> , 72, 67-85	4
1243	Management of metastatic castration-resistant prostate cancer: recent advances. <b>2012</b> , 72, 1011-28	28
1242	Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. <b>2012</b> , 11, 195-9	22
1241	Tumor burden analysis on computed tomography by automated liver and tumor segmentation. <b>2012</b> , 31, 1965-76	77
1240	Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era. <b>2012</b> , 11, 287-302	6
1239	Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors. <b>2012</b> , 91, 1785-93	47
1238	Immunotherapy for castration-resistant prostate cancer. <b>2012</b> , 39, 465-81	6
1237	RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. <b>2012</b> , 39, 677-84	37
1236	Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. <b>2012</b> , 7, 723-43	25
1235	Introduction to Regulated Clinical Trials. <b>2012</b> , 17-50	1
1234	EORTC Imaging Group. <b>2012</b> , 10, 82-87	2
1233	Measuring the response to selective internal radiation therapy. <b>2012</b> , 10, 57-58	
1232	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. <b>2012</b> , 13, 810-6	119
1231	Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. <b>2012</b> , 13, 1025-34	110
1230	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <b>2012</b> , 13, 1087-95	708
1229	Improving outcomes for elderly patients with AML. <b>2012</b> , 13, 1065-6	4
1228	The limitations of imaging response criteria. <b>2012</b> , 13, 1064-5	1
1227	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. <b>2012</b> , 13, 1133-40	409

1226	Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy. <b>2012</b> , 14, 546-9	9
1225	Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma. <b>2012</b> , 204, 580-5	28
1224	Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. <b>2012</b> , 21, 669-77	141
1223	Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAB) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. <b>2012</b> , 13, 500-4	72
1222	Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidence. <b>2012</b> , 83, 208-15	11
1221	Integration of cell biology, pharmacological modeling and statistical analysis: part I: cell biology and PK/PD in the Oncology paradigm. <b>2012</b> , 83, 153-69	1
1220	Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use?. <b>2012</b> , 83, 194-207	52
1219	Comprehensive treatment of malignant mesothelioma patients after the failure of systemic chemotherapy. <b>2012</b> , 65, 284-8	7
1218	Percutaneous ultrasonography and computed tomography guided pancreatic cryoablation: feasibility and safety assessment. <b>2012</b> , 65, 301-7	19
1217	Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. <b>2012</b> , 38, 662-72	14
1216	The role of imaging in staging and monitoring testicular cancer. <b>2012</b> , 93, 310-8	27
1215	Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. <b>2012</b> , 44, 432-7	47
1214	Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 3240-8	7.5 64
1213	CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement. <b>2012</b> , 81, 2717-25	32
1212	Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy. <b>2012</b> , 81, 2627-31	15
1211	Semi-automatic software increases CT measurement accuracy but not response classification of colorectal liver metastases after chemotherapy. <b>2012</b> , 81, 2543-9	11
1210	Intermodality comparison between 3D perfusion CT and 18F-FDG PET/CT imaging for predicting early tumor response in patients with liver metastasis after chemotherapy: preliminary results of a prospective study. <b>2012</b> , 81, 3542-50	16
1209	Clinical lymph node staging--influence of slice thickness and reconstruction kernel on volumetry and RECIST measurements. <b>2012</b> , 81, 3124-30	7

1208	Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. <b>2012</b> , 130, 894-900	14
1207	The value of tumor diameter in predicting prognosis of oropharynx cancer treated with chemoradiation. <b>2012</b> , 48, 876-80	2
1206	Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment. <b>2012</b> , 48, 787-93	33
1205	Safety and long term efficacy of porfimer sodium photodynamic therapy in locally advanced biliary tract carcinoma. <b>2012</b> , 9, 287-92	17
1204	Role of imaging techniques in the TNM classification of non-small cell bronchogenic carcinoma. <b>2012</b> , 54, 306-320	
1203	Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?. <b>2012</b> , 188, 1108-13	33
1202	Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients. <b>2012</b> , 75, 213-6	6
1201	Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. <b>2012</b> , 76, 439-44	23
1200	Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. <b>2012</b> , 77, 121-7	60
1199	Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group. <b>2012</b> , 77, 146-50	29
1198	Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients. <b>2012</b> , 77, 427-32	10
1197	EGFR mutations as a predictive marker of cytotoxic chemotherapy. <b>2012</b> , 77, 433-7	19
1196	Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. <b>2012</b> , 78, 76-80	49
1195	PET-MRI in oncology. <b>2012</b> , 36, 459-461	
1194	Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design. <b>2012</b> , 6, 196-203	22
1193	Microcirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer. <b>2012</b> , 30, 1059-67	2
1192	3D Slicer as an image computing platform for the Quantitative Imaging Network. <b>2012</b> , 30, 1323-41	2965
1191	Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis. <b>2012</b> , 30, 1268-78	27

1190	Simultaneous PET-MRI in oncology: a solution looking for a problem?. <b>2012</b> , 30, 1342-56	59
1189	Promise and pitfalls of quantitative imaging in oncology clinical trials. <b>2012</b> , 30, 1301-12	62
1188	The clinical evaluation of novel imaging methods for cancer management. <b>2012</b> , 9, 738-44	15
1187	Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. <b>2012</b> , 12, 1137-47	41
1186	MRI in ovarian cancer. <b>2012</b> , 4, 59-75	8
1185	Response to Treatment: The Role of Imaging. <b>2012</b> , 15-37	2
1184	[Role of imaging techniques in the TNM classification of non-small cell bronchogenic carcinoma]. <b>2012</b> , 54, 306-20	0
1183	Ovarian carcinomatosis: how the radiologist can help plan the surgical approach. <b>2012</b> , 32, 1775-800; discussion 1800-3	79
1182	Radiology: criteria for determining response to treatment and recurrence of high-grade gliomas. <b>2012</b> , 23, 269-76, viii	3
1181	GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. <b>2012</b> , 29, 1421-8	29
1180	Baseline and decline of serum ADAM28 during chemotherapy of advanced non-small cell lung cancer: a probable predictive and prognostic factor. <b>2012</b> , 29, 2633-9	8
1179	A phase II trial of temsirolimus in second-line metastatic urothelial cancer. <b>2012</b> , 29, 2870-6	36
1178	Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. <b>2012</b> , 29, 3291-7	34
1177	Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. <b>2012</b> , 29, 3101-7	17
1176	Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. <b>2012</b> , 29, 3029-34	17
1175	The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience. <b>2012</b> , 14, 835-41	4
1174	Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization. <b>2012</b> , 23, 1629-37	84
1173	Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. <b>2012</b> , 22, 310-7	52

1172	Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients. <b>2012</b> , 106, 1790-7	52
1171	Inverse-planned gynecologic high-dose-rate interstitial brachytherapy: clinical outcomes and dose--volume histogram analysis. <b>2012</b> , 11, 181-91	26
1170	A Multidisciplinary Approach to Cancer. <b>2012</b> , 1-6	
1169	Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. <b>2012</b> , 199, 252-62	130
1168	Radiological Imaging in Metastatic Bone Disease and Myeloma: Current Status and Limitations. <b>2012</b> , 173-194	
1167	Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. <b>2012</b> , 39, 1858-67	22
1166	The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria. <b>2012</b> , 39, 1391-9	74
1165	Standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases. <b>2012</b> , 39, 1441-8	19
1164	Optimizing the role of FDG PET-CT for potentially operable metastatic colorectal cancer. <b>2012</b> , 37, 1021-31	11
1163	Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. <b>2012</b> , 35, 1363-71	38
1162	Irreversible electroporation for focal ablation at the porta hepatis. <b>2012</b> , 35, 1531-4	19
1161	The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. <b>2012</b> , 70, 539-46	3
1160	A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. <b>2012</b> , 70, 583-90	5
1159	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. <b>2012</b> , 70, 399-405	212
1158	Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis. <b>2012</b> , 70, 451-9	8
1157	Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. <b>2013</b> , 23, 632-9	27
1156	Bone Metastases. <b>2012</b> , 591-609	2
1155	Assessing Response to Therapy. <b>2012</b> , 25-33	

1154 Lung Cancer. **2012**, 35-61

1153 Melanoma. **2012**, 633-652

1152 Extraskeletal myxoid chondrosarcoma: a review of 23 patients treated at a single referral center with long-term follow-up. **2012**, 132, 1379-86 32

1151 Management of non-small cell lung in cancer patients with stable disease. **2012**, 72 Suppl 1, 20-7 4

1150 Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma. **2012**, 29, 3298-305 20

1149 Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status. **2012**, 47, 296-314 49

1148 Thyroid Cancer. **2012**, 5

1147 Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review. **2012**, 4, 995-1009 7

1146 Follow-up CT and MR findings of osteoblastic spinal metastatic lesions after stereotactic radiotherapy. **2012**, 30, 492-8 3

1145 An algorithm for longitudinal registration of PET/CT images acquired during neoadjuvant chemotherapy in breast cancer: preliminary results. **2012**, 2, 62 10

1144 Her2-enriched breast cancer brain metastases exhibit resistance to Gamma Knife radiosurgery: findings from a single institutional series review. **2012**, 1, 283-290 1

1143 Imaging in Clinical Trials. **2012**, 597-617

1142 What inference for two-stage phase II trials?. **2012**, 12, 117 13

1141 Semi-automatic analysis of standard uptake values in serial PET/CT studies in patients with lung cancer and lymphoma. **2012**, 12, 6 1

1140 R le de l'imagerie dans le bilan d'extension et la surveillance du cancer du testicule. **2012**, 93, 334-343

1139 Systematic pelvic and aortic lymphadenectomy in advanced ovarian cancer patients at the time of interval debulking surgery: a double-institution case-control study. **2012**, 19, 3522-7 28

1138 Dabrafenib and its potential for the treatment of metastatic melanoma. **2012**, 6, 391-405 70

1137 Design considerations for using PET as a response measure in single site and multicenter clinical trials. **2012**, 19, 184-90 23

1136	EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. <b>2012</b> , 7, 181	49
1135	Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors. <b>2012</b> , 7, 148	13
1134	Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. <b>2012</b> , 7, 67	76
1133	Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer. <b>2012</b> , 7, e41380	31
1132	Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. <b>2012</b> , 7, e29794	163
1131	Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. <b>2012</b> , 4, 341-5	17
1130	Vinorelbine-Based Chemo-Radiotherapy in Non-Small Cell Lung Cancer. <b>2012</b> , 98, 464-470	2
1129	Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. <b>2012</b> , 41, 611-20	15
1128	Response to Concurrent Chemoradiotherapy as a Prognostic Marker in Elderly Patients with Locally Advanced Esophageal Cancer. <b>2012</b> , 98, 225-232	3
1127	Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. <b>2012</b> , 12, 126-35	55
1126	Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. <b>2012</b> , 13, 371-90	56
1125	Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma. <b>2012</b> , 2, 459-71	24
1124	Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumours. <b>2012</b> , 12, 497-505	21
1123	Stereotactic body radiation therapy for liver metastases from colorectal cancer: analysis of safety, feasibility, and early outcomes. <b>2012</b> , 2, 8	24
1122	A gist of gastrointestinal stromal tumors: A review. <b>2013</b> , 5, 102-12	104
1121	[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France]. <b>2012</b> , 99, 609-18	6
1120	In Vivo Imaging of Apoptosis in Cancer: Potentials and Drawbacks of Molecular Probes. <b>2012</b> , 1, 55-62	3
1119	Assessment of quantitative perfusion parameters by dynamic contrast-enhanced sonography using a deconvolution method: an in vitro and in vivo study. <b>2012</b> , 31, 595-608	27

1118 Resection for Colorectal Liver Metastases. **2012**,

1117 New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma. **2012**,

1116 Cetuximab alleviates neuropathic pain despite tumour progression. **2012**, 2012, 26

1115 Oral vinorelbine: a Better Choice for Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer. **2012**, 2, 2

1114 The Role of Mutation Status of the Epidermal Growth Factor Receptor Gene In Advanced NonSmall Cell Lung Cancer. **2012**, 48, 25 1

1113 Imaging paradigms in assessment of rectal carcinoma: loco-regional and distant staging. **2012**, 12, 290-303 10

1112 Single nucleotide polymorphisms in NOS2A and NOS3 genes are not associated with treatment response of non-small cell lung cancer patients following the definitive radiochemotherapy. **2012**, 59, 631-40 1

1111 Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma. **2013**, 60, 83-91 3

1110 [The effect of metformin on responses to chemotherapy and survival in stage IV colorectal cancer with diabetes]. **2012**, 60, 355-61 14

1109 Hepatocellular carcinoma: initial tumour response after short-term and long-interval chemoembolization with drug-eluting beads using modified RECIST. **2012**, 24, 1325-32 13

1108 High dose involved field radiation therapy as salvage for loco-regional recurrence of non-small cell lung cancer. **2012**, 53, 1120-7 15

1107 Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?. **2012**, 13, 702-10 49

1106 Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. **2012**, 53, 352-7 46

1105 Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer. **2012**, 3, 66-71 5

1104 Evaluation of therapeutic effect of tumor-targeted therapy. **2012**, 5, 191-8

1103 Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer. **2012**, 12, 212-24 7

1102 New ways of assessing ovarian cancer response: metabolic imaging and beyond. **2012**, 12, 310-4 10

1101 Multiparametric PET/CT in oncology. **2012**, 12, 336-44 22

1100	RECIST rules. <b>2012</b> , 12, 345-6	25
1099	Imaging beyond RECIST: CT and MRI in molecular therapies. <b>2012</b> , 12, 347-50	12
1098	Cetuximab in refractory skin cancer treatment. <b>2012</b> , 3, 257-61	41
1097	Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report. <b>2012</b> , 6, 38	11
1096	Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. <b>2012</b> , 2, 2	41
1095	Attenuation of treatment effect due to measurement variability in assessment of progression-free survival. <b>2012</b> , 11, 394-402	7
1094	Overcoming resistance of cancer stem cells. <b>2012</b> , 13, e187-8	24
1093	High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. <b>2012</b> , 18, 1374-85	131
1092	recurrence following hepatectomy for metastatic colorectal cancer: development of a model that predicts patterns of recurrence and survival. <b>2012</b> , 19, 139-44	32
1091	Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. <b>2012</b> , 106, 1722-7	194
1090	$\beta$ -tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer. <b>2012</b> , 107, 823-30	27
1089	Tumor response assessments with diffusion and perfusion MRI. <b>2012</b> , 35, 745-63	131
1088	Optimizing the functional diffusion map using Monte Carlo simulations. <b>2012</b> , 36, 1002-9	2
1087	Peri-operative chemotherapy for resectable colorectal liver metastasis: does timing of systemic therapy matter?. <b>2012</b> , 105, 511-9	20
1086	A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer. <b>2012</b> , 105, 577-85	17
1085	Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer. <b>2012</b> , 34, 1634-9	1
1084	Correspondence. <b>2012</b> , 56, 787-787	
1083	Early diagnosis of hepatocellular carcinoma: it's not a matter of opinion. <b>2012</b> , 56, 787; author reply 787	

1082	Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for progressive liver histology and cardiovascular risk in nonalcoholic fatty liver disease. <b>2012</b> , 56, 788-9	22
1081	Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. <b>2012</b> , 4, 128ra39	866
1080	Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. <b>2012</b> , 17, 321	88
1079	Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic adenocarcinoma following neoadjuvant therapy. <b>2012</b> , 16, 1152-9	64
1078	KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. <b>2012</b> , 107, 626-31	22
1077	Mechanisms of resistance to vascular endothelial growth factor blockade. <b>2012</b> , 118, 3455-67	56
1076	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. <b>2012</b> , 118, 3330-6	97
1075	3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. <b>2012</b> , 118, 3135-44	37
1074	Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. <b>2012</b> , 118, 5358-65	12
1073	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <b>2012</b> , 118, 5857-66	73
1072	Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. <b>2012</b> , 118, 5749-56	375
1071	Improved survival with MEK inhibition in BRAF-mutated melanoma. <b>2012</b> , 367, 107-14	1634
1070	Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome. <b>2012</b> , 82, 168-74	13
1069	Neo adjuvant treatment with targeted molecules for renal cell cancer in current clinical practise. <b>2012</b> , 3, 114-9	3
1068	Stereotactic body radiotherapy for adrenal metastases from lung cancer. <b>2012</b> , 1, 155-163	24
1067	CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. <b>2012</b> , 134, 401-10	71
1066	Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. <b>2012</b> , 30, 1628-40	66
1065	Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. <b>2012</b> , 7, 127-33	40

1064	Irinotecan drug-eluting beads in the treatment of chemo-naïve unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. <b>2012</b> , 16, 1531-8	65
1063	Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers. <b>2012</b> , 26, 426-35	19
1062	Assessment of pituitary adenoma volumetric change using longitudinal MR image registration. <b>2012</b> , 54, 435-43	5
1061	Functional imaging techniques in hepatocellular carcinoma. <b>2012</b> , 39, 1070-9	13
1060	Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. <b>2012</b> , 39, 1107-16	29
1059	Colorectal cancer: prognostic role of 18F-FDG-PET/CT. <b>2012</b> , 37, 575-9	19
1058	Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy. <b>2012</b> , 61, 725-32	25
1057	Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). <b>2012</b> , 69, 1181-8	9
1056	Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer. <b>2012</b> , 69, 1529-36	5
1055	FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. <b>2012</b> , 69, 1641-5	68
1054	The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. <b>2012</b> , 27, 715-20	42
1053	An essential dose of cisplatin for super-selective intra-arterial infusion concomitant with radiotherapy in patient with maxillary squamous cell carcinoma. <b>2012</b> , 269, 1985-91	2
1052	Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival. <b>2012</b> , 461, 33-9	20
1051	Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. <b>2012</b> , 138, 687-93	19
1050	Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors. <b>2012</b> , 26, 2288-98	15
1049	Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. <b>2012</b> , 15, 154-61	93
1048	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. <b>2012</b> , 16, 464-7	25
1047	Quantified visual scoring of metastatic melanoma patient treatment response using computed tomography: improving on the current standard. <b>2012</b> , 25, 258-65	1

1046	The clinical research of elemene emulsion combined with FOLFOX4 regimen in the treatment of advanced gastric carcinoma. <b>2012</b> , 11, 336-339	1
1045	First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. <b>2012</b> , 103, 150-3	47
1044	Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer. <b>2012</b> , 12, 151-6	7
1043	Diffusion-weighted magnetic resonance imaging of lung cancer at 3.0 T: a preliminary study on monitoring diffusion changes during chemoradiation therapy. <b>2012</b> , 36, 98-103	31
1042	Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?. <b>2012</b> , 36, 360-4	7
1041	The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy. <b>2012</b> , 13, 59-67	2
1040	Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib + megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. <b>2012</b> , 31, 176-82	89
1039	Automating the tracking of lymph nodes in follow-up studies of thoracic CT images. <b>2012</b> , 106, 150-9	4
1038	The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. <b>2012</b> , 61, 639-47	24
1037	Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?. <b>2012</b> , 61, 307-16	43
1036	Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. <b>2012</b> , 61, 1132-8	95
1035	Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?. <b>2012</b> , 62, 68-75	212
1034	Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system. <b>2012</b> , 33, 2701-9	28
1033	Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. <b>2012</b> , 21, 40-5	11
1032	Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer. <b>2012</b> , 21, 556-61	13
1031	Strategies to use immune modulators in therapeutic vaccines against cancer. <b>2012</b> , 39, 348-57	28
1030	Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). <b>2012</b> , 271, 366-78	39
1029	Comparison of abdominal computed tomography and abdominal ultrasound in sedated dogs. <b>2012</b> , 53, 513-7	30

1028	Asian Oceanian Congress of Radiology 2012 and The Royal Australian and New Zealand College of Radiologists 63rd Annual Scientific Meeting. <b>2012</b> , 56, 78-162	
1027	Anti-angiogenic therapy: concept to clinic. <b>2012</b> , 19, 115-25	27
1026	Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer. <b>2012</b> , 3, 19-26	1
1025	Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon- $\beta$ for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. <b>2012</b> , 42, 442-53	21
1024	Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. <b>2012</b> , 42, 879-86	74
1023	A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs. <b>2012</b> , 26, 598-607	31
1022	Cancer stem cells as a predictive factor in radiotherapy. <b>2012</b> , 22, 151-74	74
1021	Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?. <b>2012</b> , 75, 1276-83	24
1020	Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma. <b>2012</b> , 75, 1577-89	16
1019	Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. <b>2012</b> , 75, 2745-52	28
1018	Mediastinal atlas creation from 3-D chest computed tomography images: application to automated detection and station mapping of lymph nodes. <b>2012</b> , 16, 63-74	33
1017	Prognostic studies of canine and feline mammary tumours: the need for standardized procedures. <b>2012</b> , 193, 24-31	58
1016	In vitro evaluation of the impact of ultrasound scanner settings and contrast bolus volume on time-intensity curves. <b>2012</b> , 52, 12-9	18
1015	A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. <b>2012</b> , 125, 367-71	68
1014	Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. <b>2012</b> , 125, 661-6	117
1013	FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread. <b>2012</b> , 126, 64-8	64
1012	Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer. <b>2012</b> , 103, 1065-70	16
1011	The use of tumour volumetrics to assess response to therapy in anticancer clinical trials. <b>2012</b> , 73, 846-54	24

1010	Malignancy-associated chylothorax: a 20-year study of 18 patients from a single institution. <b>2012</b> , 21, 599-605	17
1009	Tumor-Cut: segmentation of brain tumors on contrast enhanced MR images for radiosurgery applications. <b>2012</b> , 31, 790-804	153
1008	Impact of neoadjuvant transarterial chemoembolization on tumor recurrence and patient survival after liver transplantation for hepatocellular carcinoma: a retrospective analysis. <b>2012</b> , 26, 764-74	31
1007	Clinical features and outcomes of primary hepatic neuroendocrine carcinomas. <b>2012</b> , 27, 1306-11	59
1006	Clinical significance of carcinoembryonic antigen-, cytokeratin 19-, or survivin-positive circulating tumor cells in the peripheral blood of esophageal squamous cell carcinoma patients treated with radiotherapy. <b>2012</b> , 25, 750-6	22
1005	Sorafenib rechallenge in patients with metastatic renal cell carcinoma. <b>2012</b> , 110, E228-34	29
1004	Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care. <b>2012</b> , 110, 1289-300	10
1003	The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. <b>2012</b> , 110, E575-82	27
1002	Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. <b>2012</b> , 110, E628-34	55
1001	Neck control after definitive radiochemotherapy without planned neck dissection in node-positive head and neck cancers. <b>2012</b> , 12, 59	5
1000	Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment. <b>2012</b> , 2, 5	25
999	Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. <b>2012</b> , 14, R29	62
998	Reirradiation and hyperthermia for radiation-associated sarcoma. <b>2012</b> , 118, 180-7	36
997	Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. <b>2012</b> , 118, 147-56	217
996	Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. <b>2012</b> , 118, 1422-8	65
995	The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. <b>2012</b> , 105, 206-11	18
994	Oncologic applications of diffusion-weighted MRI in the body. <b>2012</b> , 35, 257-79	92
993	Evaluation of treatment response in patients with metastatic renal cell carcinoma: role of state-of-the-art cross-sectional imaging. <b>2012</b> , 13, 70-81	9

992	Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma. <b>2012</b> , 30, 62-8	12
991	Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. <b>2012</b> , 41, 40-52	54
990	Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor. <b>2012</b> , 29, 185-92	6
989	Retrocral Lymph Node Metastasis Disclosed by (18)F-FDG PET/CT: A Predictor of Supra-diaphragmatic Spread in Ovarian Cancer. <b>2012</b> , 46, 41-7	5
988	Image-guided drug delivery in lung cancer. <b>2012</b> , 2, 31-44	2
987	Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy. <b>2012</b> , 16, 320-4	26
986	A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). <b>2012</b> , 69, 115-23	42
985	Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). <b>2012</b> , 69, 351-6	7
984	A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. <b>2012</b> , 69, 415-24	33
983	A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. <b>2012</b> , 69, 743-51	31
982	Incremental increase in VEGFR1+ hematopoietic progenitor cells and VEGFR2+ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. <b>2012</b> , 132, 235-42	28
981	Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI. <b>2012</b> , 29, 51-62	30
980	Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. <b>2012</b> , 30, 758-64	13
979	Progression of the lung cancer primary correlates with the identification of new brain metastases after initial radiosurgery. <b>2012</b> , 106, 161-7	3
978	Phase I trial of dose escalation of capecitabine combined with fixed docetaxel in previously treated patients with non-small cell lung cancer. <b>2012</b> , 11, 6-10	3
977	Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. <b>2013</b> , 41, 417-24	30
976	Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer. <b>2013</b> , 69, 1721-34	21
975	Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography. <b>2013</b> , 26, 185-92	27

974	External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. <b>2013</b> , 73, 211-8	45
973	Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors. <b>2013</b> , 11, 166	17
972	Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy. <b>2013</b> , 11, 112	50
971	Surgical decompression improves recovery from neurological deficit and may provide a survival benefit in patients with diffuse large B-cell lymphoma-associated spinal cord compression: a case-series study. <b>2013</b> , 11, 90	15
970	High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. <b>2013</b> , 11, 41	35
969	Late tumor pseudoprogression followed by complete remission after lung stereotactic ablative radiotherapy. <b>2013</b> , 8, 167	10
968	SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. <b>2013</b> , 8, 148	68
967	Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. <b>2013</b> , 8, 44	77
966	CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. <b>2013</b> , 6, 14	19
965	A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatic HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. <b>2013</b> , 14, 228	29
964	Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs. <b>2013</b> , 6, 139	18
963	ESR statement on the stepwise development of imaging biomarkers. <b>2013</b> , 4, 147-52	33
962	Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies. <b>2013</b> , 98, E1567-74	11
961	Abstracts of the American Conference on Pharmacometrics 2013. May 12-15, 2013. Fort Lauderdale, Florida, USA. <b>2013</b> , 40 Suppl 1, 15-149	2
960	Quantification of 99mTc-DPD concentration in the lumbar spine with SPECT/CT. <b>2013</b> , 3, 45	73
959	The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. <b>2013</b> , 3, 7	62
958	Clinical and prognostic significance of coagulation assays in gastric cancer. <b>2013</b> , 44, 285-92	12
957	Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. <b>2013</b> , 119, 3761-8	37

956	Characterization and therapy monitoring of head and neck carcinomas using diffusion-imaging-based intravoxel incoherent motion parameters-preliminary results. <b>2013</b> , 55, 527-36	64
955	Management of Lung Cancer in Older People. <b>2013</b> ,	
954	Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. <b>2013</b> , 201, 80-96	62
953	Multidisciplinary Treatment of Hepatocellular Carcinoma. <b>2013</b> ,	2
952	Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. <b>2013</b> , 58, 2023-31	162
951	Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. <b>2013</b> , 28, 1834-41	16
950	A radiologist's guide to treatment response criteria in oncologic imaging: anatomic imaging biomarkers. <b>2013</b> , 201, 237-45	14
949	A radiologist's guide to treatment response criteria in oncologic imaging: functional, molecular, and disease-specific imaging biomarkers. <b>2013</b> , 201, 246-56	14
948	The shifting landscape of metastatic breast cancer to the CNS. <b>2013</b> , 36, 377-82	24
947	Imaging tumor angiogenesis: the road to clinical utility. <b>2013</b> , 201, W183-91	48
946	Microwave ablation of liver metastases to overcome the limitations of radiofrequency ablation. <b>2013</b> , 118, 949-61	47
945	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. <b>2013</b> , 14, 901-8	389
944	Imaging tumor response following liver-directed intra-arterial therapy. <b>2013</b> , 38, 1286-99	25
943	Cell mates: paracrine and stromal targets for prostate cancer therapy. <b>2013</b> , 10, 441-51	28
942	Review of current thermal ablation treatment for lung cancer and the potential of electrochemotherapy as a means for treatment of lung tumours. <b>2013</b> , 39, 862-71	48
941	Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. <b>2013</b> , 13, 279	203
940	Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study. <b>2013</b> , 13, 254	37
939	Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. <b>2013</b> , 13, 239	13

938	Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients. <b>2013</b> , 13, 232	11
937	Evaluation of hypoxia in a feline model of head and neck cancer using $^{64}\text{Cu}$ -ATSM positron emission tomography/computed tomography. <b>2013</b> , 13, 218	14
936	Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. <b>2013</b> , 13, 190	7
935	[ $^{18}\text{F}$ ]FDG and [ $^{18}\text{F}$ ]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. <b>2013</b> , 13, 168	20
934	Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. <b>2013</b> , 13, 78	77
933	A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. <b>2013</b> , 13, 67	37
932	Encyclopedia of Radiation Oncology. <b>2013</b> , 355-364	
931	Intra-arterial radioembolization of breast cancer liver metastases: a structured review. <b>2013</b> , 709, 37-42	20
930	Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy. <b>2013</b> , 40, 668-76	26
929	Staging of colorectal liver metastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy. <b>2013</b> , 23, 739-47	40
928	Laparoscopic versus open radical hysterectomy for stage IB2-IIIB cervical cancer in the setting of neoadjuvant chemotherapy: a multi-institutional cohort study. <b>2013</b> , 20, 2007-15	34
927	Special session on validating new procedures. <b>2013</b> , 8, 209-212	
926	Prognostic role of E-cadherin in patients with advanced serous ovarian cancer. <b>2013</b> , 287, 1219-24	11
925	Neoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm?. <b>2013</b> , 15, 162-9	10
924	Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. <b>2013</b> , CD009256	44
923	Survival and failure outcomes in locally advanced esthesioneuroblastoma: a single centre experience of 15 patients. <b>2013</b> , 270, 1897-901	9
922	Can a less radical surgery using photodynamic therapy with acridine orange be equal to a wide-margin resection?. <b>2013</b> , 471, 792-802	14
921	Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. <b>2013</b> , 44, 313-7	9

920	Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma. <b>2013</b> , 7, 703-13	4
919	Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases. <b>2013</b> , 15, 484-91	11
918	Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. <b>2013</b> , 462, 547-56	11
917	Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. <b>2013</b> , 139, 981-6	5
916	A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. <b>2013</b> , 139, 367-78	24
915	WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial. <b>2013</b> , 139, 457-63	27
914	Irreversible Electroporation: a Novel Option for Treatment of Hepatic Metastases. <b>2013</b> , 9, 191-197	9
913	Non-size-based response criteria to preoperative chemotherapy in patients with colorectal liver metastases: the morphologic response criteria. <b>2013</b> , 9, 198-202	16
912	Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. <b>2013</b> , 13, 347	93
911	Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma. <b>2013</b> , 27, 839-46	24
910	Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. <b>2013</b> , 27, 802-7	35
909	Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy. <b>2013</b> , 27, 748-55	20
908	Effect of censoring due to progressive disease on tumor size kinetic parameter estimates. <b>2013</b> , 15, 832-9	4
907	Early evaluation of neoadjuvant chemotherapy response using FDG-PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma. <b>2013</b> , 18, 402-10	38
906	[Rational imaging of metastasized tumor diseases]. <b>2013</b> , 54, 803-9	
905	Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs. <b>2013</b> , 30, 1047-62	47
904	Volumetric changes after (90)Y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?. <b>2013</b> , 20, 2518-25	64
903	Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients. <b>2013</b> , 16, 324-8	13

902	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <b>2013</b> , 31, 1182-91	45
901	Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors. <b>2013</b> , 31, 959-66	21
900	A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. <b>2013</b> , 31, 974-85	24
899	A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. <b>2013</b> , 31, 1016-22	38
898	Imaging breast cancer bone metastases: current status and future directions. <b>2013</b> , 43, 317-23	21
897	Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. <b>2013</b> , 109, 926-33	208
896	Cancer Immunotherapy. <b>2013</b> ,	1
895	Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer. <b>2013</b> , 40, 832-41	10
894	Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study. <b>2013</b> , 40, 80-90	33
893	Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. <b>2013</b> , 62, 1499-509	169
892	Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. <b>2013</b> , 62, 471-9	121
891	Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer. <b>2013</b> , 37, 169-78	60
890	Radiofrequency ablation of liver tumors in combination with local OK-432 injection prolongs survival and suppresses distant tumor growth in the rabbit model with intra- and extrahepatic VX2 tumors. <b>2013</b> , 36, 1383-92	9
889	Transcatheter arterial embolization with spherical embolic agent for pulmonary metastases from renal cell carcinoma. <b>2013</b> , 36, 1527-1535	18
888	Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma. <b>2013</b> , 72, 231-40	16
887	A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder. <b>2013</b> , 72, 263-7	6
886	Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases. <b>2013</b> , 71, 1493-8	3
885	Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. <b>2013</b> , 71, 1183-90	28

884	Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination. <b>2013</b> , 71, 937-43	7
883	Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation. <b>2013</b> , 71, 705-11	6
882	Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma. <b>2013</b> , 71, 399-404	5
881	Erlotinib in patients with advanced lung squamous cell carcinoma. <b>2013</b> , 71, 203-8	6
880	Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy. <b>2013</b> , 23, 3450-5	89
879	Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation. <b>2013</b> , 23, 805-15	9
878	Analysis of the layering pattern of the apparent diffusion coefficient (ADC) for differentiation of radiation necrosis from tumour progression. <b>2013</b> , 23, 879-86	32
877	Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature. <b>2013</b> , 45, 1017-21	9
876	Summary report of the First International Workshop on PET/MR imaging, March 19-23, 2012, Tübingen, Germany. <b>2013</b> , 15, 361-71	29
875	Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer. <b>2013</b> , 28, 527-35	30
874	PET/CT in Oncology: Current Status and Perspectives. <b>2013</b> , 1, 177-190	53
873	Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. <b>2013</b> , 52, 593-609	64
872	Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites. <b>2013</b> , 9, 419-26	7
871	[ <sup>18</sup> F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging in oncology: initial staging and evaluation of cancer therapy. <b>2013</b> , 22, 427-37	23
870	Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. <b>2013</b> , 109, 1230-42	34
869	Cancer concepts and principles: primer for the interventional oncologist-part I. <b>2013</b> , 24, 1157-64	17
868	Drug rechallenge and treatment beyond progression—implications for drug resistance. <b>2013</b> , 10, 571-87	174
867	Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case. <b>2013</b> , 43, 556-61	16

866	CyberKnife robotic image-guided stereotactic radiotherapy for oligometastatic cancer : A prospective evaluation of 95 patients/118 lesions. <b>2013</b> , 189, 448-55	19
865	Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer. <b>2013</b> , 44, 543-53	22
864	Whole-body PET/MRI in oncology: current status and clinical applications. <b>2013</b> , 1, 31-44	35
863	Encyclopedia of Radiation Oncology. <b>2013</b> , 364-373	
862	[Imaging in oncology: terms and definitions]. <b>2013</b> , 53, 303-12	
861	[Criteria for radiological assessment of therapy response: criteria-based appraisal]. <b>2013</b> , 53, 322-8	
860	Combination percutaneous cryotherapy and iodine-125 seed implantation for unresectable malignant thymoma: experience in 19 patients. <b>2013</b> , 67, 170-4	5
859	Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. <b>2013</b> , 14, 1175-82	134
858	Semiautomatic volumetric tumor segmentation for hepatocellular carcinoma: comparison between C-arm cone beam computed tomography and MRI. <b>2013</b> , 20, 446-52	44
857	Abdominal Imaging. Computation and Clinical Applications. <b>2013</b> ,	1
856	Minimum detectable change in lung nodule volume in a phantom CT study. <b>2013</b> , 20, 1364-70	16
855	Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria. <b>2013</b> , 82, 951-8	24
854	Diffusion weighted MRI: overview and implications for rectal cancer management. <b>2013</b> , 15, 655-61	22
853	Response criteria in oncologic imaging: review of traditional and new criteria. <b>2013</b> , 33, 1323-41	189
852	Reduction in radiation and contrast medium dose via optimization of low-kilovoltage CT protocols using a hybrid iterative reconstruction algorithm at 256-slice body CT: phantom study and clinical correlation. <b>2013</b> , 68, e128-35	39
851	CT-based response assessment of advanced gastrointestinal stromal tumor: dual energy CT provides a more predictive imaging biomarker of clinical benefit than RECIST or Choi criteria. <b>2013</b> , 82, 923-8	53
850	Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3850-5	7.5 12
849	Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survival. <b>2013</b> , 88, 309-17	6

848	Survivorship--competing mortalities, morbidities, and second malignancies. <b>2013</b> , 46, 681-710	12
847	A clinical experience of single agent bevacizumab in relapsing ovarian cancer. <b>2013</b> , 129, 459-62	19
846	The predictive and prognostic significance of pre- and post-treatment topoisomerase II $\beta$ in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer. <b>2013</b> , 39, 619-26	9
845	An update on criteria for assessing tumor response to treatment. <b>2013</b> , 42, 209-19	1
844	Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients. <b>2013</b> , 39, 1377-83	49
843	Renal Cell Carcinoma. <b>2013</b> ,	3
842	Liver PET/CT and Molecular Imaging. <b>2013</b> , 943-954	
841	Liver Intervention: Angiography. <b>2013</b> , 969-982	
840	Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. <b>2013</b> , 24, 655-61	37
839	Advanced chondrosarcomas: role of chemotherapy and survival. <b>2013</b> , 24, 2916-22	142
838	Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. <b>2013</b> , 31, 2024-8	305
837	A novel synergistic effect of iron depletion on antiangiogenic cancer therapy. <b>2013</b> , 132, 2705-13	21
836	Quantitative Ultrasound in Soft Tissues. <b>2013</b> ,	80
835	Treatment outcome of Photofrin-based photodynamic therapy for T1 and T2 oral squamous cell carcinoma and dysplasia. <b>2013</b> , 10, 229-35	29
834	'Rapid Learning health care in oncology' - an approach towards decision support systems enabling customised radiotherapy'. <b>2013</b> , 109, 159-64	147
833	Biopsy specimens obtained 7 days after starting chemoradiotherapy (CRT) provide reliable predictors of response to CRT for rectal cancer. <b>2013</b> , 85, 1232-8	24
832	Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. <b>2013</b> , 44, 1638-47	30
831	Evaluation and management of pulmonary nodules: state-of-the-art and future perspectives. <b>2013</b> , 7, 629-44	11

830	Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. <b>2013</b> , 100, 1777-83	77
829	Emerging antiangiogenics for renal cancer. <b>2013</b> , 18, 495-511	15
828	Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. <b>2013</b> , 31, 4453-61	128
827	Volumetric response classification in metastatic solid tumors on MSCT: initial results in a whole-body setting. <b>2013</b> , 82, e567-73	12
826	Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. <b>2013</b> , 5, 208ra147	169
825	mTORC1 inhibition is required for sensitivity to PI3K p110 $\beta$ inhibitors in PIK3CA-mutant breast cancer. <b>2013</b> , 5, 196ra99	203
824	Lung Cancer Imaging. <b>2013</b> ,	1
823	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. <b>2013</b> , 139, 2047-56	26
822	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <b>2013</b> , 14, e396-406	92
821	CA125-related measures of tumor kinetics and outcome of patients with recurrent ovarian cancer receiving chemotherapy: a retrospective evaluation. <b>2013</b> , 43, 1203-9	3
820	Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design. <b>2013</b> , 11, 163	5
819	Statistics of Survival Prediction and Nomogram Development. <b>2013</b> , 7-28	
818	Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. <b>2013</b> , 31, 1573-9	58
817	Statistical issues and challenges in immuno-oncology. <b>2013</b> , 1, 18	99
816	A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. <b>2013</b> , 8, 239	23
815	A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. <b>2013</b> , 11, 259	83
814	Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer. <b>2013</b> , 8, 238	14
813	Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. <b>2013</b> , 11, 246	69

812	Diagnostic validity of CT gastrography versus gastroscopy for primary lesions in gastric cancer: evaluating the response to chemotherapy, a retrospective analysis. <b>2013</b> , 16, 543-8	7
811	Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. <b>2013</b> , 9, 190	61
810	Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial. <b>2013</b> , 13, 419	21
809	CONCURRENT WHOLE BRAIN RADIOTHERAPY AND SHORT-COURSE CHLOROQUINE IN PATIENTS WITH BRAIN METASTASES: A PILOT TRIAL. <b>2013</b> , 2, 315	44
808	Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer. <b>2013</b> , 32, 61	11
807	Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial. <b>2013</b> , 8, 201	18
806	Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial. <b>2013</b> , 13, 345	7
805	Complete response of esophageal small cell carcinoma amrubicin treatment. <b>2013</b> , 19, 770-5	5
804	Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology?. <b>2013</b> , 20, 3009-14	24
803	Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. <b>2013</b> , 32, 179-88	195
802	Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. <b>2013</b> , 139, 135-43	13
801	Common toxicities and objective response rate in metastatic colorectal cancer patients treated with irinotecan based regimens. <b>2013</b> , 12, 109-112	
800	Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients. <b>2013</b> , 14, 139	15
799	Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer. <b>2013</b> , 1, 3-19	1
798	Radiofrequency induction on sodium/iodide symporter expression of thyroid cancer. <b>2013</b> , 12, 516-520	
797	S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. <b>2013</b> , 13, 583	6
796	Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer. <b>2013</b> , 142, 549-58	26
795	Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications. <b>2013</b> , 8, 295-300	9

794	The role of F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma. <b>2013</b> , 2, 341-352	5
793	Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships. <b>2013</b> , 2, 413-425	57
792	Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. <b>2013</b> , 30, 746	9
791	Sunitinib treatment enabling resection of massive liver metastasis: a case report. <b>2013</b> , 7, 234	0
790	[Pharmacological therapy of urogenital cancer: rational routine diagnostic imaging]. <b>2013</b> , 52, 1564-73	
789	Management of Colorectal Cancers in Older People. <b>2013</b> ,	1
788	Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). <b>2013</b> , 130, 269-74	79
787	Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. <b>2013</b> , 21, 904-12	460
786	Metastatic disease to the lungs and pleura: an overview. <b>2013</b> , 48, 335-43	3
785	Predictive value of apparent diffusion coefficient in evaluation of colorectal carcinoma hepatic metastases' response to radiofrequency ablation. <b>2013</b> , 38, 1027-32	8
784	A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. <b>2013</b> , 131, 357-61	25
783	High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. <b>2013</b> , 11, 283-289.e1	5
782	Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?. <b>2013</b> , 11, 141-8	38
781	Results of gamma knife surgery for Cushing's disease. <b>2013</b> , 119, 1486-92	72
780	Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. <b>2013</b> , 22, 1-7	11
779	Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. <b>2013</b> , 108, 1440-8	56
778	Sequencing therapy in metastatic renal cell cancer. <b>2013</b> , 40, 465-71	9
777	Blinded independent central reviews: The FDA weighs in. <b>2013</b> , 30, 33-37	

776	Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. <b>2013</b> , 26, 499-508	31
775	Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. <b>2013</b> , 104, 718-24	45
774	Can C-arm cone-beam CT detect a micro-embolic effect after TheraSphere radioembolization of neuroendocrine and carcinoid liver metastasis?. <b>2013</b> , 28, 459-65	14
773	Response to a costly revolution for a subgroup of patients with metastatic melanoma. <b>2013</b> , 168, 470-471	
772	Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. <b>2013</b> , 29, 8-16	33
771	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. <b>2013</b> , 31, 3327-34	2262
770	Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions. <b>2013</b> , 12, 1219-34	7
769	Texture analysis in assessment and prediction of chemotherapy response in breast cancer. <b>2013</b> , 38, 89-101	144
768	The effect of XELOX plus bevacizumab on rectal hepatoid adenocarcinoma. <b>2013</b> , 2, 22-26	1
767	Pemetrexed in patients with refractory soft tissue sarcoma: a non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005. <b>2013</b> , 31, 167-74	2
766	Cancer pharmacogenomics: strategies and challenges. <b>2013</b> , 14, 23-34	154
765	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. <b>2013</b> , 14, 55-63	453
764	Computed tomography and magnetic resonance imaging. <b>2013</b> , 187, 3-63	5
763	Selection for hepatic resection of colorectal liver metastases: expert consensus statement. <b>2013</b> , 15, 91-103	214
762	Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes. <b>2013</b> , 52, 910-8	40
761	Stereotactic ablative radiotherapy for small lung tumors with a moderate dose. Favorable results and low toxicity. <b>2013</b> , 189, 33-40	25
760	FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. <b>2013</b> , 62, 17-25	11
759	Sensitivity and accuracy of volumetry of pulmonary nodules on low-dose 16- and 64-row multi-detector CT: an anthropomorphic phantom study. <b>2013</b> , 23, 139-47	42

758	Non-invasive visualisation and volume estimation of maggot masses using computed tomography scanning. <b>2013</b> , 127, 185-94	8
757	Quantitative imaging biomarkers: the application of advanced image processing and analysis to clinical and preclinical decision making. <b>2013</b> , 26, 97-108	44
756	The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. <b>2013</b> , 137, 503-10	105
755	Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. <b>2013</b> , 216, 845-56; discussion 856-7	34
754	Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. <b>2013</b> , 24, 1209-17	71
753	Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification. <b>2013</b> , 22, 1101-7	13
752	Pre-hysterectomy cone biopsy is able to predict response in locally advanced cervical cancer patients submitted to neo-adjuvant chemoradiation. <b>2013</b> , 39, 1025-9	5
751	A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two Year Outcomes.	0
750	Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.	0
749	Intra- and inter-operator variability in MRI-based manual segmentation of HCC lesions and its impact on dosimetry. <b>2022</b> , 9,	0
748	FDA Approval Summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.	2
747	Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC. 12,	0
746	Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis. 12,	0
745	The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients.	1
744	Does 18F-FDG PET/CT add value to conventional imaging in clinical assessment of chronic disseminated candidiasis?. 9,	0
743	Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden.	0
742	Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer.	0
741	Prognostic nutritional index of early post-pembrolizumab therapy predicts long-term survival in patients with advanced urothelial carcinoma. <b>2022</b> , 25,	0

740	WVOX-rs13338697 genotype predicts therapeutic efficacy of ADI-PEG 20 for patients with advanced hepatocellular carcinoma. 12,	1
739	Estimated Costs of the Ipilimumab/Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. <b>2023</b> , 15, 31	0
738	Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.	0
737	Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer. <b>2022</b> , 7, 100651	0
736	Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor. <b>2022</b> , 7, 100630	0
735	A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.	0
734	AAPM task group report 273: Recommendations on best practices for ai and machine learning for computer-aided diagnosis in medical imaging.	1
733	Patient-reported outcomes in terms of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced oropharyngeal cancer patients treated with definitive chemo-radiotherapy: Swall PEG study. <b>2022</b> , 23,	0
732	Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. <b>2022</b> ,	0
731	lncRNA MALAT1 regulates the resistance of breast cancer cells to paclitaxel via the miR-497-5p/SHOC2 axis. <b>2022</b> , 23, 973-985	0
730	Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). <b>2022</b> ,	0
729	SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?. <b>2022</b> , 22,	0
728	Imaging of pediatric head and neck tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee/ASPNR White Paper.	0
727	Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.	0
726	Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. <b>2022</b> , 10, 3172	0
725	Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy. <b>2022</b> , 5, e2245596	1
724	Baseline extracellular vesicle TGF- $\beta$ is a predictive biomarker for response to immune-checkpoint inhibitors and survival in non-small-cell lung cancer.	2
723	Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series.	1

722	Correlation between immune-related adverse events and treatment efficacy of anti-PD1 immunotherapy in patients with esophageal squamous cell carcinoma. <b>2022</b> , 25,	o
721	Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer. <b>2022</b> , 1-9	o
720	Body mass index and immune checkpoint inhibitor efficacy in metastatic cancer patients: A Brazilian retrospective study. 2,	o
719	Prognostic Factors and Clinical Outcomes in Extraskkeletal Ewing Sarcoma: A Cohort Study.	o
718	Supervised discovery of interpretable gene programs from single-cell data.	o
717	Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer. <b>2022</b> , 107572	o
716	CT-Based Radiomics Can Predict the Efficacy of Anlotinib in Advanced Non-Small-Cell Lung Cancer. <b>2022</b> , 2022, 1-11	o
715	Treatment outcomes of mucosal melanoma of head and neck: Efficacy of immune checkpoint inhibitors for advanced disease. 9,	o
714	Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies.	o
713	Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial.	3
712	Impact of consolidation chemotherapy after delayed complete surgery in advanced epithelial ovarian cancer: a propensity score analysis. <i>ijgc-2022-003920</i>	o
711	Assessment of immunotherapy response in intracranial malignancy using semi-automatic segmentation on magnetic resonance images. 13,	o
710	Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis.	o
709	A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer.	o
708	Multicentre retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma.	o
707	A Prospective Randomized Crossover Trial of Systemic Chemotherapy in Patients with Low-Grade Mucinous Appendiceal Adenocarcinoma.	o
706	Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.	o
705	Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer. <b>2022</b> , 25,	o

- 704 Pattern of failure and clinical value of local therapy for oligo-recurrence in locally advanced non-small cell lung cancer after definitive chemoradiation: Impact of driver mutation status. ○
- 703 A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma. **2022**, 20, ○
- 702 Multidisciplinary management of pediatric malignant rhabdoid tumor based on 5 years of experience at a tertiary care center. **2023**, 39, ○
- 701 Decomposition-based framework for tumor classification and prediction of treatment response from longitudinal MRI. ○
- 700 Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10. ○
- 699 Safety and efficacy analysis of chemoradiotherapy/radiotherapy combined with nimotuzumab for treating unresectable oesophageal squamous cell carcinoma in elderly patients: a retrospective analysis. **2022**, 22, ○
- 698 A Multicenter Retrospective Cohort Study on Superior Vena Cava Resection in Non-Small-Cell Lung Cancer Surgery. **2022**, 14, 6138 ○
- 697 Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer. **2022**, 12, ○
- 696 An Artificial Neural Network-based Radiomics model for Predicting Radiotherapy response of Advanced Esophageal Squamous Cell Carcinoma patients: A multi-center Study. ○
- 695 Muscle mass loss in breast cancer patients of reproductive age (≤45 years) undergoing neoadjuvant chemotherapy. 1
- 694 Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. ○
- 693 Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. ○
- 692 Translational analysis and final efficacy of the AVETUX trial [Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer. 12, 1
- 691 Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT. **2022**, 9, 1-92 ○
- 690 27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study. **2022**, ○
- 689 Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade. **2022**, 10, e005670 ○
- 688 Pathological complete response in multimodal treatment of esophageal cancer: a retrospective cohort study. ○
- 687 Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort. **2022**, ○

686	Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma.	o
685	Study protocol of an open-label prospective phase II umbrella study of precise neoadjuvant therapy for patients with stage II-IIIB resectable non-small cell lung cancer (PURPOSE). 12,	o
684	Outcomes following posttransplant viral-specific T-cell therapy in patients with sickle cell disease.	o
683	Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity. <b>2022</b> , 15, e252590	o
682	A case of thoracic SMARCA4 -Deficient undifferentiated tumor successfully treated with combination IpilimumabNivolumab. <b>2022</b> , 10,	o
681	Modulation of radiation biomarkers in a randomized phase II study of <sup>131</sup> I-MIBG with or without radiation sensitizers for relapsed or refractory neuroblastoma. <b>2022</b> ,	o
680	Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese populationBased analysis. 13,	o
679	Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3.	o
678	Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. <b>2022</b> ,	2
677	Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework. 13,	o
676	Treatment outcomes and radiotherapy deintensification strategies in human papillomavirus-associated tonsil cancer. <b>2022</b> , 17,	o
675	Anlotinib plus etoposide increases survival in patients with small-cell lung cancer after chemoradiotherapy. <b>2022</b> , 15, 100482	o
674	Developing Artificial Intelligence Models for Extracting Oncologic Outcomes from Japanese Electronic Health Records.	o
673	United Kingdom criteria for liver transplantation in the setting of isolated unresectable colorectal liver metastases.	1
672	Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma. <b>2022</b> , 5, e2244619	o
671	Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. <b>2022</b> ,	o
670	Effectiveness and safety of anti-PD-1 monotherapy or combination therapy in Chinese advanced gastric cancer: A real-world study. 12,	o
669	Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.	o

668	Treatment of Peritoneal Metastasis with Pressurized Intraperitoneal Aerosol Chemotherapy: Results from the Prospective PIPAC-OPC2 Study.	1
667	The Impact of COVID-19 Pandemic on Surgical Treatment of Resectable Non-Small Cell Lung Cancer in Greece. <b>2023</b> , 13, 218	0
666	Could conventionally fractionated radiation therapy coupled with stereotactic body radiation therapy improve local control in bone oligometastases?. <b>2023</b> ,	0
665	Time Course Changes of Synthetic Relaxation Time During Neoadjuvant Chemotherapy in Breast Cancer: The Optimal Parameter for Treatment Response Evaluation.	0
664	Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.	0
663	Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study. jnumed.122.264964	0
662	Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood.	0
661	Relationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafenib. <b>2022</b> , 0	0
660	Breast Cancer Workup and Surgical Planning. <b>2022</b> , 341-383	0
659	Deep learning-based Segmentation of Multi-site Disease in Ovarian Cancer.	0
658	Immunotherapy Assessment: A New Paradigm for Radiologists. <b>2023</b> , 13, 302	1
657	Niche stiffness sustains cancer stemness via TAZ and NANOG phase separation. <b>2023</b> , 14,	0
656	Criterios PERCIST, Hopkins y parámetros metabólicos de la PET/TC como factores pronósticos en el cáncer escamoso de cabeza y cuello. <b>2023</b> ,	0
655	Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer. <b>2023</b> , 15, 358	0
654	Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. <b>2023</b> , 26, 105799	2
653	Microstructural parameters from DW-MRI for tumour characterization and local recurrence prediction in particle therapy of skull-base chordoma.	0
652	The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma. 13,	0
651	Safety and Utility of Endoscopic Ultrasound with Bronchoscope-guided Fine Needle Aspiration (EUS-B-FNA) in Suspected Lung Cancer Patients with Poor Respiratory or General Conditions: A Prospective Multicenter Observational Study.	0

650	Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer. <b>2023</b> , 23,	o
649	Developments in the Surgical Approach to Staging and Resection of Rhabdomyosarcoma. <b>2023</b> , 15, 449	o
648	Extended Lymphadenectomy for Gastric Cancer in the Neoadjuvant Era: Current Status, Clinical Implications and Contentious Issues. <b>2023</b> , 30, 875-896	1
647	Quality-of-life outcomes and risk prediction for patients randomized to Nivolumab/Ipilimumab vs Nivolumab on LungMAP-S1400I.	o
646	Efficacy Endpoints in Phase II Clinical Trials for Meningioma: An Analysis of Recent Clinical Trials.	o
645	Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study.	1
644	ENDOBONCHIAL ULTRASOUND-GUIDED TRANSBRONCHIAL NEEDLE INJECTION OF CISPLATIN RESULTS IN DYNAMIC CHANGES IN THE TUMOR IMMUNE MICROENVIRONMENT. <b>2023</b> , 100994	o
643	Correlation analysis of HIF-1 $\beta$ and Ca15-3 in response to neoadjuvant chemotherapy in locally advanced breast cancer: A cohort study in Indonesia. <b>2023</b> , 41, 481-487	o
642	Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer. <b>2023</b> ,	o
641	A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. <b>2023</b> , 15, 329	o
640	Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch RepairDeficient Colorectal Cancer. <b>2023</b> , 21, 60-66.e5	o
639	Microwave ablation using two simultaneous antennas for the treatment of liver malignant lesions: a 3 year single-Centre experience. <b>2023</b> , 40,	o
638	Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. 106002802211491	o
637	Treating mast cell tumours in first opinion practice: is it time to put down the knife?. <b>2023</b> , 28, 2-7	o
636	Combination of MRI-based temporal tumor response and Epstein-Barr DNA level changes after radiotherapy leads to improved prognostic stratification of patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.	o
635	Interdisziplinäre Besprechungen.	o
634	Tumor Hyperprogression and Pseudoprogression After Immunotherapy. <b>2023</b> , 1-24	o
633	Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment. <b>2023</b> , 5,	o

- 632 Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase 2 study. ○
- 631 FOLFOX -bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors. ○
- 630 Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma. **2023**, 11, 119 ○
- 629 Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406).. ○
- 628 The IASLC grading system for invasive pulmonary adenocarcinoma: a potential prognosticator for patients receiving neoadjuvant therapy. **2023**, 15, 175883592211480 ○
- 627 Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma. **2023**, 6, e2249720 ○
- 626 Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. **2023**, 1 ○
- 625 Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor Based Systemic Therapy in BRAF-Mutation Positive Non-Small Cell Lung Cancer. **2023**, 100460 ○
- 624 Correlation of radiological and histopathological response after neoadjuvant radiotherapy in soft tissue sarcoma. 1-8 ○
- 623 A case of pancreatic head cancer with Trousseau's syndrome treated with radical resection and anticoagulant therapy. **2023**, 9, ○
- 622 Effects of the Introduction of Modern Immunotherapy on the Outcome of Isolated Limb Perfusion for Melanoma In-Transit Metastases. **2023**, 15, 472 ○
- 621 Landmark mediation survival analysis using longitudinal surrogate. 12, ○
- 620 Differential prognostic significance of sarcopenia in metastatic esophageal squamous and adenocarcinoma. ○
- 619 Radiological response criteria in non-small cell lung cancer treated with immunotherapy: RECIST1.1 vs. iRECIST. **2023**, 9, ○
- 618 Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors. 13, ○
- 617 Real-World Study of Bevacizumab Treatment in Patients with Ovarian Cancer: A Chinese single-institution study of 155 patients. ○
- 616 Quantitative analysis of superb microvascular imaging for monitoring tumor response to chemoradiotherapy in locally advanced cervical cancer. 12, ○
- 615 Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study. **2023**, 21, ○

614	Role of advanced imaging techniques in the evaluation of oncological therapies in patients with colorectal liver metastases. 29, 521-535	o
613	Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives. <b>2023</b> , 11,	o
612	Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity. <b>2023</b> , 13, e067691	o
611	Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma. <b>2023</b> , 12, 309-319	o
610	Real-world treatment patterns and outcomes in patients with metastatic melanoma. <b>2023</b> , 6-6	o
609	Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer. <b>2023</b> , 21,	o
608	The maximum tumor growth rate predicts clinical outcomes of patients with small-cell lung cancer undergoing first-line chemotherapy plus immune-checkpoint inhibitor therapy.	o
607	Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.	o
606	Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.	o
605	Disparity in the era of personalized medicine for epithelial ovarian cancer. <b>2023</b> , 15, 175883592211480	o
604	Proteomic discovery of plasma protein biomarkers and development of models predicting prognosis of high-grade serous ovarian carcinoma. <b>2023</b> , 100502	1
603	Assessment of diffusion-weighted MRI in predicting response to neoadjuvant chemotherapy in breast cancer patients. <b>2023</b> , 13,	o
602	A cross-sectional study evaluating health-related quality of life of Chinese pediatric patients with hematological malignancies using EQ-5D-Y. 10,	o
601	Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up <b>2023</b> ,	o
600	Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. <b>2023</b> , 30, 1381-1394	o
599	Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma. <b>2023</b> , 16,	o
598	Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy.	o
597	Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer.	o

- 596 Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients. 1-14 ○
- 595 Exploration of Immunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma. ○
- 594 Clinical impact of MRI-detected additional lesions in breast cancer patients with neoadjuvant systemic therapy at the Netherlands cancer institute. 1
- 593 Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions. **2023**, 15, 473 ○
- 592 Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer. 12, ○
- 591 Breast-Conserving Surgery in Triple-Negative Breast Cancer: A Retrospective Cohort Study. **2023**, 2023, 1-8 ○
- 590 Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial. ○
- 589 WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1. **2023**, 15, 393 ○
- 588 Semiautomated pelvic lymph node treatment response evaluation for patients with advanced prostate cancer: based on MET-RADS-P guidelines. **2023**, 23, ○
- 587 The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. ○
- 586 Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy. **2023**, 28, ○
- 585 Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC. **2023**, 30, 575-585 ○
- 584 Sunitinib therapy for imatinib-resistant and/or intolerant gastrointestinal stromal tumors: comparison of safety and efficacy between standard and reduced dosage regimens. ○
- 583 Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). ○
- 582 High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study. **2023**, 176, 98-102 ○
- 581 Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors. **2023**, 137, 106297 ○
- 580 CGBO-Net: Cruciform structure guided and boundary-optimized lymphoma segmentation network. **2023**, 153, 106534 ○
- 579 Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. **2023**, 43, ○

- 578 Cholesterol and C-reactive protein prognostic score predicted prognosis of immune checkpoint inhibitors based interventional therapies for intermediate-to-advanced hepatocellular carcinoma patients. **2023**, 115, 109651 ○
- 577 A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma. **2023**, 181, 119-134 ○
- 576 Combination of endoscopic ultrasound-guided radiofrequency ablation and adaptive radiation therapy for the treatment of lymph node metastases from colon adenocarcinoma: A case report. **2023**, 9, 100216 ○
- 575 Correlation between late gadolinium enhancement sequences in MRI and pathologic response after neoadjuvant chemotherapy in breast cancer. **2023**, 36, 100438 ○
- 574 Covariate-adjusted response-adaptive designs for censored survival responses. **2023**, 225, 219-242 ○
- 573 Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice. ○
- 572 Colorectal Liver Metastases: A Literature Review of Viable Surgical Options with a Special Focus on Microwave Liver Thermal Ablation and Mini-Invasive Approach. **2023**, 13, 33 ○
- 571 Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses. **2023**, 15, 185 ○
- 570 The Applications of Artificial Intelligence in Digestive System Neoplasms: A Review. ○
- 569 Intrinsic and Extrinsic Transcriptional Profiles That Affect the Clinical Response to PD-1 Inhibitors in Patients with NonSmall Cell Lung Cancer. **2023**, 15, 197 ○
- 568 Diagnostic Value of Contrast-Enhanced Digital Mammography Versus Contrast-Enhanced MRI for Detecting Residual Disease After Neoadjuvant Chemotherapy for Breast Cancer. **2022**, 10, 69-76 ○
- 567 Efficacy and safety of denosumab de-escalation in giant cell tumor of bone. ○
- 566 Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer. **2023**, 46, 50-57 ○
- 565 Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer. **2022**, 12, ○
- 564 Roadmap for Precision preclinical x-ray radiation studies. ○
- 563 Old Discovery Leading to New Era: Metabolic Imaging of Cancer with Deuterium MRI. **2023**, 9, 6 ○
- 562 Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer. **2022**, 8, ○
- 561 Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab. ○

- 560 The prognostic role of <sup>68</sup>Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy. *jnumed*.122.264962 ○
- 559 Major pathologic response exhibited distinct prognostic significance for lung adenocarcinoma post different modalities of neoadjuvant therapy. ○
- 558 Telomere Status of Advanced Non-Small-Cell Lung Cancer Offers a Novel Promising Prognostic and Predictive Biomarker. **2023**, 15, 290 ○
- 557 Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes. **2022**, ○
- 556 Clinical efficacy and safety analysis of CT-guided <sup>125</sup>I implantation in the treatment of recurrent or metastatic pelvic malignant tumor. **2022**, ○
- 555 PET-CT in the Evaluation of Neoadjuvant/Adjuvant Treatment Response of Soft-tissue Sarcomas. **2022**, 10, ○
- 554 Tumoral reduction in patients with intra-abdominal tumors treated with CyberKnife: a single center's experience. **2022**, 54, ○
- 553 The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy. **2023**, 12, 325 ○
- 552 Grundlagen der medikamentösen Tumorthherapie. **2022**, 1-23 ○
- 551 Apatinib in recurrent or metastatic head and neck cancer patients. ○
- 550 Radiologic assessment of tumor response to immunotherapy and its complications. **2023**, 239-261 ○
- 549 Prognostic impact of sarcopenia in patients with locally advanced adenocarcinoma of the esophagogastric junction treated with neoadjuvant chemoradiotherapy. 10, ○
- 548 Nephron-sparing surgery for Wilms tumor. 11, ○
- 547 Re: Maria S. Lindgren, Eric Hansen, Nessim Azawi, Anna M. Nielsen, Lars Dyrskjøl, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. *J Clin Oncol*. In press. <https://doi.org/10.1200/JCO.22.00470>. **2023**, ○
- 546 Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects. Volume 16, 71-86 ○
- 545 Use of Programmed Cell Death Protein 1 (PD-1) Inhibitor Therapy in HIV-infected Patients with Advanced Cancer: a single-center study from China. ○
- 544 Predicting Soft Tissue Sarcoma Response to Neoadjuvant Chemotherapy Using an MRI-Based Delta-Radiomics Approach. ○
- 543 A Case of Bilateral Internal Mammary Arterial Infusion Chemotherapy Using Implantable Port-catheter Systems for Anterior Chest Wall Metastasis of Breast Cancer. **2023**, ○

542	Clinical Complete Response of Recurrent Gastric Cancer after Third-line CPT-11 Chemotherapy. <b>2023</b> ,	o
541	Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. <b>2023</b> ,	1
540	Predictive value of enhanced CT and pathological indicators in lymph node metastasis in patients with gastric cancer based on GEE model.	o
539	Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).	o
538	Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer. <b>2023</b> , 23,	o
537	Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab.	o
536	AI-Enhanced Digital Pathology and Radiogenomics in Precision Oncology. <b>2023</b> , 93-113	o
535	Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy. <b>2023</b> , 13,	o
534	Immune Checkpoint Inhibitor-Induced Primary Hyperparathyroidism in a Small-Cell Lung Cancer Patient: A Case Report. <b>2023</b> , 59, 215	o
533	Survival benefits of para-aortic lymphadenectomy in colorectal cancer with clinically suspected para-aortic lymph node metastasis: a meta-analysis and systematic review. <b>2023</b> , 21,	o
532	Resistance of neuroendocrine tumours to somatostatin analogs. <b>2023</b> , 18, 33-52	o
531	Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. <b>2023</b> ,	o
530	Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study.	o
529	The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy.	o
528	Single-center analysis of percutaneous ablation in the treatment of hepatocellular carcinoma: long-term outcomes of a 7-year experience.	o
527	In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III. <b>2023</b> , 24, 2239	1
526	Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study. <b>2023</b> , 18,	o
525	Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. <b>2023</b> , 11, e005007	o

524	Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. <b>2023</b> , 8,	1
523	Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer.	0
522	Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer. 12,	0
521	Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer. 108155892311512	0
520	Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.	0
519	Efficacy and safety of carboplatin and etoposide in older extensive-stage small-cell lung cancer patients with a poor performance status.	0
518	Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma. <b>2023</b> , 15, 593	0
517	Charachterization of spatially mapped volumetric molecular ultrasound signals for predicting response to anti-vascular therapy. <b>2023</b> , 13,	0
516	Fecal levels of SCFA and BCFA during capecitabine in patients with metastatic or unresectable colorectal cancer.	0
515	Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer. <b>2023</b> , 14,	0
514	Molecular Tumor Board at European Institute of Oncology: report of the first three year activity of an Italian precision oncology experience.. <b>2023</b> ,	0
513	Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. <b>2023</b> , 15, 175883592211489	0
512	Scoring System to Predict Survival After Resection of Locally Advanced Pancreas Cancer: What is Achieved?.	0
511	Ferroptosis-Related Prognostic Gene LAMP2 Is a Potential Biomarker Differential Expressed in Castration Resistant Prostate Cancer. <b>2023</b> , 2023, 1-14	0
510	Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer.	0
509	Hyperthermic Extracorporeal Applied Tumor Therapy for Six Cycles for Recurrent Metastatic Peritoneal Serous Papillary Carcinoma. <b>2023</b> ,	0
508	Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer. <b>2023</b> , 14,	0
507	A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. <b>2023</b> , 22, 153303382311523	0

506	Imaging Recommendations for Diagnosis, Staging, and Management of Lung Cancer.	0
505	Unresectable stage III non-small cell lung cancer: Insights from a Portuguese expert panel. <b>2023</b> ,	0
504	Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. <b>2023</b> ,	0
503	Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer. <b>2023</b> ,	1
502	Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.	1
501	Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients With Advanced Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations. Publish Ahead of Print,	0
500	A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.	1
499	Human papillomavirus independent status on pathologic response and outcomes in locally advanced cervical cancer managed with chemoradiotherapy followed by surgery. <i>ijgc-2022-003940</i>	0
498	Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas. <b>2023</b> , 15, 700	0
497	Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. <b>2023</b> , 11, e005809	0
496	Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.	0
495	Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxelBased regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer. 12,	0
494	Response to induction chemotherapy predicts survival outcomes in oropharyngeal cancer.	0
493	WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer. <b>2023</b> ,	0
492	High-risk HPV-related squamous cell carcinoma in the temporal bone: a rare but noteworthy subtype.	0
491	Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies.	0
490	Clinical Outcomes of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Patients with Lymph Node Metastases from Gynecological Cancers. <b>2023</b> , 13, 229	0
489	Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <b>2023</b> ,	0

- 488 Hypertension, type 2 diabetes, obesity, and p53 mutations negatively correlate with metastatic colorectal cancer patients' survival. 10, ○
- 487 The Efficacy of Using Patient-Derived Organoids to Predict Treatment Response in Colorectal Cancer. **2023**, 15, 805 ○
- 486 Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. ○
- 485 NPY methylated ctDNA is a promising biomarker for treatment response monitoring in metastatic colorectal cancer. ○
- 484 The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria. **2023**, 12, 879 ○
- 483 Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis. 14, ○
- 482 Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC. **2023**, ○
- 481 A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer. **2023**, 17, 117955492311520 ○
- 480 Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. **2023**, 388, 228-239 7
- 479 A radiomic biomarker for prognosis of resected colorectal cancer liver metastases generalizes across MRI contrast agents. 13, ○
- 478 Therapeutic effect of haploidentical peripheral blood stem cell treatment on relapsed/refractory ovarian cancer. **2023**, ○
- 477 A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. ○
- 476 Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. **2023**, ○
- 475 Association between PD -1 inhibitor-related adverse events and frailty assessed by frailty index in lung cancer patients. ○
- 474 A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignancies. **2023**, 15, 175883592311659 ○
- 473 Recent Advances in Fibrinogen Research in Colorectal Cancer. **2023**, 11, 28-38 ○
- 472 Cone Beam Computed Tomography Image Fusion with Cross Sectional Images for Percutaneous Renal Tumor Ablation: Preliminary Data. **2023**, 22, 153303382311549 ○
- 471 Efficacy of lymph node dissection on stage IIICr of cervical cancer before CCRT: study protocol for a phase III, randomized controlled clinical trial (CQGOG0103). 34, ○

- 470 Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC. **2023**, 15, 175883592311563 ○
- 469 Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission. ○
- 468 Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report. **2023**, 11, e006467 ○
- 467 Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. ○
- 466 Safety and efficacy of stereotactic ablative brachytherapy as a salvage therapy for recurrent chest wall cancer: A retrospective, multicenter study. 12, ○
- 465 Characteristics and outcomes of gallbladder cancer patients at the Tata Medical Center, Kolkata 2017-2019. ○
- 464 TGF- $\beta$  in the microenvironment induces a physiologically occurring immune-suppressive senescent state. **2023**, 42, 112129 ○
- 463 Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy. ○
- 462 Long-term survivors with desmoplastic small round cell tumor (DSRCT): Results from a retrospective single-institution case series analysis. 1
- 461 Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. ○
- 460 Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study. ○
- 459 Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. ○
- 458 Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma. **2023**, ○
- 457 Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis. ○
- 456 Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer. Volume 16, 215-225 ○
- 455 The prognostic role of whole-body volumetric 68GA-DOTATATE PET/computed tomography parameters in patients with gastroenteropancreatic neuroendocrine tumor treated with 177Lu-DOTATATE. Publish Ahead of Print, ○
- 454 Use of Pretreatment Multiparametric MRI to Predict Tumor Regression Pattern to Neoadjuvant Chemotherapy in Breast Cancer. **2023**, ○
- 453 Impacts of additional cycles of neoadjuvant immunotherapy on surgery in non-small-cell lung cancer. ○

- 452 Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer. 13, ○
- 451 Predictive power of deep-learning segmentation based prognostication model in non-small cell lung cancer. 13, ○
- 450 Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial. **2023**, 58, 101897 ○
- 449 Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer. **2023**, 49, 102666 ○
- 448 Predicting lung cancer treatment response from CT images using deep learning. ○
- 447 Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial. **2023**, 23, ○
- 446 2-[18F]FDG-PET/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancer. **2023**, 13, ○
- 445 FDG PET/CTBased Response Assessment in Malignancies. **2023**, 43, ○
- 444 Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). **2023**, 184, 62-72 ○
- 443 Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy. **2023**, ○
- 442 A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850. **2023**, 14, 302-315 ○
- 441 Intravoxel incoherent motion radiomics nomogram for predicting tumor treatment responses in nasopharyngeal carcinoma. **2023**, 31, 101648 ○
- 440 Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study. **2023**, 31, 101657 ○
- 439 Instant Oncology: OlympiAD. **2023**, 35, 329-330 ○
- 438 Patterns of Failure After Stereotactic Body Radiotherapy to Sacral Metastases. **2023**, 35, 339-346 ○
- 437 CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma. **2023**, 185, 167-177 ○
- 436 Neoadjuvant chemotherapy combined with transoral robotic surgery for stage III and IV laryngeal and hypopharyngeal carcinomas. **2023**, 140, 106371 ○
- 435 Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma. **2023**, 183, 109635 ○

- 434 Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies. **2023**, 186, 27-37 ○
- 433 Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX [The LAPC-2 trial. **2023**, 183, 109541 ○
- 432 Gastric cancer derived mesenchymal stem cells promoted DNA repair and cisplatin resistance through up-regulating PD-L1/Rad51 in gastric cancer. **2023**, 106, 110639 ○
- 431 Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer. **2023**, 15, 2318 ○
- 430 Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial. **2023**, 171, 23-30 ○
- 429 Toxicity and therapy outcome associations in LIG3 , SLCO1B3 , ABCB1 , OPRM1 and GSTP1 in high-grade serous ovarian cancer. ○
- 428 Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113). **2023**, 163, 110834 ○
- 427 Aggressive Pituitary Adenomas. **2022**, 637-648 ○
- 426 Recent Developments in the Management of Orbital and Periocular Neoplasms. **2022**, 311-325 ○
- 425 Validation of the North America expert consensus statement on reporting CT findings for COVID-19 in individuals with lung cancer. 55, ○
- 424 Upfront Surgery versus Neoadjuvant Perioperative Chemotherapy for Resectable Colorectal Liver Metastases: A Machine-Learning Decision Tree to Identify the Best Potential Candidates under a Parenchyma-Sparing Policy. **2023**, 15, 613 ○
- 423 Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients [Knowledge from two independent international studies. **2023**, 37, 100877 ○
- 422 Impact of appendectomy of a grossly normal appendix on the survival outcomes of mucinous ovarian carcinomas in a tertiary hospital. ○
- 421 Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. **2023**, 138, 106311 ○
- 420 First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors. **2023**, ○
- 419 The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center. 13, ○
- 418 Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. **2023**, 1 ○
- 417 Melanome der Haut und Schleimhaut. **2022**, 205-236 ○

- 416 Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations. Publish Ahead of Print, ○
- 415 Could nucleolin and nucleophosmin levels be prognostic indicators in non-small cell lung cancer?. **2023**, 39, 433-442 ○
- 414 Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study. **2023**, 22, 153473542211511 ○
- 413 The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial. **2023**, 183, 49-59 ○
- 412 Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR $\alpha$ )-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. **2023**, 170, 241-247 1
- 411 Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community. **2023**, 25, 1455-1462 ○
- 410 Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. ○
- 409 Management of Recurrent Well-Differentiated Thyroid Carcinoma in the Neck: A Comprehensive Review. **2023**, 15, 923 ○
- 408 Tensor Radiomics: Paradigm for Systematic Incorporation of Multi-Flavoured Radiomics Features. ○
- 407 Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers. **2023**, 12, 1119 ○
- 406 Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens. ○
- 405 Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer. **2023**, 47, 101909 ○
- 404 The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis. ○
- 403 Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Non-Metastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Publish Ahead of Print, ○
- 402 SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma. **2023**, 15, 906 ○
- 401 Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials. ○
- 400 A phase 1 trial of NY-ESO -1-specific TCR -engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. **2023**, 152, 2554-2566 ○
- 399 Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNIP-RCC trial. ○

- 398 Comparison of Neoadjuvant Systemic Chemotherapy Protocols for the Curative-Intent Management of Peritoneal Metastases from Colorectal Cancer, Regarding Morphological Response, Pathological Response, and Long-Term Outcomes: A Retrospective Study. ○
- 397 Effects of selenium supplementation on concurrent chemoradiotherapy in patients with cervical cancer: A randomized, double-blind, placebo-parallel controlled phase II clinical trial. 10, ○
- 396 Immunotherapy combined with chemotherapy in the treatment for rare primary mucoepidermoid carcinoma of the liver: a case report. **2023**, 34, 582-588 ○
- 395 JGOG2046: a feasibility study of neoadjuvant chemotherapy followed by debulking surgery for clinically diagnosed FIGO stage IVb endometrial cancer. **2023**, 28, 436-444 ○
- 394 The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study. **2023**, 15, 947 ○
- 393 Salvage Surgery for Advanced Lung Adenocarcinoma After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment. **2023**, ○
- 392 Posttransplant sequential adrenal and spine metastasis of hepatocellular carcinoma responsive to combined regorafenib and radiotherapy: a case report. **2023**, 37, 69-75 ○
- 391 Resonancia magnética en la detección, estadificación y seguimiento del cáncer de próstata: síntesis de las guías PI-RADS v2.1, MET-RADS, PRECISE y PI-RR. **2023**, ○
- 390 Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review. **2023**, 13, 564 ○
- 389 Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized-controlled open-label Phase II study. **2022**, 11, ○
- 388 Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer. **2023**, 5, ○
- 387 Integration of artificial intelligence in lung cancer: Rise of the machine. **2023**, 4, 100933 ○
- 386 The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score-matched analyses. ○
- 385 MiR-7-5p/KLF4 signaling inhibits stemness and radioresistance in colorectal cancer. **2023**, 9, ○
- 384 Combined Resection Approaches: Decision Making for Synchronous Resection, Timing of Staged Intervention to Optimize Outcome. ○
- 383 A case of hepatocellular carcinoma with pseudoprogression followed by complete response to atezolizumab plus bevacizumab. ○
- 382 Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF- $\beta$ -trap bifunctional antibody, in patients with advanced solid tumors. **2023**, 11, e005267 1
- 381 Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response. 13, ○

- 380 A prospective study on tumour response assessments methods after neoadjuvant endocrine therapy in early oestrogen receptor positive breast cancer. ○
- 379 Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study. **2023**, 23, ○
- 378 Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response. **2023**, 24, 3151 1
- 377 Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. ○
- 376 Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations. **2023**, 11, 6 ○
- 375 Canine squamous cell carcinoma: Electrochemotherapy association with surgery and correlation with overall survival. ○
- 374 Transplant for colorectal cancer liver metastases. **2023**, ○
- 373 Salvage surgery after combination immunotherapy for initially unresectable hepatocellular carcinoma: A retrospective clinical study. ○
- 372 The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers chemoresistance in ovarian cancer. ○
- 371 Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. **2023**, 18, e0281459 ○
- 370 Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial. **2023**, 178, 96-102 ○
- 369 Response Evaluation in Patients with Peritoneal Metastasis Treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). **2023**, 12, 1289 ○
- 368 Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. **2023**, 170, 300-308 ○
- 367 Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. **2023**, 14, ○
- 366 Relevance of Volumetric Parameters Applied to [68Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT. **2023**, 13, 606 ○
- 365 Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases. **2023**, 6, e2255050 ○
- 364 Establishing a Prediction Model for the Efficacy of Platinum-Based Chemotherapy in NSCLC Based on a Two Cohorts GWAS Study. **2023**, 12, 1318 ○
- 363 Effects of Fractionated Radiation Exposure on Vimentin Expression in Cervical Cancers: Analysis of Association with Cancer Stem Cell Response and Short-Term Prognosis. **2023**, 24, 3271 ○

- 362 Imaging of Small-Bowel Neuroendocrine Neoplasms: AJR Expert Panel Narrative Review. o
- 361 MRI of cervical cancer. **2023**, 319-344 o
- 360 Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer. **2023**, 13, o
- 359 Pediatric Rhabdomyosarcoma Protocols Should Include More Detailed Imaging Guidelines to Ensure Homogeneous Response Assessment. o
- 358 A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma. 13, o
- 357 Association of Treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid Cancer. **2023**, 149, 300 o
- 356 Deformable registration with intensity correction for CESM monitoring response to Neoadjuvant Chemotherapy. **2023**, 9, 035003 o
- 355 Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. **2023**, 18, e0277708 o
- 354 The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer. **2023**, 15, 880 o
- 353 Dynamic tumor-tracking stereotactic body radiotherapy with real-time monitoring of liver tumors using a gimbal-mounted linac: A multi-institutional phase II study. **2023**, 39, 100591 o
- 352 Variation in the management of benign liver tumors: A European survey and case vignette study. **2023**, 47, 102094 o
- 351 Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. **2023**, 33, 484-491 o
- 350 Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. **2023**, 4, 100474 o
- 349 Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study. **2023**, 79, 503-511 o
- 348 Long-Term Outcomes of Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse after Definitive Radiotherapy for Prostate Cancer: Patterns of Failure and Association between Volume of Irradiation and Late Toxicity. **2023**, 15, 1180 o
- 347 Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines. **2023**, 15, 1170 o
- 346 Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer. **2023**, 19, 147-158 o
- 345 Automatic Classification of Tumor Response From Radiology Reports With Rule-Based Natural Language Processing Integrated Into the Clinical Oncology Workflow. **2023**, o

- 344 Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer. **2023**, 15, 1151 ○
- 343 Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. **2023**, ○
- 342 Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program. **2023**, ○
- 341 A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients. ○
- 340 The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review. **2023**, 128, 316-329 ○
- 339 Tumor Burden Monitoring with Circulating Tumor DNA During Treatment in Patients with Esophageal Squamous Cell Carcinoma. ○
- 338 Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study. ○
- 337 Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors. **2023**, 21, 133-142.e3 ○
- 336 Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab. ○
- 335 Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis. 10, ○
- 334 Clinical Experience of Intra-tumoral Central-Dose Escalated Volumetric Modulated Arc Therapy for Lymph Node Metastases in Patients With Advanced Cancer. **2023**, ○
- 333 Treatment of vulvar cancer recurrences with electrochemotherapy & detailed analysis of possible causes for unsuccessful treatment. **2023**, 57, 121-126 ○
- 332 Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer. 14, ○
- 331 The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients. **2023**, 11, 591 ○
- 330 Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2&T3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. **2023**, 8, 356-367 ○
- 329 Real-world treatment response in Japanese patients with cancer using unstructured data from electronic health records. **2023**, 13, 253-262 ○
- 328 Rucaparib or Physician's Choice in Metastatic Prostate Cancer. **2023**, 388, 719-732 1
- 327 Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. **2023**, 24, 3994 ○

- 326 A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. **2023**, 128, 1418-1428 ○
- 325 First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors. **2023**, 18, 181-193 ○
- 324 USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer. **2023**, 24, 143-156 ○
- 323 Downsizing of rectal cancer following neoadjuvant radiotherapy (5 15 Gy) and long interval surgery evaluated using MRI semiautomated volumetric measurements, a retrospective study. 10, ○
- 322 DZIP1 expressed in fibroblasts and tumor cells may affect immunosuppression and metastatic potential in gastric cancer. **2023**, 117, 109886 ○
- 321 Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events. 14, ○
- 320 Intentional R1 resection of liver metastases: A new treatment paradigm for patients with advanced colorectal cancer based on a propensity scoreMatched case-control analysis. **2023**, 47, 102097 ○
- 319 Using the analytic hierarchy process to elicit patient preference in the evaluation of first-line treatment of HER2-overexpressing metastatic breast cancer. **2023**, 31, ○
- 318 Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment. **2023**, 13, 793 ○
- 317 Clinicopathological Features and Prognosis of Gastrointestinal Metastases From Breast Carcinoma: A Clinicopathological Study of 22 Patients. 106689692311525 ○
- 316 Liver transplantation for isolated unresectable colorectal liver metastases - Protocol for a service evaluation in the United Kingdom - UKCoMET study. **2023**, ○
- 315 MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma. 13, ○
- 314 Number of healthy teeth can predict the response of rectal cancer to chemoradiotherapy. ○
- 313 Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors. **2023**, 96, ○
- 312 FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study. **2023**, 23, ○
- 311 Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial. OF1-OF10 ○
- 310 Vertical level of blood cell division cycle 42 predicts response and survival benefits to PD-1 inhibitor-based regimen in metastatic colorectal cancer patients. **2023**, 83, 103-110 ○
- 309 Case report: PD-1 inhibitor-based treatment strategies in gastric cancer complicated by bone marrow metastasis and disseminated intravascular coagulation: A report of two cases. 13, ○

- 308 A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥ lines) anti-programmed death-1 monotherapy. **2023**, 139, 106336 o
- 307 Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. 10, o
- 306 ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling in a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. **2023**, 23, 1
- 305 Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer. 13, o
- 304 Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial. **2023**, 57, 101873 o
- 303 Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway). 13, o
- 302 The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors. o
- 301 PET-MRI for evaluation of response to radiochemotherapy in patients with locally advanced cervical cancer. *ijgc-2022-003958* o
- 300 Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. **2023**, 40, 1686-1704 o
- 299 The performance of 68Ga-FAPI-04 PET/CT in head and neck squamous cell carcinoma: a prospective comparison with 18F-FDG PET/CT. o
- 298 Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study. **2023**, 18, o
- 297 PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score. **2023**, 13, 611 o
- 296 A COMPARATIVE PROSPECTIVE STUDY BETWEEN STANDARD AND ALTERED FRACTIONATED RADIOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA. **2023**, 11-14 o
- 295 Changes in the urine proteome in patients with advanced lung cancer after different drug treatments. **2023**, 5, 1-12 o
- 294 Magnetic resonance imaging presentation of diffuse and focal adenomyosis before and after pregnancy. **2023**, o
- 293 Immune checkpoint inhibitors for advanced pancreatic cancer. **2023**, 2023, o
- 292 Multicenter real-world experience of the clinical efficacy and tolerance of pazopanib in high-risk pediatric solid tumors (PazoPed). 1-16 o
- 291 The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors. o

- 290 Long-Term Outcomes After Chemoradiotherapy and Surgery for Superior Sulcus Tumors. **2023**, 4, 100475 ○
- 289 Prostate-specific Membrane Antigen Positron Emission Tomography as a Biomarker to Assess Treatment Response in Patients with Advanced Prostate Cancer. **2023**, ○
- 288 Efficacy of Recombinant Human Endostatin plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP-9 Levels. **2023**, 2023, 1-10 ○
- 287 Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL). **2023**, 4, 100484 ○
- 286 LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC. **2023**, 4, 100490 ○
- 285 Thyroid Transcription Factor-1, Tumor Proportion Score and Treatment Effect in Combination Therapy with Carboplatin, Pemetrexed, and Pembrolizumab as a First-line Therapy. **2023**, 63, 15-21 ○
- 284 Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers. **2023**, 24, 4601 ○
- 283 Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter?. **2023**, ○
- 282 Intratumoral and Microenvironmental Heterogeneity in Patient Outcome Prediction. **2023**, ○
- 281 Title Pending 169. ○
- 280 Mapping Tumor Heterogeneity via Local Entropy Assessment: Making Biomarkers Visible. ○
- 279 PERCIST and Hopkins criteria and PET/CT metabolic parameters as prognostic factors in squamous head and neck cancer. **2023**, ○
- 278 Imaging in rhabdomyosarcoma: a patient journey. **2023**, 53, 788-812 ○
- 277 Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. **2023**, 8, ○
- 276 Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody. **2023**, 11, e006234 ○
- 275 Is High Score of Preoperative Lactate Dehydrogenase to Albumin Ratio Predicting Poor Survivals in Esophageal Carcinoma Patients?. **2023**, ○
- 274 Neuroendocrine Tumor Therapy Response Assessment. **2023**, 18, 267-286 ○
- 273 Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma. **2023**, 15, 1523 ○

272	Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer. <b>2023</b> , 23,	0
271	The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma.	0
270	Neoadjuvant Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. <b>2023</b> , 388, 813-823	3
269	Treatment Response After Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases of Colorectal Origin. <b>2022</b> , 3, e203	0
268	Stereotactic body radiotherapy for metastatic sarcoma to the lung: adding to the arsenal of local therapy. <b>2023</b> , 18,	0
267	Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma.	0
266	Neoplastic Diseases of the Respiratory System in Geriatric Patients. <b>2023</b> , 171-216	0
265	Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis. <b>2023</b> , 13,	0
264	Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study. <b>2023</b> , 102, e33157	0
263	Clinical Relevance of Uterine Manipulation on Oncologic Outcome in Robot-Assisted versus Open Surgery in the Management of Endometrial Cancer. <b>2023</b> , 12, 1950	0
262	Influence of Extraperitoneal Metastases on the Curative-Intent Management of Colorectal Peritoneal Metastases.	0
261	Feasibility assessment of global standard chemoradiotherapy followed by surgery in patients with esophageal cancer. <b>2023</b> , 18,	0
260	Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Hepatocellular Carcinoma.	0
259	Patient outcomes following a response biomarker-guided approach to treatment using <sup>177</sup> Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). <b>2023</b> , 15, 175883592311563	0
258	<sup>89</sup> Zr-immuno-PET using the anti-LAG-3 tracer [ <sup>89</sup> Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC.	0
257	Alleviating Morbidity From Locally Advanced Breast Cancer Using a Practical and Short Radiation Therapy Regimen: Results of the HYPORP Palliative Studies. <b>2023</b> ,	0
256	SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post <sup>177</sup> Lu-DOTATATE and <sup>177</sup> Lu-PSMA617 setting.	0
255	Preclinical PET Imaging of Tumor Cell Death following Therapy Using Gallium-68-Labeled C2Am. <b>2023</b> , 15, 1564	1

- 254 A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. ○
- 253 Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours. **2023**, 23, ○
- 252 ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors. **2023**, 5, ○
- 251 Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. **2023**, 15, 175883592311561 ○
- 250 Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study. ○
- 249 Imaging recommendations for the management of pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Consensus statement of the International Soft Tissue Sarcoma Consortium (INSTRuCT). **2023**, 1, 100008 ○
- 248 Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC. ○
- 247 A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer. **2023**, 15, 1606 ○
- 246 Advances in Boron Neutron Capture Therapy (BNCT) for Recurrent Intracranial Meningioma. **2023**, 24, 4978 ○
- 245 Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients. **2023**, 21, ○
- 244 Comparison of radiomics models and dual-energy material decomposition to decipher abdominal lymphoma in contrast-enhanced CT. ○
- 243 Eosinophil and IFN- $\gamma$  associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. 14, ○
- 242 Role of GSDMD and VEGF in differentiating between malignant and non-malignant pleural effusions. **2023**, 12, ○
- 241 Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study. Volume 16, 157-163 ○
- 240 How Do Cancer-Specific Computed Tomography Protocols Compare With the American College of Radiology Dose Index Registry? An Analysis of Computed Tomography Dose at 2 Cancer Centers. Publish Ahead of Print, ○
- 239 Pegylated liposomal doxorubicin (Duomeisu<sup>®</sup>) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study. ○
- 238 A large-scale retrospective study in metastatic breast cancer patients using circulating tumor DNA and machine learning to predict treatment outcome and progression-free survival. ○
- 237 Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan. **2023**, 20, 4545 ○

- 236 Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer. **2023**, 28, 688-697 ○
- 235 DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Triple-Negative and Luminal B Breast Cancer. **2023**, 15, 1630 ○
- 234 A 3-month survival model after Gamma Knife surgery in patient with brain metastasis from lung cancer with Karnofsky performance status  $\geq 70$ . ○
- 233 Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. 14, ○
- 232 Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study. ○
- 231 PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial. **2023**, 4, 100972 ○
- 230 Impact of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma. ○
- 229 Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study. ○
- 228 Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity. **2023**, 11, e006462 ○
- 227 A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors. ○
- 226 Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer. **2023**, 178, 247-253 ○
- 225 Low-Baseline PD1+ Granulocytes Predict Responses to AtezolizumabBevacizumab in Hepatocellular Carcinoma. **2023**, 15, 1661 ○
- 224 Therapiesteuerung in der medikamentösen Tumorthherapie. **2022**, 1-7 ○
- 223 A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. **2023**, 8, 101183 ○
- 222 Tumor Volume Nadir in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Treated With Alectinib. **2023**, ○
- 221 Exploration of new positions for cabozantinib for advanced hepatocellular carcinoma in the latest real-world practice. ○
- 220 Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. ○
- 219 Patient-Derived Tumor Organoids Can Predict the Progression-Free Survival of Patients With Stage IV Colorectal Cancer After Surgery. **2023**, 66, 733-743 ○

218	Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma. <b>2023</b> , 6, e232526	o
217	Single Center Outcomes from Parenchymal-sparing Resections and Microwave Ablations for Neuroendocrine Tumor Liver Metastases.	o
216	A Correlative Approach to Breast Imaging. <b>2023</b> , 351-382	o
215	M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: A pilot study. 13,	o
214	Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis. <b>2023</b> , 102, e33204	o
213	Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients. 14,	o
212	Is the Juice Worth the Squeeze? Overall Survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers.	o
211	Meta-Analysis of 49 Roche Oncology Trials Comparing Blinded Independent Central Review (BICR) and Local Evaluation to Assess the Value of BICR.	o
210	Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN G114-198). <b>2023</b> ,	o
209	LncRNA CACCLnc promotes chemoresistance of colorectal cancer by modulating alternative splicing of RAD51. <b>2023</b> , 42, 1374-1391	o
208	Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma. <b>2023</b> , 18, 235-245	o
207	Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma.	o
206	Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins. <b>2023</b> , 13, 417	o
205	Prognostic Awareness, Palliative Care Use, and Barriers to Palliative Care in Patients Undergoing Immunotherapy or Chemo-Immunotherapy for Metastatic Lung Cancer.	o
204	Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?. <b>2023</b> , 59, 557	o
203	Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors. <b>2023</b> , 23,	o
202	Real-world clinical outcomes of the combination of anti-PD -1 antibody, trastuzumab, and chemotherapy for HER2 -positive gastric/gastroesophageal junction cancer.	o
201	Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma. <b>2023</b> , 12, 2211	o

- 200 BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. **2023**, 14, ○
- 199 A Deep Learning Radiomics Nomogram to Predict Response to Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer: A Two-Center Study. **2023**, 13, 1073 ○
- 198 Different treatment efficacies and T790M acquisition of EGFR-TKIs on NSCLC patients with variable Del-19 subtypes of EGFR . ○
- 197 Evaluation of entropy and fractal dimension as biomarkers for tumor growth and treatment response using cellular automata. **2023**, 564, 111462 ○
- 196 Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4 / CyclinD1-pRB-E2F1 pathway. **2023**, 27, 991-1005 ○
- 195 Pilot Study on the Impact of Polymorphisms Linked to Multi-Kinase Inhibitor Metabolism on Lenvatinib Side Effects in Patients with Advanced Thyroid Cancer. **2023**, 24, 5496 ○
- 194 Comparing the effectiveness of 2D and 3D features on predicting the response to chemotherapy for ovarian cancer patients. **2023**, ○
- 193 Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma. **2023**, 249, 109290 ○
- 192 PD-1/LAG-3 Dysfunctionality Signatures in Human Cancers. ○
- 191 Advanced CT Imaging, Radiomics, and Artificial Intelligence to Evaluate Immune Checkpoint Inhibitors Effects on Metastatic Renal Cell Carcinoma. **2023**, 13, 3779 ○
- 190 A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. **2023**, 29, 859-868 ○
- 189 Outcomes and endpoints of relevance in gynecologic cancer clinical trials. **2023**, 33, 323-332 ○
- 188 Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. **2023**, 29, 593-604 ○
- 187 Breaking down the RECIST 1.1 double read variability in lung trials: What do baseline assessments tell us?. 13, ○
- 186 Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. ○
- 185 On the correction of respiratory motion-induced image reconstruction errors in positron-emission tomography-guided radiation therapy. **2023**, 26, 100430 ○
- 184 The prognostic significance of serum lactate dehydrogenase for patients with small cell lung cancer treated first-line therapy: a retrospective analysis of 163 consecutive cases. ○
- 183 Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg. **2023**, 15, 175883592311601 ○

- 182 Advances in Molecular Imaging and Therapy and Its Impact in Oncologic Imaging. **2023**, 31-45 ○
- 181 Imaging Features of Immunotherapy. **2023**, 169-176 ○
- 180 Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials. **2023**, ○
- 179 Identification of LSM family members as potential chemoresistance predictive and therapeutic biomarkers for gastric cancer. 13, ○
- 178 Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. ○
- 177 Nomogram for predicting axillary upstaging in clinical node-negative breast cancer patients receiving neoadjuvant chemotherapy. ○
- 176 Update of the Bologna Experience in Radioembolization of Intrahepatic cholangiocarcinoma. **2023**, 22, 153303382311556 ○
- 175 Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). ○
- 174 The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer. **2023**, 24, 5767 ○
- 173 Delta computed tomography radiomics features-based nomogram predicts long-term efficacy after neoadjuvant chemotherapy in advanced gastric cancer. **2023**, 128, 402-414 ○
- 172 Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study. **2023**, 18, 209-220 ○
- 171 A phase-field model for non-small cell lung cancer under the effects of immunotherapy. ○
- 170 Interactive process mining of cancer treatment sequences with melanoma real-world data. 13, ○
- 169 Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC. **2023**, ○
- 168 Can Ki-67 predict radiotherapy response in neuroendocrine tumors? Retrospective analysis of a monocentric series of patients. 030089162311605 ○
- 167 Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. **2023**, 15, 175883592311601 ○
- 166 CT Radiomics Predict EGFR-T790M Resistance Mutation in Advanced Non-Small Cell Lung Cancer Patients After Progression on First-line EGFR-TKI. **2023**, ○
- 165 Multimodality liver directed treatment for colorectal liver metastasis: Array of complementary options can improve outcomes - A single centre experience from India. 13, ○

- 164 DeepGeni: deep generalized interpretable autoencoder elucidates gut microbiota for better cancer immunotherapy. **2023**, 13, ○
- 163 Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. ○
- 162 Whole exon capture sequencing for identifying mutations associated with pulmonary benign metastasising leiomyoma. **2023**, 16, e251072 ○
- 161 The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients. **2023**, 14, 101474 ○
- 160 Predicting pathological complete response after neoadjuvant chemotherapy: A nomogram combining clinical features and ultrasound semantics in patients with invasive breast cancer. 13, ○
- 159 Case report: Stem cell-based suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene reduces tumor progression in multifocal glioblastoma. 14, ○
- 158 Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: readdressing the roles of platinum and cytotoxic therapies. ○
- 157 Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging. **2023**, 13, ○
- 156 Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. ○
- 155 Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study. ○
- 154 Backfilling cohorts in phase I dose-escalation studies. 174077452311600 ○
- 153 Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy. ○
- 152 Mutation Status Analysis Of 58 Patients With Advanced ALK Fusion Gene Positive Non Small Cell Lung Cancer. ○
- 151 Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy – durvalumab maintenance treatment. ○
- 150 MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics. **2023**, 13, ○
- 149 Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis. 14, ○
- 148 Difference after radiotherapy observed in patients with nasopharyngeal carcinoma. **2023**, ○
- 147 Contribution of diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) measurements in determining response to treatment in lung cancer. **2023**, 48, 187-193 ○

- 146 Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non-small cell lung cancer. **2023**, ○
- 145 Multidisciplinary nutritional management improves nutritional and hospitalized outcomes of patients with esophageal cancer undergoing chemoradiotherapy: A randomized control trial. **2023**, 102, e33335 ○
- 144 Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab. **2023**, 23, ○
- 143 A novel method to identify and characterize personalized functional driver lncRNAs in cancer samples. **2023**, 21, 2471-2482 ○
- 142 New frontiers in oncological imaging with Computed Tomography: from morphology to function. **2023**, ○
- 141 Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs. ○
- 140 Are more courses of immunochemotherapy beneficial for the short-term outcome of locally advanced esophageal squamous cell carcinoma?. ○
- 139 Quantitative Diffusion-Weighted MRI of Neuroblastoma. **2023**, 15, 1940 ○
- 138 Identification of prognostic and therapeutic biomarkers in type 2 papillary renal cell carcinoma. **2023**, 21, ○
- 137 Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. **2023**, 58, 413-424 ○
- 136 Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma. **2023**, 23, ○
- 135 MRI fat fraction imaging of nodal and bone metastases in prostate cancer. ○
- 134 Low diffusion capacity predicts poor prognosis in extensive stage small cell lung cancer: a single-center analysis of 10 years. ○
- 133 Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study. ○
- 132 Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. **2023**, 24, 323-334 1
- 131 Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. ○
- 130 Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma. ○
- 129 Chemical Exchange Saturation Transfer MRI : Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non-Small Cell Lung Cancer Patients. ○

- 128 A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. ○
- 127 Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST. **2023**, 28, 680-687 ○
- 126 Molecular imaging for cancer immunotherapy. **2023**, 1, 3-17 ○
- 125 Response to induction chemotherapy in sinonasal malignancies: A single-institutional experience. ○
- 124 Prediction of response to preoperative neoadjuvant chemotherapy in extremity high-grade osteosarcoma using X-ray and multiparametric MRI radiomics. **2023**, 1-16 ○
- 123 Response Evaluation of Neoadjuvant Therapies in Sarcoma. ○
- 122 Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC). **2023**, 19, 193-203 ○
- 121 Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens. **2023**, 15, 175883592311637 ○
- 120 Predicting Pathological Complete Response in Breast Cancer After Two Cycles of Neoadjuvant Chemotherapy by Tumor Reduction Rate: A Retrospective Case-Control Study. 26, ○
- 119 Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies. ○
- 118 Liquid biopsy using cfDNA to predict radiation therapy response in solid tumors. **2023**, 41, 32-39 ○
- 117 A SPONTANEOUS MELANOMA MOUSE MODEL APPLICABLE FOR A LONGITUDINAL CHEMOTHERAPY AND IMMUNOTHERAPY STUDY. **2023**, ○
- 116 High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study. ○
- 115 A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation. 23, ○
- 114 Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma. ○
- 113 PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study. **2023**, ○
- 112 Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. ○
- 111 Radiomics and Radiogenomics of Ovarian Cancer. **2023**, ○

110	Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer.	o
109	Test-Retest, inter- and intra-rater reproducibility of size measurements of focal bone marrow lesions in MRI in patients with multiple myeloma.	o
108	Proton or Carbon Ion Therapy for Skull Base Chordoma: Rationale and First Analysis of a Mono-Institutional Experience. <b>2023</b> , 15, 2093	o
107	ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers. <b>2023</b> , 11, e006345	o
106	FIGHT -102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies.	o
105	Epigenetic control of CD1D expression as a mechanism of resistance to immune checkpoint therapy in poorly immunogenic melanomas. 14,	o
104	Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC.	o
103	Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.	o
102	Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma. Volume 19, 329-339	o
101	Safety and efficacy of self-expandable metallic stent combined with 125I brachytherapy for the treatment of malignant obstructive jaundice. <b>2023</b> , 23,	o
100	German specialists treating testicular cancer follow different guidelines with resulting inconsistency in assessment of retroperitoneal lymph-node metastasis: clinical implications and possible corrective measures.	o
99	Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors.	o
98	Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer.	o
97	Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment. Publish Ahead of Print,	o
96	First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.	o
95	The SINTART 1 Study. A Phase II Nonrandomized Controlled Trial Of Induction Chemotherapy, Surgery, Photon-, Proton-And Carbon Ion- Based Radiotherapy Integration In Patients With Locally Advanced Resectable Sinonasal Tumors. <b>2023</b> ,	o
94	Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations.	o
93	The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy. <b>2023</b> , 13,	o

92	Abdominal Emergencies in Cancer and Immunocompromised Patients. <b>2023</b> , 81-99	o
91	Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response.	o
90	Vimentin expression correlates with immune-checkpoint inhibitor efficacy in non-small cell lung cancer.	o
89	A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA). <b>2023</b> , 8, 101207	o
88	Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. <b>2023</b> , 11, e005828	o
87	Fecal levels of SCFA and BCFA during capecitabine in patients with metastatic or unresectable colorectal cancer.	o
86	Observational study of HR+/HER2- metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS).	o
85	The SINTART 2 Study. A Phase II Nonrandomized Controlled Trial of Induction Chemotherapy, Photon-, Proton- And Carbon Ion-Based Radiotherapy Integration In Patients With Locally Advanced Unresectable Sinonasal Tumors. <b>2023</b> ,	o
84	Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. <b>2023</b> ,	o
83	HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.	o
82	Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma. Volume 16, 263-273	o
81	PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.	1
80	Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study.	o
79	Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events. 13,	o
78	Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.	o
77	PET/CT in Synovial Tumors and Tumor-Like Conditions. <b>2023</b> ,	o
76	Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study. <b>2023</b> , 23,	o
75	Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicenter observational study. <b>2023</b> , 40,	o

74	Toward Practical Integration of Omic and Imaging Data in Co-Clinical Trials. <b>2023</b> , 9, 810-828	o
73	Prognostic assessment in patients operated for brain metastasis from systemic tumors.	o
72	Treatment of melanoma with dendritic cell vaccines and immune checkpoint inhibitors: A mathematical modeling study. <b>2023</b> , 111489	o
71	Impact of COVID-19 pandemic among patients with lung and head and neck cancer assisted in a public cancer center in Brazil.	o
70	Fast, light, and scalable: harnessing data-mined line annotations for automated tumor segmentation on brain MRI.	o
69	Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.	o
68	Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. <b>2023</b> , 59, 101955	o
67	Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach. <b>2023</b> , 21,	o
66	Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients. <b>2023</b> , 23,	o
65	Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort. <b>2023</b> , 23,	o
64	Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial. <b>2023</b> , 13, e067925	o
63	Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. <b>2023</b> ,	o
62	The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis. <b>2023</b> , 15, 175883592311659	o
61	Validation of an orthotopic non-small cell lung cancer mouse model, with left or right tumor growths, to use in conformal radiotherapy studies. <b>2023</b> , 18, e0284282	o
60	Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein. <b>2023</b> , 15, 2304	o
59	Combined CT and serum CA19-9 for stratifying risk for progression in patients with locally advanced pancreatic cancer receiving intraoperative radiotherapy. 13,	o
58	Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer. <b>2023</b> , 15, 2297	o
57	Therapeutic mastoplasty: a wise oncoplastic choice—lessons from the largest single-center cohort from Asia. 13,	o

- 56 Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. ○
- 55 Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients. ○
- 54 The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. ○
- 53 Comparison of the efficacy between immunochemotherapy and chemotherapy in gastric cancer accompanied with synchronous liver metastases: A real-world retrospective study. ○
- 52 Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil. ○
- 51 Draft of clinical guidelines for the diagnosis and treatment of medullary thyroid cancer in adult patients. **2023**, 16, 5-23 ○
- 50 Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy had a higher ORR than mono-immunotherapy in untreated HNSCC: Meta-analysis. ○
- 49 CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer. *ijgc-2023-004308* ○
- 48 Central nervous system efficacy of Rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: a pooled analysis of two clinical studies. **2023**, 107194 ○
- 47 Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancer. ○
- 46 Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group. **2023**, 15, 2314 ○
- 45 Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. **2023**, 7, ○
- 44 Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial. ○
- 43 Single Arm Phase II Clinical Trial. **2023**, 91-118 ○
- 42 Outcome of Children and Adolescents With Primary Intracranial Germinoma Treated With Chemotherapy and Reduced Dose-Field Irradiation: A Prospective Brazilian Experience. **2023**, ○
- 41 Camrelizumab plus taxanes and cisplatin (TP) chemotherapy or TP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma. ○
- 40 Afatinib in Pediatric Patients With Recurrent/Refractory ErbB-dysregulated Tumors: Results of a Phase I/Expansion Trial. **2023**, ○
- 39 Is CT or FDG-PET more useful for evaluation of the treatment response in metastatic HER2-positive breast cancer? a case report and literature review. 13, ○

- 38 Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC. **2023**, 13, 1051 ○
- 37 Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. **2023**, ○
- 36 Circulating tumor DNA kinetics in recurrent/metastatic Head & Neck Squamous Cell Cancer (R/M HNSCC) patients. **2023**, ○
- 35 Efficacy and predictive factors of endoscopic ultrasound-guided ethanol ablation in benign solid pancreatic tumors. ○
- 34 Preliminary report on the short-term efficacy and safety of SAPO-S1 therapy for locally advanced gastric cancer with a deep learning perspective. 1-16 ○
- 33 Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor  $\beta 2$  Shows a Poor Response to Gemcitabine-Based Chemotherapy. **2022**, 51, 1133-1139 ○
- 32 Genomic characterization of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-TKIs for EGFR mutated non-small cell lung cancer. **2023**, ○
- 31 Clinicopathological Characteristics, Treatment Patterns, and Outcomes in Patients with Laryngeal Cancer. **2023**, 30, 4289-4300 ○
- 30 Magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) for oligometastatic patients: a single-center experience. ○
- 29 Predicting conversion surgery in patients with locally advanced pancreatic cancer after modified FOLFIRINOX treatment. **2023**, ○
- 28 Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. ○
- 27 Nomogram Based on Preoperative Absolute Lymphocyte Count to Predict Local Recurrence in Patients with Non-Small Cell Lung Cancer After Microwave Ablation. Volume 16, 1761-1770 ○
- 26 Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features. ○
- 25 Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial. ○
- 24 Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study. **2023**, 11, e006633 ○
- 23 Real-world comprehensive diagnosis and Surgery + X treatment strategy of early-stage synchronous multiple primary lung cancer. ○
- 22 Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma. ○
- 21 Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, meta-analysis, and meta-regression analysis. ○

- 20 The efficacy of neoadjuvant chemotherapy as compared to upfront surgery for the management of oral squamous cell carcinoma: a systematic review and meta-analysis. **2023**, ○
- 19 Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study. **2023**, 107213 ○
- 18 A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma. Volume 10, 673-686 ○
- 17 Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients. **2023**, 15, 175883592311678 ○
- 16 Effects of Deep Hyperthermia Combined with Intraperitoneal Chemotherapy on Liver-Kidney Function, Immune Function, and Long-Term Survival in Patients with Abdominal Metastases. **2023**, 2023, 1-7 ○
- 15 Skeletal muscle mass and quality before preoperative chemotherapy influence postoperative long-term outcomes in esophageal squamous cell carcinoma patients. 15, 621-633 ○
- 14 Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. ○
- 13 Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial. **2023**, 12, 1246 ○
- 12 Pituitary adenoma consistency affects postoperative hormone function: a retrospective study. **2023**, 23, ○
- 11 Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy. ○
- 10 The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index. **2023**, 19, 517-529 ○
- 9 Nutri-PEITC Jelly Significantly Improves Progression-Free Survival and Quality of Life in Patients with Advanced Oral and Oropharyngeal Cancer: A Blinded Randomized Placebo-Controlled Trial. **2023**, 24, 7824 ○
- 8 Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival. ○
- 7 Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study. 14, ○
- 6 Immune-related thyroid dysfunctions during anti PD-1/PD-L1 inhibitors: new evidence from a single centre experience. ○
- 5 A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma. ○
- 4 Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma. ○
- 3 Pegylated liposomal doxorubicin ( PLD ) in daily practice: a single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer. ○

2

Liver Transplantation for Colorectal Liver Metastases. **2023**,

o

1

Postchemoradiotherapy systemic inflammation response index predicts treatment response and overall survival for patients with locally advanced nasopharyngeal cancer. **2023**,

o